Skip to main content

Instillinger æresdoktorer 2015

Ved at klikke på hvert navn kommer du til indstillingen for den pågældende

Catherine E. Carr

Wolfgang Streeck

Michel Eichelbaum

Vladimir M. Shalaev

Jonathan Phillips


Catherine E. Carr

Indstilling af professor Catherine E. Carr, University of Maryland til æresdoktorat ved SDU.

Professor Catherine Carr, University of Maryland, er en af de førende forskere i neuroetologi, dvs. sammenhængen mellem dyrs adfærd og de underliggende neurale processer i sanseorganer og centralnervesystemet, CNS. . Hendes forskning er internationalt anerkendt og  drejer sig om retningshørelse og hvordan neuroner i  CNS sammenligner ankomsttidspunkt og lydtryk i lydinput til de to øren for at bestemme retningen til lydkilden.
Modelorganismen for disse undersøgelser er sløruglen, der har en ekstremt skarp retningshørelse Professor Carrs banebrydende undersøgelser har kombineret anatomiske og neurofysiologiske eksperimenter med matematisk modellering og vist, at neuroner i CNS skal stimuleres samtidig fra de to øren for at give et nervesignal. Hun har vist, at denne koincidens-detektor er realiseret morfologisk: Det er simpelthen længere axoner, der giver større forsinkelser, og axonlængderne er organiseret systematisk, så de repræsenterer de forskellige akustiske forsinkelser, der svarer til forskellige vinkler til lydkilden, så der morfologisk er  en systematisk repræsentation af tidsforskelle i CNS. Teorien bag denne model blev udviklet af psykologen Lloyd  Jeffress allerede i 1948, og professor Carrs påvisning af, at modellen er realiseret fysisk  i uglens hjerne har været enormt inspirerende for stort set alle studier af retningshørelse i hvirveldyr, siden hendes klassiske arbejde blev publiceret i 1990 (Carr & Konishi 1990, se publikationsliste). Modellen har klarlagt det biofysiske grundlag for denne koincidensdetektion, som også har været brugt som forklaring af vor egen retningshørelse og vist i praksis, hvordan neuroner kan udføre beregninger.
 Professor Carr er ikke ”bare” neurofysiolog, men også en eminent og bredt interesseret biolog, som altid vurderer sine resultater i lyset af evolutionære mekanismer: Hun har undersøgt den evolutionære baggrund for disse mekanismer ved sammenligning af CNS-kodning hos ugler, emuer, høns, alligatorer, øgler og skildpadder. Der er således tale om en skelsættende og omfattende  videnskabelig produktion, der spænder over mange biologiske discipliner.
Udover det videnskabelige arbejde har professor Carr haft en vigtig rolle som mentor, bl.a. ved at lede det fremragende og prestigiøse sommerkursus på Marine Biological Laboratory, Woods Hole. Som mentor og rollemodel for yngre kvindelige forskere har hun sandsynligvis bidraget væsentligt til den relativt gode repræsentation af kvinder i forskningsfeltet neuroetologi.Hun har siddet i editorial board for adskillige tidsskrifter. I 2012 blev hun fellow ved American Academy for the Advancement of Science (AAAS).
Professor Carr har besøgt SDU som Velux-professor og har forskningssamarbejde med Biologisk Institut, bl.a. som ekstern samarbejdspartner i Center for Biorobotics. Hun er derfor en internationalt anerkendt forsker med tilknytning til og engagement i SDU, som det vil være naturligt at hædre.

CV:
Stillinger
1984-1987 National Research Service Award fellow, Division of Biology, Caltech, Pasadena, CA
1987-1990 Assistant Professor of Neurobiology & Anatomy, Univ Rochester, Rochester, NY
1990-1995 Assistant Professor of Zoology, University of Maryland, College Park, MD
1999- Professor of Biology, University of Maryland, College Park, MD

Medlemskaber
1992-1998  Member of Hearing Research panel (NIDCD) NIH
2000-2005  Co-Director, Neurobiology & Behavior course at MBL, Woods Hole.
2001-2005  Director, Howard Hughes Undergraduate Research Program, Univ.    Maryland.
2002-2006  Member of Hearing Research panel (NIDCD) NIH
2002-2009  Editorial Board, Brain Behavior and Evolution
2002-2005  Member, Society for Neuroscience program committee
2004-   Action Editor, Journal Neurophysiology
2004-  Associate Editor, Journal of Computational Neuroscience
2005-2011  Member, MBL Science council
2006-2008  Director, Grass Lab, MBL
2010-2013  International Education Committee for the Society for Neuroscience, IBRO delegate

Hædersbevisninger
1980  Grass Scholarship at Cold Spring Harbor
1986   Society for Neuroethology prize for an outstanding paper by a Young Investigator
1988 Alfred P Sloan Research Fellow
1998 Univ Maryland Life Sciences excellence in research award
2004 Humboldt Senior Research Prize, Technical Univ Munich
2010 Velux Visiting Professor, Univ. Southern Denmark
2011 Humboldt Senior Research Prize, Univ Oldenburg
2012 Fellow, AAAS

Udvalgte publikationer:
Professor Carr’s publikationsliste (over 100 publikationer) imponerer ikke bare ved antal, men især ved den, uden undtagelse, exceptionelt høje kvalitet af hvert eneste arbejde. Hendes publikationsstrategi er eksemplarisk og har medvirket til hendes gennemslagskraft: Man ved at hendes artikler er værd at læse
Bierman HS, Thornton JL, Jones HG, Koka K, Young BA, Brandt C, Christensen-Dalsgaard J, Carr CE, Tollin DJ. 2014. Biophysics of directional hearing in the American alligator (Alligator mississippiensis). J Exp Biol. 2014 Apr 1;217(Pt 7):1094-107. doi: 10.1242/jeb.092866.
Kuokkanen PT, Ashida G, Carr CE, Wagner H, Kempter R. 2013 Linear Summation in the Barn Owl's Brainstem Underlies Responses to Interaural Time Differences. J. Neurophys. 110:117-30. doi: 10.1152/jn.00410.2012
Christensen-Dalsgaard J, Carr CE, Brandt C, Willis KL, Bech Christensen C,  Ketten D, Edds-Walton P, Fay RR, Madsen PT 2012. Specialization for underwater hearing by the tympanic middle ear of the turtle, Trachemys scripta elegans.  Proc. R. Soc. B. 279: 2816-2824 .
Tang YZ, Christensen-Dalsgaard J, Carr CE. 2011 Organization of the Auditory Brainstem in a Lizard, Gekko gecko. I. Auditory Nerve, Cochlear Nuclei and Superior Olivary Nuclei. J. Comp Neurol. 520, 8, p. 1784-1799 16 p.
Christensen-Dalsgaard J, Tang YZ, Carr CE. 2011 Binaural processing by the gecko auditory periphery. J Neurophysiol. 105:1992-2004. PMID: 22120438
Ashida G, Carr CE. 2011 Sound localization: Jeffress and beyond. Curr Opin Neurobiol. 21:745-51. PMID: 21646012
Ashida G, Carr CE. 2010 Effect of sampling frequency on the measurement of phase-locked action potentials. Front Neurosci. 4. pii: 172. PMID: 20953249
Kuokkanen PT, Wagner H, Ashida G, Carr CE, Kempter R. 2010 On the origin of the extracellular field potential in the nucleus laminaris of the barn owl (Tyto alba). J Neurophysiol. 104:2274-90. PMID: 20685926
Yan, K, Tang YZ, Carr CE. 2010 Calcium binding protein immunoreactivity characterizes the auditory system of Gekko gecko. J. Comp Neurol. 518:3409-26. PMID: 20589907
Carr CE, Macleod KM. 2010 Microseconds matter. PLoS Biol. 2010 Jun 29;8(6):e1000405
Schnupp, JWH and Carr CE 2009. On hearing with more than one ear: lessons from evolution. Nature Neurosci. 12:692-697
Carr CE, Soares D, Smolders J and Simon JZ. 2009. Detection of interaural time differences in the alligator. J. Neurosci. 29:7978-90.
Wagner H, Brill S, Kempter R, Carr CE 2009 Auditory responses in the barn owl's nucleus laminaris to clicks: impulse response and signal analysis of neurophonic potential. J Neurophysiol.102:1227-40.
Köppl, C. and Carr, CE. 2008. A Map of Interaural Time Differences in the Chicken's Brainstem. Biological Cybernetics 2008 98:541-59.
Carr, CE and Edds-Walton, P. 2008. Vertebrate Auditory Pathways. In: Handbook of the Senses Volume 1. Audition. Eds. Hoy, R, Dallos, P and Oertel, D (eds) Elsevier, Oxford.
Macleod KM, Carr CE. 2007. Beyond timing in the auditory brainstem: intensity coding in the avian cochlear nucleus angularis. Prog Brain Res. 165:123-33.
Macleod KM, Horiuchi TK, Carr CE. 2007 A role for short-term synaptic facilitation and depression in the processing of intensity information in the auditory brainstem. J Neurophysiol. 97:2863-74
Macleod KM, Soares, D, Carr CE. 2006 Interaural timing difference circuits in the auditory brainstem of the emu (Dromaius novaehollandiae). J. Comp Neurol. 495:185-201
Grothe B, CE Carr, J Cassedy, B Fritzsch, C Köppl 2005 Brain pathway evolution and neural processing patterns - parallel evolution? In: Evolution of the Vertebrate Auditory System Springer Handbook of Auditory Research. Ed. Manley, Popper and Fay. Springer, New York
Wagner H, Brill S, Kempter R, Carr CE. 2005 Microsecond precision of phase delay in the auditory system of the barn owl. J Neurophysiol. 94:1655-8
Macleod KM, Carr CE. 2005 Synaptic physiology in the cochlear nucleus angularis of the chick. J Neurophysiol. 93(5):2520-9.
Carr CE, Koppl C.2004 Coding interaural time differences at low best frequencies in the barn owl. J Physiol Paris. 98:99-112.
Köppl, C. and C. E. Carr. 1997 A pathway for low frequency sound in the brainstem of the barn owl. J. Comp. Neurol. 378:265-282
Carr CE, Konishi M. 1990 A Circuit for Detection of Interaural Time Differences in the Brain
Stem of the Barn Owl. J Neurosci 10: 3227-3246

Wolfgang Streeck

Nomination of Wolfgang Streeck for SDU’s Æresdoktorgrad

Nominated by: Pieter Vanhuysse, Professor, SDU, Centre for Welfare State Research Paul Marx, Associate Professor, SDU, Centre for Welfare State Research Peter Starke, Associate Professor, SDU, Centre for Welfare State Research Klaus Petersen, Professor, SDU, Centre for Welfare State Research

We write to nominate Professor Wolfgang Streeck for SDU’s Æresdoktorgrad.
Wolfgang Streeck is without doubt one of the most important contemporary European social scientists generally. His academic influence spans numerous fields and indeed disciplines. Spanning comparative political economy, historical institutionalism and economic and political sociology, Streeck’s prolific research output, which is listed below by subject matter, has been hugely influential in advancing social science knowledge on topics and research areas as varied as varieties of capitalism, production strategies, modes of corporatism, skills, trade unions, collective bargaining, institutional change, macro-socio-economic developments in Germany, European integration, and contradictions and crisis elements in various modes and models of post-war welfare capitalism.
As we point out below, Streeck has produced path-breaking theoretical innovations on why and how capitalist institutions evolve, particularly in Beyond Continuity (2005, OUP), with Kathleen Thelen and Re-forming Capitalism (2009, OUP). As an empirical researcher, social theorist, and public intellectual, Wolfgang Streeck continues to have an enormous impact on social science and public debates. As a Director of Max Planck Institute for the Study of Societies in Cologne for two decades, he has created one of the leading institutes in political economy research in all of Europe.

As a researcher, Wolfgang Streeck’s early career contributions have been mainly on collective representation, tripartism and trade union decision-making, and collective bargaining in contemporary democracies. Streeck has been an innovator as regards the study of corporatism, and how this mode of collective governance has driven many postwar European societies since the 1960s. Streeck studied the relationship between labor relations and the nature of the products and the product markets on which national producers specialized.

This early work has been a direct influence on, and driver of, what later emerged as the influential literature "varieties of capitalism," a highly influential research strand in political economy that which studied the complementarity of social and political institutions with economic strategies of firms drive a country’s economic performance in a competitive global economy.

Streeck and co-authors studied comparative capitalism through the lens of various institutions, while at the same time being a rare voice against overly functionalist explanation modes aiming to explain institutions by their consequences. Instead, Streeck proposed more historically grounded approaches. From the mid-1990s on, he added to this historical and institutional lens the notion of market governance, all the while further focusing theoretically on the concept of political-economic change and methodologically on the need to resist the static-functionalist-economistic outlook of the now-dominant paradigm in comparative political economy - varieties of capitalism.

A seminal contribution and theoretical-methodological turning point in this respect were Streeck’s two later books on change in capitalism: his 2009 monograph Re-Forming Capitalism: Institutional Change in the German Political Economy, and his co-edited volume Beyond Continuity: Institutional Change in Advanced Political Economies. These works made major contributions to the emerging field of historical institutionalism by further developing the theoretical notion of transformative gradual change, bridging the gap between adaptive-incremental and fundamental-discontinuous change. Streeck has never shied away from tackling truly big social science questions. His current research addresses the causes and consequences of the European debt crisis, arguably the biggest challenge Europe faces in decades. His book Buying Time (2014, Verso) is a lucid analysis of this challenge, uncovering the political as well as cultural and structural reasons for the current crisis. Its ability to speak to a broad public and specialists alike make this book one of the most important contributions to the Euro crisis.

Moreover, in parallel to these multiple research contributions, Streeck has also contributed to the development of an international community supportive of an ambitious and influential comparative political economy research agenda at the Max Planck Institute for the Study of Societies. From 1999-2000 he was president of the Society for the Advancement of Socio-Economics (SASE), which is one of the most lively scholarly associations in the social sciences, with annual meetings in the United States and Europe, as well as, increasingly, in Asia and Latin America. In recognition of all these achievements, Wolfgang Streeck has received various awards and prizes in a number of countries, listed below. In addition to being an editorial board member of various journals in sociology, political science and industrial relations, from 2007 to 2011, Streeck was also a hugely influential chief editor of Socio-Economic Review, which under his editorship has become a top-ten ranked journal in both sociology and political science.

For all these reasons, and to honor his outstanding academic achievements across a wide-ranging set of social science sub-disciplines, we are therefore pleased to nominate Wolfgang Streeck for SDU’s Æresdoktorgrad.

Pieter Vanhuysse, Paul Marx, Peter Starke, and Klaus Petersen Centre for Welfare State Research Department of Political Science and Public Management University of Southern Denmark

Publications Wolfgang Streeck, arranged by subject

(1) Articles in Handbooks and Encyclopedias

(2) Capitalism

(3) The Fiscal Crisis of the State

(4) Flexible Markets, Stable Societies?

(5) Institutional Change

(6) Production Systems

(7) Skills

(8) The Political Economy of Germany

(9) European Integration

(10) Corporatism and Interest Groups

(11) Organized Business

(12) Trade Unions and Industrial Relations

(13) Miscellaneous * Books

(1) Articles in Handbooks and Encyclopedias E Pluribus Unum? Varieties and Commonalities of Capitalism. In: Granovetter, Mark and Richard Swedberg, eds., 2011: The Sociology of Economic Life. 3rd edition. Boulder, Colorado: Westview, 419-455. MPIfG Discussion Paper 10/12, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2010. Institutions in History. Bringing Capitalism Back In. In: Glenn Morgan, John L. Campbell, Colin Crouch, Ove Kaj Pedersen and Richard Whitley (Ed.), The Oxford Handbook of Comparative Institutional Analysis. Oxford/New York: Oxford University Press, 2010, 659-686. Auch als MPIfG Discussion Paper 09/8, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2009. Korporatismus. In: Gosepath, Stefan, Wilfried Hinsch und Axel von Werder (Hg.), Handbuch der Politischen Philosophie und Sozialphilosophie, Bd. 1. Berlin: De Gruyter, 2008, 655-658.

Business Associations. In: Beckert, Jens, and Milan Zafirovsky, eds., 2005: International Encyclopedia of Economic Sociology. London and New York: Routledge, 33-35. Theories and Practices of Neocorporatism (with Lane Kenworthy). In: Janoski, Thomas, Robert R. Alford, Alexander M. Hicks and Mildred A. Schwartz, eds., 2005: The Handbook of Political Sociology. Cambridge: Cambridge University Press, 441-460. The Sociology of Labor Markets and Trade Unions. In: Smelser, Neil J. and Richard Swedberg, eds., 2005: The Handbook of Economic Sociology: Second Edition, Princeton: Princeton University Press, 254-283. Mitbestimmung, unternehmerische. In: Schreyögg, Georg and Axel von Werder, eds., 2004: Handwörterbuch Unternehmensführung und Organisation. Stuttgart: Schäffer-Poechel Verlag, 880-888. Trade Unions as Political Actors (with Anke Hassel). In: Addison, John T. and Claus Schnabel, eds., 2003: International Handbook of Trade Unions. Cheltenham: Edward Elgar Publishing, 335-365. Interest Group Organization (with Anke Hassel). In: Malcolm Warner, ed., 2002: International Encyclopedia of Business and Management, Second Edition. London: Thomson Learning, Vol. 4, 3182-3192. Labor Unions. In: Smelser, Neil and Paul Baltes, eds., 2001: International Encyclopedia of the Social and Behavioral Sciences. Amsterdam etc.: Elsevier, 8214-8220. Western Europe (The History of Unions in Western Europe). Encyclopedia Britannica, Macropedia, Work and Employment, 1993, 953-956. (2) Capitalism The Rise of the European Consolidation State. MPIfG Discussion Paper 15/1, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2015. Comment on Wolfgang Merkel, “Is Capitalism Compatible with Democracy?” In: Zeitschrift für Vergleichende Politikwissenschaft, published online, 7. Februar 2015. Politische Ökonomie als Soziologie: Kann das gutgehen? In: Zeitschrift für Theoretische Soziologie 1/2014, 147-166.

How Will Capitalism End? In: New Left Review 87, May/June 2014, 35-64. Deutsche Übersetzung: Wie wird der Kapitalismus enden? In: Blätter für deutsche und internationale Politik 3/2015, 99-111 (Teil I) und 4/2015, 109-120 (Teil II). Taking Crisis Seriously: Capitalism on Its Way Out. In: Stato e mercato, Nr. 100, April 2014, 45-67. The Politics of Public Debt: Neoliberalism, Capitalist Development, and the Restructuring of the State. In: German Economic Review 15, 2014, 143-165. Also as MPIfG Discussion Paper 13/7, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2013. Will Expansion Work? On Mark Blyth, Austerity: The history of a dangerous idea. In: Comparative European Politics 11, 2013, No. 6, 722-728. Moral Categories in the Financial Crisis (with Marion Fourcade, Philippe Steiner and Cornelia Woll). In: Socio-Economic Review, Vol. 11, 2013, 601-627. Auch als MaxPo Discussion Paper 13/1, Paris: Max Planck Sciences Po Center on Coping with Instability in Market Societies, 2013. Die Krise der Staatsfinanzen: Demokratieversagen? Kapitalismusversagen! In: Der moderne Staat 6, 2013, H. 1, 7-20. Auch in: Nonnenmacher, Günther und Andreas Rödder (Hg.), Kapitalismus und Demokratie: Vierte Tendenzwende-Konferenz der F.A.Z. am 15. und 16. November 2012 in Berlin. Frankfurt: F.A.Z., 2013, 14-20. * Politics in the Age of Austerity (ed., with Armin Schäfer). Cambridge: Polity Press, 2013. Introduction: Politics in the Age of Austerity (with Armin Schäfer). In: Schäfer, Armin and Wolfgang Streeck, eds., 2013: Politics in the Age of Austerity. Cambridge: Polity Press, 1-25. Public Finance and the Decline of State Capacity in Democratic Capitalism (with Daniel Mertens). In: Schäfer, Armin and Wolfgang Streeck, eds., 2013: Politics in the Age of Austerity. Cambridge: Polity Press, 26-58. The Crisis in Context: Democratic Capitalism and its Contradictions. In: Schäfer, Armin and Wolfgang Streeck, eds., 2013: Politics in the Age of Austerity. Cambridge: Polity Press, 262-286. * Gekaufte Zeit: Die vertagte Krise des demokratischen Kapitalismus. Berlin: Suhrkamp, 2013. On Fred Block, Varieties of what? Should we still be using the Concept of Capitalism? In: Julian Go (Ed.), Political Power and Social Theory, Bingley: Emerald Group Publishing Limited, Vol. 23, 2012, 311-321. Citizens as Customers: Considerations on the New Politics of Consumption. In: New Left Review 76, July/August 2012, 27-47. Wissen als Macht, Macht als Wissen: Kapitalversteher im Krisenkapitalismus. In: Merkur: Deutsche Zeitschrift für europäisches Denken 66, 2012, No. 9/10, 776-787. How to Study Contemporary Capitalism? In: European Journal of Sociology 53, 2012, No. 1, 1-28. Der öffentliche Auftrag der Soziologie. In: Leviathan 40, 2012, No. 1, 129-147. On Greta R. Krippner “Capitalizing on Crisis: The Political Origin of the Rise of Finance”, Cambridge, Harvard University Press, 2011. In: Socio-Economic Review, Vol. 10, 2012, No. 2, 408-414. The Crises of Democratic Capitalism. In: New Left Review 71, Sept/Oct 2011, 5-29. German translation: Lettre International 95, Winter 2011, 7-17. French translation: Le Monde diplomatique, Janvier 2012, 10-11. A slightly extended version: The Crisis in Context: Democratic Capitalism and its Contradictions. MPIfG Discussion Paper 11/15, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2011. Taking Capitalism Seriously: Towards an Institutional Approach to Contemporary Political Economy. In: Socio-Economic Review, Vol. 9, 2011, No. 1, 137-167. MPIfG Discussion Paper 10/15, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2010. E Pluribus Unum? Varieties and Commonalities of Capitalism. In: Granovetter, Mark and Richard Swedberg, eds., 2011: The Sociology of Economic Life. 3rd edition. Boulder, Colorado: Westview, 419-455. MPIfG Discussion Paper 10/12, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2010. Institutions in History: Bringing Capitalism Back In. In: Glenn Morgan, John L. Campbell, Colin Crouch, Ove Kaj Pedersen and Richard Whitley (Ed.), The Oxford Handbook of Comparative Institutional Analysis. Oxford/New York: Oxford University Press, 2010, 659-686. MPIfG Discussion Paper 09/8, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2009. Und wenn jetzt noch eine Krise käme? In: Frank Schirrmacher, Thomas Strobl (Hg.), Die Zukunft des Kapitalismus. Berlin: Suhrkamp, 2010, 144-148. * Re-Forming Capitalism: Institutional Change in the German Political Economy. Oxford and New York: Oxford University Press, 2009. ● On Re-Forming Capitalism: Institutional Change in the German Political Economy. Reply. In: Socio-Economic Review, Vol. 8, 2010, No. 3, 573-580. ● The fiscal crisis continues: From liberalization to consolidation. In: Comparative European Politics, Vol. 8, 2010, 505-514. Four Books On Capitalism. In: Socio-Economic Review, Vol. 7, 2009, No. 4, 741-754. Educating Capitalists: A Rejoinder to Wright and Tsakalatos. In: Socio-Economic Review, Vol. 2, No. 3, 2004, 425-483. Taking Uncertainty Seriously: Complementarity as a Moving Target. Österreichische Nationalbank Wien: Proceedings of OeNB Workshops, Vol. 1, No.1, 2004, 101-115. The Transformation of Corporate Organization in Europe: An Overview. In: Jean-Philippe Touffut, ed., 2003 : Institutions, Innovation and Growth. Cheltenham: Edward Elgar Publishing, 4-44. French: La transformation de‘l organisation de l‘enterprise en Europe: une vue d‘esemble. In: Robert M. Solow, ed., 2001 : Institutions et croissance: les chances d‘un modele economique europeen. Paris: Bibliotheque Albin Michel Economie, 175-230. * The End of Diversity? Prospects for German and Japanese Capitalism (ed., with Kozo Yamamura). Ithaca, NY: Cornell University Press, 2003. Introduction: Convergence or Diversity? Stability and Change in German and Japanese Capitalism (with Kozo Yamamura). In: Yamamura, Kozo and Wolfgang Streeck, eds., 2003: The End of Diversity? Prospects for German and Japanese Capitalism. Ithaca, NY: Cornell University Press, 1-50. * The Origins of Nonliberal Capitalism: Germany and Japan (ed., with Kozo Yamamura). Ithaca and London: Cornell University Press, 2001. Introduction: Explorations into the Origins of Nonliberal Capitalism in Germany and Japan. In: Streeck, Wolfgang and Kozo Yamamura, eds., 2001: The Origins of Nonliberal Capitalism: Germany and Japan. Ithaca and London: Cornell University Press, 1-38.
Entstaatliche Wirtschaft, vermarktete Demokratie? Spekulationen über demokratische Beteiligung in expandierenden Märkten. In: Hans Georg Zilian, ed., 2000: Politische Teilhabe und politische Entfremdung im Zeitalter der Internationalisierung. Steirische Winterakademie für Gesellschaftsanalyse. Graz and Wien: Nausner und Nausner, 53-68. * Internationale Wirtschaft, nationale Demokratie: Herausforderungen für die Demokratietheorie (ed.). Schriften des Max-Planck-Instituts für Gesellschaftsforschung, Köln (Sonderband). Frankfurt am Main: Campus, 1998. Einleitung: Internationale Wirtschaft, nationale Demokratie? In: Streeck, Wolfgang, (ed.), 1998: Internationale Wirtschaft, nationale Demokratie: Herausforderungen für die Demokratietheorie. Schriften des Max-Planck-Instituts für Gesellschaftsforschung, Köln (Sonderband). Frankfurt am Main: Campus, 1998, 11-58. * Political Economy of Modern Capitalism: Mapping Convergence and Diversity (ed., with Colin Crouch). London: Sage, 1997. French: Les capitalismes en Europe. Paris: Editions La Découverte, 1996. Japanese Version (translated by Toshio Yamada): Gendai no Shihonshugi-sei: guroobarizumu to iyousei. Nagoya: NTT Shuppan, 2001. Introduction: The Future of Capitalist Diversity (with Colin Crouch). In: Crouch, Colin and Wolfgang Streeck, eds., 1997: Political Economy of Modern Capitalism: Mapping Convergence and Diversity, London: Sage, 1-18. German Capitalism: Does it Exist? Can it Survive? In: Crouch, Colin and Wolfgang Streeck, eds., 1997: Political Economy of Modern Capitalism: Mapping Convergence and Diversity. London: Sage, 33-54. Also in: New Political Economy, Vol. 2, No. 2, 1997, 237-256. French: Le capitalisme allemand: Existe-t-il? A-t-il des chances de survivre? In: Crouch, Colin and Wolfgang Streeck, eds., 1996: Les capitalismes en Europe, 47-75. Expanded Version: The German Social Market Economy: External Competitiveness and Internal Cohesion. In: Lee-Jay Cho and Yoon Hyung Kim, eds., 1998: Ten Paradigms of Market Economies and Land Systems. Korea Research Institute for Human Settlements, 59-98. (3) The Fiscal Crisis of the State The Rise of the European Consolidation State. MPIfG Discussion Paper 15/1, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2015. The Politics of Public Debt: Neoliberalism, Capitalist Development, and the Restructuring of the State. In: German Economic Review 15, 2014, 143-165. Also as MPIfG Discussion Paper 13/7, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2013. Will Expansion Work? On Mark Blyth, Austerity: The history of a dangerous idea. In: Comparative European Politics 11, 2013, No. 6, 722-728. Moral Categories in the Financial Crisis (with Marion Fourcade, Philippe Steiner and Cornelia Woll). In: Socio-Economic Review, Vol. 11, 2013, 601-627. Auch als MaxPo Discussion Paper 13/1, Paris: Max Planck Sciences Po Center on Coping with Instability in Market Societies, 2013. Die Krise der Staatsfinanzen: Demokratieversagen? Kapitalismusversagen! In: Der moderne Staat 6, 2013, H. 1, 7-20. Auch in: Nonnenmacher, Günther und Andreas Rödder (Hg.), Kapitalismus und Demokratie: Vierte Tendenzwende-Konferenz der F.A.Z. am 15. und 16. November 2012 in Berlin. Frankfurt: F.A.Z., 2013, 14-20. Nach der Krise ist in der Krise: Aussichten auf die Innenpolitik des europäischen Binnenmarktstaats. In: Leviathan 41, 2013, H. 2, 324-342. * Politics in the Age of Austerity (ed., with Armin Schäfer). Cambridge: Polity Press, 2013. Introduction: Politics in the Age of Austerity (with Armin Schäfer). In: Schäfer, Armin and Wolfgang Streeck, eds., 2013: Politics in the Age of Austerity. Cambridge: Polity Press, 1-25. Public Finance and the Decline of State Capacity in Democratic Capitalism (with Daniel Mertens). In: Schäfer, Armin and Wolfgang Streeck, eds., 2013: Politics in the Age of Austerity. Cambridge: Polity Press, 26-58. The Crisis in Context: Democratic Capitalism and its Contradictions. In: Schäfer, Armin and Wolfgang Streeck, eds., 2013: Politics in the Age of Austerity. Cambridge: Polity Press, 262-286. * Gekaufte Zeit: Die vertagte Krise des demokratischen Kapitalismus. Berlin: Suhrkamp, 2013. Italian translation: Tempo guadagnato: La crisi rinviata del capitalismo democratico. Mailand. Giangiacomo Feltrinelli, 2013. Wissen als Macht, Macht als Wissen: Kapitalversteher im Krisenkapitalismus. In: Merkur: Deutsche Zeitschrift für europäisches Denken 66, 2012, No. 9/10, 776-787. On Greta R. Krippner “Capitalizing on Crisis: The Political Origin of the Rise of Finance”, Cambridge, Harvard University Press, 2011. In: Socio-Economic Review, Vol. 10, 2012, No. 2, 408-414.
Markets and Peoples: Demokratic Capitalism and European Integration. In: New Left Review 73, Jan/Feb 2012, 63-71. Französische Übersetzung/French translation: Les marchés et les peuples: capitalisme démocratique et intégration européenne. In: Durand, Cédric (Ed.): En finir avec l’Europe. Paris: La Fabrique éditions, 2013, 59-70. Germany. In: European Societies, 14, 2012, No. 1, 136-138. Die Fiskalkrise und die Einheit Europas (mit Jens Beckert). In: Aus Politik und Zeitgeschichte, 4/2012, 7-17. The Crises of Democratic Capitalism. In: New Left Review 71, Sept/Oct 2011, 5-29. German translation: Lettre International 95, Winter 2011, 7-17. French translation: Le Monde diplomatique, Janvier 2012, 10-11. A slightly extended version: The Crisis in Context: Democratic Capitalism and its Contradictions. MPIfG Discussion Paper 11/15, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2011. Fiscal Austerity and Public Investment: Is the Possible the Enemy of the Necessary? (with Daniel Mertens). MPIfG Discussion Paper 11/12, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2011. Politik im Defizit: Austerität als fiskalpolitisches Regime (mit Daniel Mertens). In: Der moderne Staat 3, 2010, No. 1, 7–29. MPIfG Discussion Paper 10/5, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2010. Noch so ein Sieg, und wir sind verloren. Der Nationalstaat nach der Finanzkrise. In: Leviathan 38, 2010, No. 2, 159-173. An Index of Fiscal Democracy (mit Daniel Mertens). MPIfG Working Paper 10/3, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2010. Politik im Defizit (mit Daniel Mertens). In: Berliner Republik 4/2010, 14-17. The fiscal crisis continues: From liberalization to consolidation. In: Comparative European Politics, Vol. 8, 2010, 505-514. Endgame? The Fiscal Crisis of the German State. In: Miskimmon, Alister, William E. Paterson und James Sloam (Hg.), Germany‘s Gathering Crisis: The 2005 Federal Election and the Grand Coalition. Basingstoke: Palgrave Macmillan, 2009, 38-63. Siehe auch MPIfG Discussion Paper 07/7. Fino-gioco? La crisi fiscale dello stato tedesco. In: Stato e mercato, Nr. 80, August 2007, 177-207. Endgame? The Fiscal Crisis of the German State. MPIfG Discussion Paper 07/7, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2007. A State of Exhaustion: A Comment on the German Election of 18 September. In: The Political Quaterly, Vol. 77, No. 1, January-March 2006, 79-88. (4) Flexible Markets, Stable Societies? * Gekaufte Zeit: Die vertagte Krise des demokratischen Kapitalismus. Berlin: Suhrkamp, 2013. Itaian translation: Tempo guadagnato: La crisi rinviata del capitalismo democratico. Mailand. Giangiacomo Feltrinelli, 2013. Flexible Employment, Flexible Families, and the Socialization of Reproduction. In: Coulmas, Florian and Ralph Lützeler, eds., 2011: Imploding Populations in Japan and Germany: A Comparison. Leiden: Brill, 63-95. Extended Version as MPIfG Working Paper 09/13, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2009. Volksheim oder Shopping Mall? Die Reproduktion der Gesellschaft im Dreieck von Markt, Sozialstruktur und Politik. In: WestEnd. Neue Zeitschrift für Sozialforschung, Jg. 8, 2011, Heft 2, 43-64. Flexible Markets, Stable Societies? MPIfG Working Paper 08/6, Max-Planck-Institut für Gesellschaftsforschung, Köln. Auch in: Soeffner, Hans-Georg (Hg.), Unsichere Zeiten: Herausforderungen gesellschaftlicher Transformationen. Verhandlungen des 34. Kongresses der Deutschen Gesellschaft für Soziologie in Jena 2008, Bd. 1. Wiesbaden: VS Verlag für Sozialwissenschaften, 2010, 445-458. Sowie in: Herbert Obinger, Elmar Rieger (Hg.), Wohlfahrtsstaatlichkeit in entwickelten Demokratien: Herausforderungen, Reformen und Perspektiven: Festschrift für Stephan Leibfried. Schriften des Zentrums für Sozialpolitik, Bd. 20. Frankfurt/New York: Campus, 2009, 137-150. Industrial Relations Today: Reining in Flexibility. MPIfG Working Paper 08/3, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2008. Also in: Economics, Management, and Financial Markets, Vol. 4, 2009, No. 3, 15-36. (5) Institutional Change Von der Gesellschaftssteuerung zur sozialen Kontrolle: Rückblick auf ein halbes Jahrhundert Soziologie in Theorie und Praxis. In: Blätter für deutsche und internationale Politik 1/2015, 63-80. Die Fiskalkrise und die Einheit Europas (mit Jens Beckert). In: Aus Politik und Zeitgeschichte, 4/2012, 7-17. Institutions in History: Bringing Capitalism Back In. In: Glenn Morgan, John L. Campbell, Colin Crouch, Ove Kaj Pedersen and Richard Whitley (Ed.), The Oxford Handbook of Comparative Institutional Analysis. Oxford/New York: Oxford University Press, 2010, 659-686. MPIfG Discussion Paper 09/8, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2009. * Re-Forming Capitalism: Institutional Change in the German Political Economy. Oxford and New York: Oxford University Press, 2009. * Beyond Continuity: Institutional Change in Advanced Political Economies (ed., with Kathleen Thelen). Oxford and New York: Oxford University Press, 2005, xviii + 290. Introduction: Institutional Change in Advanced Political Economies (with Kathleen Thelen). In: Streeck, Wolfgang and Kathleen Thelen, eds., 2005: Beyond Continuity: Institutional Change in Advanced Political Economies. Oxford and New York: Oxford University Press, 1-39. Also as: Institutional Change in Advanced Political Economies (with Kathleen Thelen). In: Bob Hancké (ed.), Debating Varieties of Capitalism: A Reader. Oxford: Oxford University Press, 2009, 95-131. Rejoinder: On Terminology, Functionalism (historical), Institutionalism and Liberalization. In: Socio-Economic Review, Vol. 3, 2005, 577-587. Dialogue on Instutional Complementarity and Political Economy (with Colin Crouch, Robert Boyer, Bruno Amable, Peter A. Hall and Gregory Jackson). Socio-Economic Review, Vol. 3, No. 2, 2005, 359-382. (6) Production Systems Skills and Politics: General and Specific. In: Busemeyer, Marius R. and Christine Trampusch, eds., 2012: The Political Economy of Collective Skill Formation. Oxford: Oxford University Press, 317-352. Also as MPIfG Discussion Paper 11/1, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2011. On Suzanne Berger, How We Compete: What Companies Around the World Are Doing to Make it in Today‘s Global Economy, New York, Doubleday, 2005. Panel at the SASE 2008 Annual Meeting, San José, Costa Rica (with Kathleen Thelen, Joshua Whitford, Jonathan Zeitlin and Suzanne Berger). In: Socio-Economic Review, Vol. 7, 2009, No. 3, 505-533.

Rejoinder: On Terminology, Functionalism (historical), Institutionalism and Liberalization. In: Socio-Economic Review, Vol. 3, 2005, 577-587. Dialogue on Instutional Complementarity and Political Economy (with Colin Crouch, Robert Boyer, Bruno Amable, Peter A. Hall and Gregory Jackson). Socio-Economic Review, Vol. 3, No. 2, 2005, 359-382. Beneficial Constraints: On the Economic Limits of Rational Voluntarism, in: Hollingsworth, J. Rogers and Robert Boyer, eds., 1997: Contemporary Capitalism: The Embeddedness of Institutions. Cambridge: Cambridge University Press, 197-219. Italian: Vincoli benefici: sui limiti economici del attore razionale. Stato e mercato, No. 41, 1994, 185-213. Lean Production in the German Automobile Industry? A Test Case for Convergence Theory. In: Berger, Suzanne and Ronald Dore, eds., 1996: National Diversity and Global Capitalism. Ithaca: Cornell University Press, 138-170. * Governing Capitalist Economies: Performance and Control of Economic Sectors (ed., with J. Rogers Hollingsworth and Philippe C. Schmitter), New York and Oxford: Oxford University Press, 1994. Capitalism, Sectors, Institutions and Performance (with J. Rogers Hollingsworth and Philippe C. Schmitter). In: J. Rogers Hollingsworth, Philippe C. Schmitter and Wolfgang Streeck, eds., 1994: Governing Capitalist Economies: Performance and Control of Economic Sectors. New York and Oxford: Oxford University Press, 3-16. Countries and Sectors: Concluding Remarks on Performance, Convergence and Competitiveness (with J. Rogers Hollingsworth). In: Hollingsworth, J. Rogers, Philippe C. Schmitter and Wolfgang Streeck, eds., 1994: Governing Capitalist Economies: Performance and Control of Economic Sectors. New York and Oxford: Oxford University Press, 270-300. * Social Institutions and Economic Performance: Studies of Industrial Relations in Advanced Capitalist Economies. London and Beverly Hills: Sage, 1992. Successful Adjustment to Turbulent Markets: The Automobile Industry. In: Katzenstein, Peter J., ed., 1989: Industry and Politics in West Germany: Toward the Third Republic. Ithaca and London: Cornell University Press, 113-156. * Beyond Keynesianism: The Socio-Economics of Production and Employment (ed., with Egon Matzner). London: Edward Elgar, 1991. Paperback 1994.

On the Institutional Conditions of Diversified Quality Production. In: Matzner, Egon and Wolfgang Streeck, eds., 1991: Beyond Keynesianism: The Socio-Economics of Production and Employment. London: Edward Elgar, 21-61. (7) Skills Skills and Politics: General and Specific. In: Busemeyer, Marius R. and Christine Trampusch, eds., 2012: The Political Economy of Collective Skill Formation. Oxford: Oxford University Press, 317-352. Also as MPIfG Discussion Paper 11/1, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2011. Training and the New Industrial Relations: A Strategic Role for Unions? In: Regini, Marino, ed., 1992: The Future of Labour Movements. London: Sage, 250-269. Also in: Sleigh, Steven R., ed., 1993: Economic Restructuring and Emerging Patterns of Industrial Relations; Kalamazoo, Michigan: W. E. Upjohn Institute for Employment Research, 167-189. Earlier Version: Industrial Restructuring and Vocational Training: A Strategic Role for Unions? In: Dercksen, Willem J., ed., 1990: The Future of Industrial Relations in Europe: Proceedings of a Conference in Honour of Prof. Albeda. Den Haag: Netherlands Scientific Council for Government Policy, 133-142. Organised Interests and Vocational Training in the West German Construction Industry (with Josef Hilbert). In: Rainbird, Helen and Gerd Syben, eds., 1991: Restructuring a Traditional Industry: Construction Employment and Skills in Europe. Oxford: Berg Publishers, 241-260. Skills and the Limits of Neo-Liberalism: The Enterprise of the Future as a Place of Learning. Work, Employment and Society, Vol. 3, 1989, 90-104. Italian in: Paolo Ceri, ed., 1988: Impresa e lavoro in trasformazione: Italia—Europa. Milano: Società editrice Il Mulino, 71-109. * Steuerung und Regulierung der beruflichen Bildung: Die Rolle der Sozialpartner in der Ausbildung und beruflichen Weiterbildung in der BR Deutschland (with Josef Hilbert, Karl-Heinz van Kevelaer, Friederike Maier and Hajo Weber), Berlin: Edition Sigma, 1987. English: The Role of the Social Partners in Vocational Training and Further Training in the Federal Republic of Germany, Berlin: European Centre for the Development of Vocational Training (CEDEFOP), 1987. (8) The Political Economy of Germany Germany. In: European Societies, 14, 2012, No. 1, 136-138. ● On Re-Forming Capitalism: Institutional Change in the German Political Economy. Reply. In: Socio-Economic Review, Vol. 8, 2010, No. 3, 573-580. ● The fiscal crisis continues: From liberalization to consolidation. In: Comparative European Politics, Vol. 8, 2010, 505-514. * Re-Forming Capitalism: Institutional Change in the German Political Economy. Oxford and New York: Oxford University Press, 2009. Nach dem Korporatismus: Neue Eliten, neue Konflikte. In: Herfried Münkler, Grit Straßenberger, Matthias Bohlender (Hg.), Deutschlands Eliten im Wandel. Frankfurt und New York: Campus, 2006, 149-175. Auch in: Berlin-Brandenburgische Akademie der Wissenschaften: Berichte und Abhandlungen, Band 11. Akademie-Verlag 2006, 265-290. Economic Reform and the Political Economy of the German Welfare State (with Christine Trampusch). In: German Politics, Vol. 14, No. 2, 174-195. Also in: Dyson, Kenneth and Stephen Padgett, eds., 2005: The Politics of Economic Reform in Germany. Oxford: Routledge. Industrial Relations: From State Weakness as Strength to State Weakness as Weakness: Welfare Corporatism and the Private Use of the Public Interest. In: Green, Simon and William E. Paterson, eds., 2005: Governance in Contemporary Germany: The Semisovereign State Revisited. Cambridge: Cambridge University Press, 138-164. Italienische Übersetzung: La debolezza dello stato da risorsa a vincolo: il corporativismo dello stato sociale e l'uso privato del pubblico interesse. Stato e mercato, No. 70, 2004, 3-36. Mitbestimmung, unternehmerische. In: Schreyögg, Georg and Axel von Werder, eds., 2004: Handwörterbuch Unternehmensführung und Organisation. Stuttgart: Schäffer-Poechel Verlag, 880-888. * Germany: Beyond the Stable State (ed., with Herbert Kitschelt). Special Issue of West European Politics, Vol. 26, No. 4. London: Frank Cass, 2003. Book Version: London and Portland: Frank Cass, 2003. From Stability to Stagnation: Germany at the Beginning of the Twenty-First Century (with Herbert Kitschelt).

Introduction: Kitschelt, Herbert and Wolfgang Streeck, eds., 2003: Germany: Beyond the Stable State. London: Frank Cass, 1-34. The Crumbling Pillars of Social Partnership (with Anke Hassel). In: Kitschelt, Herbert and Wolfgang Streeck, eds., 2003: Germany: Beyond the Stable State. London: Frank Cass, 101-124. * Alle Macht dem Markt? Fallstudien zur Abwicklung der Deutschland AG (ed., with Martin Höpner). Schriften des Max-Planck-Instituts für Gesellschaftsforschung Köln, Vol. 47. Frankfurt and New York: Campus, 2003. Einleitung: Alle Macht dem Markt? (with Martin Höpner). In: Streeck, Wolfgang and Martin Höpner, eds., 2003: Alle Macht dem Markt? Frankfurt am Main: Campus, 11-59. * The End of Diversity? Prospects for German and Japanese Capitalism (ed., with Kozo Yamamura). Ithaca, NY: Cornell University Press, 2003. Introduction: Convergence or Diversity? Stability and Change in German and Japanese Capitalism (with Kozo Yamamura). In: Yamamura, Kozo and Wolfgang Streeck, eds., 2003: The End of Diversity? Prospects for German and Japanese Capitalism. Ithaca, NY: Cornell University Press, 1-50. * The Origins of Nonliberal Capitalism: Germany and Japan (ed., with Kozo Yamamura). Ithaca and London: Cornell University Press, 2001. Introduction: Explorations into the Origins of Nonliberal Capitalism in Germany and Japan. In: Streeck, Wolfgang and Kozo Yamamura, eds., 2001: The Origins of Nonliberal Capitalism: Germany and Japan. Ithaca and London: Cornell University Press, 1-38. High Equality, Low Activity: The Contribution of the Social Wefare System to the Stability of the German Collective Bargaining Regime. Review Symposium on Harry C. Katz and Owen Darbishire, Converging Divergences: Worldwide Changes in Employment Systems. Industrial and Labor Relations Review, Vol. 54, April 2001, No. 3, 698-706. Die Gewerkschaften im Bündnis für Arbeit. In: Abel, Jörg and Hans-Joachim Sperling, eds. , 2001: Umbrüche und Kontinuitäten: Perspektiven nationaler und internationaler Arbeitsbeziehungen. Walther Müller-Jentsch zum 65. Geburtstag. München: Rainer Hampp Verlag, 271-279. Excerpts in: „Bewegte Zeiten - Arbeit an der Zukunft", Dokumentation der Wissenschaftlichen Konferenz des DGB, "50 Jahre DGB", am 11. und 12. Oktober 1999 in München. Gewerkschaftliche Monatshefte, Vol. 50, No. 12, 1999, 797-802.

* Benchmarking Deutschland: Arbeitsmarkt und Beschäftigung (with others). Bericht der Arbeitsgruppe Benchmarking und der Bertelsmann Stiftung. Berlin and Heidelberg: Springer, 2001. Tarifautonomie und Politik: Von der Konzertierten Aktion zum Bündnis für Arbeit. In: Gesamtverband der metallindustriellen Arbeitgeberverbände, ed., 2001: Die deutschen Arbeitsbeziehungen am Anfang des 21. Jahrhunderts. Wissenschaftliches Kolloquium aus Anlaß des Ausscheidens von Dr. Werner Stumpfe als Präsident von Gesamtmetall. Köln: Deutscher Institutsverlag, 76-102. Ist die Einrichtung eines "Niedriglohnsektors" die letzte Beschäftigungschance für gering qualifizierte Arbeitnehmer? In: Otto Brenner Stiftung, ed. , 2000: Niedriglohnsektor und Lohnsubventionen im Spiegel des Arbeits- und Sozialrechts. Frankfurt am Main: Bund Verlag, 11-23. Von Nutzen und Nutzung des Korporatismus in einer Gesellschaft im Wandel. In: Bührer, Werner and Edgar Grande, eds. , 2000: Unternehmerverbände und Staat in Deutschland. Baden-Baden: Nomos Verlag, 53-61. * Die wirtschaftlichen Folgen der Mitbestimmung (ed., with Bernd Frick and Norbert Kluge). Kommission Mitbestimmung, Bertelsmann Stiftung/Hans-Böckler-Stiftung. Frankfurt am Main: Campus, 1999. * Mitbestimmung in Deutschland: Tradition und Effizienz (ed., with Norbert Kluge). Kommission Mitbestimmung, Bertelsmann Stiftung/Hans-Böckler-Stiftung. Frankfurt am Main: Campus, 1999. An Arbeit fehlt es nicht (with Rolf G. Heinze). Der Spiegel, 19/1999, 38-45. Pay Restraint without Incomes Policy: Constitutionalized Monetarism and Industrial Unionism in Germany. In: Boyer, Robert, Ronald Dore and Zoe Mars, eds., 1994: The Return to Incomes Policy. London: Francis Pinter, 118-140. French in: Boyer, Robert and Ronald Dore, eds., 1994 : Les politiques des revenus en Europe. Paris: Editions La Découverte, 147-164. * Industrial Relations in West Germany: The Case of the Car Industry. London: Heinemann, New York: St. Martin's Press, 1984. Neo-Corporatist Industrial Relations and the Economic Crisis in West Germany. In: John Goldthorpe, ed., 1984: Order and Conflict in Contemporary Capitalism: Studies in the Political Economy of West European Nations. Oxford: Clarendon Press, 1984, 291-314. Italian in: Carrieri, Mimmo and Paolo Perulli, eds., 1985: Il teorema sindacale: Flessibilita e competizione nelle relazioni industriali. Bologna: Società Editrice Il Mulino, 185-228.

Co-Determination: The Fourth Decade. In: Wilpert, Bernhard and Arndt Sorge, eds., 1984: International Perspectives on Organizational Democracy. International Yearbook of Organizational Democracy, Vol. II. London: John Wiley & Sons, 391-422. Between Pluralism and Corporatism. German Business Associations and the State. Journal of Public Policy, Vol. 3, 1983, 265-284. (9) European Integration The Rise of the European Consolidation State. MPIfG Discussion Paper 15/1, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2015. Comment on Wolfgang Merkel, “Is Capitalism Compatible with Democracy?” In: Zeitschrift für Vergleichende Politikwissenschaft, published online, 7. Februar 2015. Monetary Disunion: The Domestic Politics of Euroland (mit Lea Elsässer). MPIfG Discussion Paper 14/17, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2014. Aus der Krise nach “Europa”? Vergangenheit und Zukunft in Geschichte und politischer Ökonomie. In: Journal of Modern European History 12, 2014, No. 3, 299-316. Small-State Nostalgia? The Currency Union, Germany, and Europe: A Reply to Jürgen Habermas. In: Constellations Vol. 21, 2014, No. 2, xxx-xxx. Translation of “Vom DM-Nationalismus zum Euro-Patriotismus? Ein Replik auf Jürgen Habermas“. In: Blätter für deutsche und internationale Politik 9/2013, 75-92. Vom DM-Nationalismus zum Euro-Patriotismus? Eine Replik auf Jürgen Habermas. In: Blätter für deutsche und internationale Politik 9/2013, 75-92. Nach der Krise ist in der Krise: Aussichten auf die Innenpolitik des europäischen Binnenmarktstaats. In: Leviathan 41, 2013, H. 2, 324-342. * Gekaufte Zeit: Die vertagte Krise des demokratischen Kapitalismus. Berlin: Suhrkamp, 2013. Auf den Ruinen der Alten Welt: Von der Demokratie zur Marktgesellschaft. In: Blätter für deutsche und

internationale Politik 12/2012, 61-72. Markets and Peoples: Demokratic Capitalism and European Integration. In: New Left Review 73, Jan/Feb 2012, 63-71. Französische Übersetzung/French translation: Les marchés et les peuples: capitalisme démocratique et intégration européenne. In: Durand, Cédric (Ed.): En finir avec l’Europe. Paris: La Fabrique éditions, 2013, 59-70. Germany. In: European Societies, 14, 2012, No. 1, 136-138. Die Fiskalkrise und die Einheit Europas (mit Jens Beckert). In: Aus Politik und Zeitschichte, 4/2012, 7-17. On Neil Fligstein, Euroclash: The EU, European Identity and the Future of Europe, Oxford, Oxford University Press, 2008 (with Colin Hay and George Ross). In: Socio-Economic Review, Vol. 7, 2009, No. 3, 535-552. Korporatismus in der Europäischen Union (mit Armin Schäfer). In: Martin Höpner, Armin Schäfer (Hg.), Die Politische Ökonomie der europäischen Integration. Schriften aus dem Max-Planck-Institut für Gesellschaftsforschung, Bd. 61. Frankfurt am Main: Campus, 2008, 203-240. International Competition, Supranational Integration, National Solidarity: The Emerging Constitution of „Social Europe”. In: Kohli, Martin and Mojca Novak, eds., 2001: Will Europe Work? Integration, Employment and the Social Order. London: Routledge, 21-34. Europäische? Sozialpolitik? Introduction: Werner Eichhorst, Europäische Sozialpolitik zwischen nationaler Autonomie und Marktfreiheit: Die Entsendung von Arbeitnehmern in der EU. Frankfurt am Main: Campus, 2000, 19-35. Competitive Solidarity: Rethinking the "European Social Model". In: Hinrichs, Karl, Herbert Kitschelt, Helmut Wiesenthal, eds. ,2000: Kontingenz und Krise: Institutionenpolitik in kapitalistischen und postsozialistischen Gesellschaften. Frankfurt am Main: Campus, 245-261. Italian: Il modello sociale europeo: dalla redistribuzione alle solidarieta competitiva. Stato e mercato, No. 58, 2000, 3-24. Reprint in: Welfare States: Construction, Deconstruction, Reconstruction. Ed. by Stephan Leibfried and Steffen Mau. Vol. II: Varieties and Transformations. Cheltenham: Edward Elgar Publishing, 2008, 549-565. The Internationalization of Industrial Relations in Europe: Prospects and Problems. Politics and Society, Vol. 26, No. 4, 1998, 429-459. Gewerkschaften zwischen Nationalstaat und Europäischer Union. WSI-Mitteilungen, Vol. 51, January 1998, 1-4.

Also in: Messner, Dirk , ed., 1998: Die Zukunft des Staates und der Politik. Möglichkeiten und Grenzen politischer Steuerung in der Weltgesellschaft. Bonn: J.H.W. Dietz Nachfolger, 1998, 218-246. Also as: Die Ent-Zivilisierung des Kapitalismus: Gewerkschaften zwischen Nationalstaat und Europäischer Integration. Internationale Politik und Gesellschaft, Vol. 4, 1996, 357-367 Neither European Nor Works Councils: A Reply. Economic and Industrial Democracy, Vol. 18, No. 2, 1997, 325-337. Industrial Citizenship under Regime Competition: The Case of the European Works Councils. Journal of European Public Policy, Vol. 4, No. 4, 1997, 643-664. Italian: I diritti di cittadinanza in un regime di competizione: il caso dei comitati aziendali europei. Inchiesta, No. 120 (Yuro Kazepov and Giovanna Procacci, eds., La cittadinanza in discussione, Vol. 28, April-Juni 1998, 14-21). * Governance in the European Union (with Gary Marks, Fritz W. Scharpf and Philippe C. Schmitter). London: Sage, 1996. Public Power Beyond the Nation-State: The Case of the European Community. In: Boyer, Robert and Daniel Drache, eds., 1996: The Future of Nations and the Limits of Markets. Toronto: McGill-Queen's University Press, 299-315. German: Öffentliche Gewalt jenseits des Nationalstaats? Das Beispiel der Europäischen Gemeinschaft. In: Fricke, Werner, ed., 1997: Jahrbuch Arbeit und Technik, Bonn: J. H. W. Dietz Nachf., 311-325. Spanish: Ciudadanía Bajo Régimen de Competencia. El Caso de los "Comités de Empresa Europeos". In: García, Soledad and Steven Lukes, eds., 1999: Ciudadanía: justicia social, identidad y participación, Madrid: Siglo XXI de España Editores, 45-89. The European Community: Between Mandatory Consultation and Voluntary Information (with Sigurt Vitols). In: Rogers, Joel and Wolfgang Streeck, eds., 1995: Works Councils: Consultation, Representation, Cooperation in Industrial Relations, Chicago: University of Chicago Press, 243-281. Neo-Voluntarism: A New European Social Policy Regime? European Law Journal, Vol. 1, No. 1, 1995, 31-59 From Market-Making to State-Building? Reflections on the Political Economy of European Social Policy. In: Leibfried, Stephan and Paul Pierson, eds., 1995: European Social Policy: Between Fragmentation and Integration. Washington, D.C.: The Brookings Institution, 389-431. German: Vom Binnenmarkt zum Bundesstaat? Überlegungen zur politischen Ökonomie der europäischen Sozialpolitik. In: Leibfried, Stefan and Paul Pierson, eds., 1997: Standort Europa: Europäische Sozialpolitik. Frankfurt am Main: Suhrkamp, 396-421.

Politikverflechtung und Entscheidungslücke: Zum Verhältnis von zwischenstaatlichen Beziehungen und sozialen Interessen im europäischen Binnenmarkt. In: Ronald Schettkat, Karlheinz Bentele, Bernd Reissert (Hg.), 1995: Reformfähigkeit von Industriegesellschaften: Festschrift für Fritz W. Scharpf. Frankfurt am Main: Campus, 101-130. European Social Policy after Maastricht: The 'Social Dialogue' and 'Subsidiarity'. Economic and Industrial Democracy, Vol. 15, 1994, 151-177. Swedish: Europeisk Socialpolitik efter Maastricht: Social Dialog och Subsidiaritet. Research Report, No. 2, Arbetslivscentrum (The Swedish Center for Working Life), 1993 * Public Interest and Market Pressures: Problems Posed by Europe 1992 (with David Mayes and Wolfgang Hager). London: MacMillan, New York: St. Martin's Press, 1993. National Diversity, Regime Competition and Institutional Deadlock: Problems in Forming a European Industrial Relations System. Journal of Public Policy, Vol. 12, 1992, 301-330. Also in: Economic and Political Changes in Europe: Implications on Industrial Relations. 3rd European Regional Congress of the International Industrial Relations Association. Bari: Cacucci Editore, 1993, 27-62. Italian: Le relazioni industriali nell' Europa che cambia. Industria e sindacato, XXXIV, 1992, 1-20. From National Corporatism to Transnational Pluralism: Organized Interests in the Single European Market (with Philippe C. Schmitter). Politics and Society, Vol. 19, No. 2, 1991, 133-164. Slightly extended Version in: Eichener, Volker and Helmut Voelzkow, eds. , 1994: Europäische Integration und verbandliche Interessenvermittlung. Marburg: Metropolis Verlag, 181-215. Republished in: Hay, Colin and Bob Jessop, eds., 1995: Beyond the State? New Directions in State Theory. London: MacMillan. And in: Gabaglio, Emilio and Reiner Hoffmann, eds., 1998: The ETUC in the Mirror of Industrial Relations Research. Brussels: European Trade Institute, 131-170. More Uncertainties: West German Unions Facing 1992. Industrial Relations, Vol. 30, 1991, 317-349. Italian: Ancora incertezze: i sindacati tedeschi e il 1992. Giornale di diritto del lavoro e di relazioni industriali, Vol. 51, 1991, 513-550. Also in: Goetz, Klaus H., ed., 1996: Germany. Volume II, The International Library of Politics and Comparative Government, Aldershot: Dartmouth, 351-384. La dimensione sociale del mercato unico europeo: verso un' economia non regolata? Stato e mercato 1990, 29-68

(10) Corporatism and Interest Groups Korporatismus in der Europäischen Union (mit Armin Schäfer). In: Martin Höpner, Armin Schäfer (Hg.), Die Politische Ökonomie der europäischen Integration. Schriften aus dem Max-Planck-Institut für Gesellschaftsforschung, Bd. 61. Frankfurt am Main: Campus, 2008, 203-240. Nach dem Korporatismus: Neue Eliten, neue Konflikte. In: Herfried Münkler, Grit Straßenberger, Matthias Bohlender (Hg.), Deutschlands Eliten im Wandel. Frankfurt und New York: Campus, 2006, 149-175. Auch in: Berlin-Brandenburgische Akademie der Wissenschaften: Berichte und Abhandlungen, Band 11. Akademie-Verlag 2006, 265-290. * Crouch, Colin and Wolfgang Streeck, eds., 2006: The Diversity of Democracy: Corporatism, Social Order and Political Conflict. London: Edward Elgar. The Study of Organized Interests: Before ‘The Century‘ and After. In: Crouch, Colin and Wolfgang Streeck, eds.: The Diversity of Democracy: Corporatism, Social Order and Political Conflict. London: Edward Elgar, 2006, 3-45. Theories and Practices of Neocorporatism (with Lane Kenworthy). In: Janoski, Thomas, Robert R. Alford, Alexander M. Hicks and Mildred A. Schwartz, eds., 2005: The Handbook of Political Sociology. Cambridge: Cambridge University Press, 441-460. http://www.mpifg.de/people No Longer the Century of Corporatism. Das Ende des "Bündnisses für Arbeit". MPIfG Working Paper 03/4, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2003. Interest Group Organization (with Anke Hassel). In: Malcolm Warner, ed., 2002: International Encyclopedia of Business and Management, Second Edition. London: Thomson Learning, Vol. 4, 3182-3192. http://www.mpifg.de/people Von Nutzen und Nutzung des Korporatismus in einer Gesellschaft im Wandel. In: Bührer, Werner and Edgar Grande, eds. , 2000: Unternehmerverbände und Staat in Deutschland. Baden-Baden: Nomos Verlag, 53-61. * Korporatismus in Deutschland: Zwischen Nationalstaat und Europäischer Union. Frankfurt am Main: Campus, 1999. * Staat und Verbände. Sonderheft der Politischen Vierteljahresschrift (ed.), Wiesbaden: Westdeutscher Verlag,

1995. Einleitung des Herausgebers. Staat und Verbände: Neue Fragen. Neue Antworten? In: Streeck, Wolfgang, ed., 1995: Staat und Verbände. Sonderheft der Politischen Vierteljahresschrift, 7-36. The Rise and Decline of Neo-Corporatism. In: Ulman, Lloyd, Barry Eichengreen and William T. Dickens, eds., 1993: Labor and an Integrated Europe. Washington, D.C.: The Brookings Institution, 80-99 From National Corporatism to Transnational Pluralism: Organized Interests in the Single European Market (with Philippe C. Schmitter). Politics and Society, Vol. 19, No. 2, 1991, 133-164. Slightly extended Version in: Eichener, Volker and Helmut Voelzkow, eds. , 1994: Europäische Integration und verbandliche Interessenvermittlung. Marburg: Metropolis Verlag, 181-215. Republished in: Hay, Colin and Bob Jessop, eds., 1995: Beyond the State? New Directions in State Theory. London: MacMillan. And in: Gabaglio, Emilio and Reiner Hoffmann, eds., 1998: The ETUC in the Mirror of Industrial Relations Research. Brussels: European Trade Institute, 131-170. Interest Heterogeneity and Organizing Capacity: Two Class Logics of Collective Action? In: Czada, Roland M. and Adrienne Windhoff-Héritier, eds., 1991: Political Choice: Institutions, Rules, and the Limits of Rationality. Boulder, Colorado: Westview Press, 161-98. Italian: Imprenditori e sindacati: eterogeneitá degli interessá e capacitá organizzativa. Stato e mercato, Vol. 31, 1991, 7-45. Vielfalt und Interdependenz: Überlegungen zur Rolle intermediärer Organisationen in sich ändernden Umwelten. Kölner Zeitschrift für Soziologie und Sozialpsychologie, Vol. 39, 1987, 471-495. * Private Interest Government: Beyond Market and State (ed., with Philippe C. Schmitter). Beverly Hills and London: Sage, 1985. Community, Market, State and Associations? The Prospective Contribution of Interest Governance to Social Order. In: Streeck, Wolfgang and Philippe C. Schmitter, eds., 1985: Private Interest Government: Beyond Market and State. Beverly Hills and London: Sage, 1-29. Also in: European Sociological Review, Vol. 1, 1985, 119-138. And in: Frances, Jennifer et al., eds., 1991: Markets, Hierarchies and Networks, London: Sage, 110-138. German: Gemeinschaft, Markt, Staat - und Verbände? Journal für Sozialforschung, Vol. 25, 1985, 133-157. Italian in: Stato e mercato, No. 13, 1985, 47-86. Spanish in: Schmitter, Philippe C., Wolfgang Streeck and Gerhard Lehmbruch, eds., 1992: Neocorporativismo II: Mas alla del Estado y el Mercado. Mexico City: Editorial Patria, 47-84. Reviewed Version in: Schneider, Volker and Patrick Kenis, 1996: Organisation und Netzwerk: Institutionelle Steuerung in Wirtschaft und Politik. Frankfurt/Main: Campus, 123-164.

Neo-Corporatist Industrial Relations and the Economic Crisis in West Germany. In: John Goldthorpe, ed., 1984: Order and Conflict in Contemporary Capitalism: Studies in the Political Economy of West European Nations. Oxford: Clarendon Press, 1984, 291-314. Italian in: Carrieri, Mimmo and Paolo Perulli, eds., 1985: Il teorema sindacale: Flessibilita e competizione nelle relazioni industriali. Bologna: Società Editrice Il Mulino, 185-228. Between Pluralism and Corporatism. German Business Associations and the State. Journal of Public Policy, Vol. 3, 1983, 265-284. Interessenverbände als Hindernisse und Vollzugsträger öffentlicher Politik. In: Scharpf, Fritz W. and Marlene Brockmann, eds., 1983: Institutionelle Bedingungen der Arbeitsmarkt und Beschäftigungspolitik. Frankfurt am Main: Campus, 179-197. Organizational Consequences of Corporatist Cooperation in West German Labor Unions: A Case Study. In: Lehmbruch, Gerhard and Philippe C. Schmitter, eds., 1982: Patterns of Corporatist Policy-Making, Beverly Hills und London: Sage, 29-81. Italian in: Lehmbruch and Schmitter, eds.: La politica degli interessi nei paesi industrializzati: Modelli di politica neocorporativa. Milano: Società Editrice Il Mulino, 41-103. Spanish in: Schmitter, Philippe C., Wolfgang Streeck and Gerhard Lehmbruch, eds. , 1992: Neocorporativismo II: Mas alla del Estado y el mercado. Mexico City: Editorial Patria, 1992, 237-296. Gewerkschaftliche Organisationsprobleme in der sozialstaatlichen Demokratie. Königstein/Ts.: Athenäum, 1981. (11) Organized Business * Streeck, Wolfgang, Jürgen Grote, Volker Schneider and Jelle Visser, eds., 2006: Governing Interests: Business Associations Facing Internationalization. London and New York: Routledge. Conclusions: Organized Business Facing Internationalization (with Jelle Visser). In: Streeck, Wolfgang et al., eds., 2006: Governing Interests: Business Associations Facing Internationalization. London and New York: Routledge, 242-272. Business Associations. In: Beckert, Jens and Milan Zafirovsky, eds., 2005: International Encyclopedia of Economic Sociology. London and New York: Routledge, 33-35. The Organization of Business Interests: Studying the Associative Action of Business in Advanced Industrial Societies (with Philippe C. Schmitter), MPIfG Discussion Paper 99/1, Köln: Max-Planck-Institut für
Gesellschaftsforschung, 1999. The Territorial Organization of Interests and the Logics of Associative Action: The Case of Handwerk Organization in West Germany. In: Coleman, William D. and Henry J. Jacek, eds., 1989: Regionalism, Business Interests and Public Policy, London: Sage, 59-94. Spanish in: Carlota Sole, ed., 1987: Corporatismo y diferencion regional. Madrid: Ministero de Trabajo y Seguridad Social, 71-114. Large Firms and the Representation of Business Interests in the UK and West German Construction Industries (with Wyn Grant). In: Cawson, Alan, ed., 1985: Organized Interests and the State: Studies in MesoCorporatism, Beverly Hills and London: Sage, 145-173. Between Pluralism and Corporatism. German Business Associations and the State. Journal of Public Policy, Vol. 3, 1983, 265-284. L' organizzazione degli interessi imprenditoriali (with Alberto Martinelli and Philippe C. Schmitter). Stato e mercato, Vol. 1, No. 3, 1981, 413-445. Das Dilemma der Organisation. Tarifverbände zwischen Interessenvertretung und Stabilitätspolitik. In: Meissner, Werner and Lutz Unterseher, eds., 1972: Verteilungskampf und Stabilitätspolitik. Stuttgart: Kohlhammer, 130167. (12) Trade Unions and Industrial Relations Industrial Relations Today: Reining in Flexibility. MPIfG Working Paper 08/3, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2008. Also in: Economics, Management, and Financial Markets, Vol. 4, 2009, No. 3, 15-36. Institutionen im Wandel: Hat die Tarifautonomie eine Zukunft? (with Britta Rehder). In: Busch, Hans Werner et al., eds., 2005: Tarifpolitik im Umbruch. Köln: Deutscher Institutsverlag, 49-82. The Sociology of Labor Markets and Trade Unions. In: Smelser, Neil J. and Richard Swedberg, eds., 2005: The Handbook of Economic Sociology: Second Edition, Princeton: Princeton University Press, 254-283. Industrial Relations: From State Weakness as Strength to State Weakness as Weakness: Welfare Corporatism and the Private Use of the Public Interest. In: Green, Simon and William E. Paterson, eds., 2005: Governance in Contemporary Germany: The Semisovereign State Revisited. Cambridge: Cambridge University Press, 138-164. Italienische Übersetzung: La debolezza dello stato da risorsa a vincolo: il corporativismo dello stato sociale e l'uso

privato del pubblico interesse. Stato e mercato, No. 70, 2004, 3-36. Der Flächentarifvertrag: Krise, Stabilität und Wandel (with Britta Rehder). Industrielle Beziehungen, Vol. 10, No. 3, 2003, 341-362. Trade Unions as Political Actors (with Anke Hassel). In: Addison, John T. and Claus Schnabel, eds., 2003: International Handbook of Trade Unions. Cheltenham: Edward Elgar Publishing, 335-365. Gewerkschaften in Westeuropa. In: Schroeder, Wolfgang and Bernhard Wessels, eds., 2003: Die Gewerkschaften in Politik und Gesellschaft der Bundesrepublik Deutschland. Wiesbaden: Westdeutscher Verlag, 86-100. Labor Unions. In: Smelser, Neil and Paul Baltes, eds., 2001: International Encyclopedia of the Social and Behavioral Sciences. Amsterdam etc.: Elsevier, 8214-8220. Die Gewerkschaften im Bündnis für Arbeit. In: Abel, Jörg and Hans-Joachim Sperling, eds. , 2001: Umbrüche und Kontinuitäten: Perspektiven nationaler und internationaler Arbeitsbeziehungen. Walther Müller-Jentsch zum 65. Geburtstag. München: Rainer Hampp Verlag, 271-279. Excerpts in: „Bewegte Zeiten - Arbeit an der Zukunft", Dokumentation der Wissenschaftlichen Konferenz des DGB, "50 Jahre DGB", am 11. und 12. Oktober 1999 in München. Gewerkschaftliche Monatshefte, Vol. 50, No. 12, 1999, 797-802. Tarifautonomie und Politik: Von der Konzertierten Aktion zum Bündnis für Arbeit. In: Gesamtverband der metallindustriellen Arbeitgeberverbände, ed., 2001: Die deutschen Arbeitsbeziehungen am Anfang des 21. Jahrhunderts. Wissenschaftliches Kolloquium aus Anlaß des Ausscheidens von Dr. Werner Stumpfe als Präsident von Gesamtmetall. Köln: Deutscher Institutsverlag, 76-102. Industrielle Beziehungen in einer internationalisierten Wirtschaft. In: Beck, Ulrich, ed., 1998: Politik der Globalisierung. Frankfurt am Main: Suhrkamp, 1998, 169-202. English Translation: Industrial Relations in an International Economy. In: Dettke, Dieter, ed., 1998: The Challenge of Globalization for Germany's Social Democracy. New York: Berghahn Books, 85-112. The Internationalization of Industrial Relations in Europe: Prospects and Problems. Politics and Society, Vol. 26, No. 4, Dezember 1998, 429-459. Gewerkschaften zwischen Nationalstaat und Europäischer Union. WSI-Mitteilungen, Vol. 51, January 1998, 1-4. Also in: Messner, Dirk , ed., 1998: Die Zukunft des Staates und der Politik. Möglichkeiten und Grenzen politischer Steuerung in der Weltgesellschaft. Bonn: J.H.W. Dietz Nachfolger, 1998, 218-246. Also as: Die Ent-Zivilisierung des Kapitalismus: Gewerkschaften zwischen Nationalstaat und Europäischer Integration. Internationale Politik und Gesellschaft, Vol. 4, 1996, 357-367 Das Zukunftsmodell – Der Flächentarifvertrag. Gewerkschaftliche Monatshefte, Vol. 49, No. 1, 1998, 6-18. English Translation: The Model for the Future? The Sectoral Collective Agreement. In: Hoffmann, Reiner et al., eds., 1998: The German Model of Industrial Relations Between Adaptation and Erosion. Düsseldorf: Hans-Böckler-Stiftung, 97-104. The Rise of the Conglomerate Union (with Jelle Visser). European Journal of Industrial Relations, Vol. 3, No. 3, 1997, 305-332. Extended Version: An Evolutionary Dynamic of Trade Union Systems, MPIfG Discussion Paper 98/4, Köln: Max-Planck-Institut für Gesellschaftsforschung, 1998 Comment on Ronald Dore's 'Unions between Class and Enterprise'. Industrielle Beziehungen, Vol. 3, No. 2, 1996, 187-196. Anmerkungen zum Flächentarif und seiner Krise. Gewerkschaftliche Monatshefte, Vol. 47, No. 2, 1996, 86-97. * Works Councils: Consultation, Representation, Cooperation in Industrial Relations (ed., with Joel Rogers), Chicago: University of Chicago Press, 1995. The Study of Works Councils: Concepts and Problems (with Joel Rogers). Introduction: Rogers, Joel and Wolfgang Streeck, eds., 1995, 3-26. The European Community: Between Mandatory Consultation and Voluntary Information (with Sigurt Vitols). In: Rogers, Joel and Wolfgang Streeck, eds., 1995: Works Councils: Consultation, Representation, Cooperation in Industrial Relations, Chicago: University of Chicago Press, 243-281. Works Councils in Western Europe: Cooperation through Representation. In: Rogers, Joel and Wolfgang Streeck, eds., 1995, 313-348. Pay Restraint without Incomes Policy: Constitutionalized Monetarism and Industrial Unionism in Germany. In: Boyer, Robert, Ronald Dore and Zoe Mars, eds., 1994: The Return to Incomes Policy. London: Francis Pinter, 118-140. French in: Boyer, Robert and Ronald Dore, eds., 1994 : Les politiques des revenus en Europe. Paris: Editions La Découverte, 147-164. Workplace Representation Overseas: The Works Councils Story (with Joel Rogers). In: Freeman, Richard B., ed.,
1994: Working under Different Rules. New York: Russell Sage Foundation, 97-156. Western Europe (The History of Unions in Western Europe). Encyclopedia Britannica, Macropedia, Work and Employment, 1993, 953-956. * Social Institutions and Economic Performance: Studies of Industrial Relations in Advanced Capitalist Economies. London and Beverly Hills: Sage, 1992. National Diversity, Regime Competition and Institutional Deadlock: Problems in Forming a European Industrial Relations System. Journal of Public Policy, Vol. 12, 1992, 301-330. Also in: Economic and Political Changes in Europe: Implications on Industrial Relations. 3rd European Regional Congress of the International Industrial Relations Association. Bari: Cacucci Editore, 1993, 27-62. Italian: Le relazioni industriali nell' Europa che cambia. Industria e sindacato, XXXIV, 1992, 1-20. More Uncertainties: West German Unions Facing 1992. Industrial Relations, Vol. 30, 1991, 317-349. Italian: Ancora incertezze: i sindacati tedeschi e il 1992. Giornale di diritto del lavoro e di relazioni industriali, Vol. 51, 1991, 513-550. Also in: Goetz, Klaus H., ed., 1996: Germany. Volume II, The International Library of Politics and Comparative Government, Aldershot: Dartmouth, 351-384. Status and Contract as Basic Categories of a Sociological Theory of Industrial Relations. In: Sugarman, David and Gunther Teubner, eds., 1990: Regulating Corporate Groups in Europe. Baden-Baden: Nomos, 105-145. German: Status und Kontrakt als Grundkategorien einer Theorie der industriellen Beziehungen. Habilitationsvortrag vor der Fakultät für Soziologie der Universität Bielefeld. Discussion Paper SP-LMP, Wissenschaftszentrum Berlin, 1988. Italian: Status e contratto nella teoria delle relazioni industriali. Giornale di diritto del lavoro e di relazioni industriali, Vol. 40, 1988, 673-719 Change in Industrial Relations: Strategy and Structure. Proceedings of the 30th Anniversary International Symposium. Tokio: Japan Institute of Labor, 1989, 59-76. Successful Adjustment to Turbulent Markets: The Automobile Industry. In: Katzenstein, Peter J., ed., 1989: Industry and Politics in West Germany: Toward the Third Republic. Ithaca and London: Cornell University Press, 113-156. * New Technology and Industrial Relations (ed., with Richard Hyman). Oxford: Basil Blackwell, 1988. 2nd Edition 1989. Spanish: Nuevas tecnologias y relaciones industriales. Madrid: Centro de Publicaciones, Ministerio de Trabajo y Seguridad Social, 1993.

Industrial Relations and Technical Change: The Case for an Extended Perspective (with Arndt Sorge). In: Hyman, Richard and Wolfgang Streeck, eds., 1988: New Technology and Industrial Relations, Oxford: Basil Blackwell, 19-47. Industrial Relations in West Germany, 1980-1987. Labour, Vol. 2, No. 3, 1988, 3-44. Comment on Ronald Dore, Rigidities in the Labour Market. The Andrew Shonfield Lectures (III). Government and Opposition, Vol. 23, 1988, 413-423 Industrial Relations and Industrial Change: The Restructuring of the World Automobile Industry in the 1970s. Economic and Industrial Democracy, Vol. 8, 1987, 437-462. Spanish: Relaciones laborales y cambio industrial: el caso de la industria automovilística. Abaco 4, 1988, 13-31. German: Kollektive Arbeitsbeziehungen und industrieller Wandel: Das Beispiel der Automobilindustrie. In: Martens, Helmut and Gerd Peters, eds., 1989: Mitbestimmung und Demokratisierung: Stand und Perspektiven der Forschung. Wiesbaden: Deutscher Universitätsverlag, 188215. The Uncertainties of Management in the Management of Uncertainty: Employers, Labour Relations and Industrial Adjustment in the 1980s. Work, Employment and Society, Vol. 1, 1987, 281-308. Also in: Peter A. Hall, ed., 1987: European Labor in the 1980s. International Journal of Political Economy, Vol. 17, No. 3, 57-87. And in: Österreichische Zeitschrift für Soziologie, Vol. 13, 1988, 44-64. Spanish: Management de la incertidumbre e incertidumbre del management: los impresarios, las relaciones laborales y el ajuste industrial durante la crisis. Papeles de Economia Espanola, 27, 1986. Italian in: Prospettiva Sindacale, Vol. 59, 1986, 118-146, and in: Baglioni, Guido and Currado Squarzon, eds., 1987: Stato, politica economica e relazioni industriali in Europa. Milano: Franco Angeli, 123-159. Industrial Relations in the Federal Republic of Germany 1974-1985: An Overview. In: Kassalow, Everett M., ed., 1987: Unions and Industrial Relations: Recent Trends and Prospects – A Comparative Treatment. Special Issue of the Bulletin of Comparative Labour Relations, Vol. 16, 151-166. * Industrial Relations in West Germany: The Case of the Car Industry. London: Heinemann, New York: St. Martin's Press, 1984. Labour Relations and Employment Adjustments (with Harry Katz). In: Altshuler, Alan et al., 1984: The Future of the Automobile: The Report of MIT's International Automobile Program. Cambridge, Mass.: The MIT Press, 199-221. Neo-Corporatist Industrial Relations and the Economic Crisis in West Germany. In: John Goldthorpe, ed., 1984:
Order and Conflict in Contemporary Capitalism: Studies in the Political Economy of West European Nations. Oxford: Clarendon Press, 1984, 291-314. Italian in: Carrieri, Mimmo and Paolo Perulli, eds., 1985: Il teorema sindacale: Flessibilita e competizione nelle relazioni industriali. Bologna: Società Editrice Il Mulino, 185-228. Co-Determination: The Fourth Decade. In: Wilpert, Bernhard and Arndt Sorge, eds., 1984: International Perspectives on Organizational Democracy. International Yearbook of Organizational Democracy, Vol. II. London: John Wiley & Sons, 391-422. Organizational Consequences of Corporatist Cooperation in West German Labor Unions: A Case Study. In: Lehmbruch, Gerhard and Philippe C. Schmitter, eds., 1982: Patterns of Corporatist Policy-Making, Beverly Hills und London: Sage, 29-81. Italian in: Lehmbruch and Schmitter, eds.: La politica degli interessi nei paesi industrializzati: Modelli di politica neocorporativa. Milano: Società Editrice Il Mulino, 41-103. Spanish in: Schmitter, Philippe C., Wolfgang Streeck and Gerhard Lehmbruch, eds. , 1992: Neocorporativismo II: Mas alla del Estado y el mercado. Mexico City: Editorial Patria, 1992, 237-296. * Gewerkschaftliche Organisationsprobleme in der sozialstaatlichen Demokratie. Königstein/Ts.: Athenäum, 1981. Competition and Monopoly in Interest Representation: A Comparative Analysis of Trade Union Structure in the Railway Industries of Great Britain and West Germany (with Peter Seglow and Pat Wallace). Organization Studies, Vol. 1, No. 2, 1981, 307-329. Qualitative Demands and the Neo-Corporatist Manageability of Industrial Relations: Trade Unions and Industrial Relations in West Germany at the Beginning of the Eighties. British Journal of Industrial Relations, Vol. 14, 1981, 149-169. Gewerkschaftsorganisation und industrielle Beziehungen. Einige Stabilitätsprobleme industriegewerkschaftlicher Interessenvertretung und ihre Lösung im System der industriellen Beziehungen der Bundesrepublik Deutschland. In: Matthes, Joachim, ed., 1979: Sozialer Wandel in Westeuropa: Verhandlungen des 19. Deutschen Soziologentags. Frankfurt am Main: Campus, 206-226. Also in: Gewerkschaftliche Monatshefte, Vol. 30, 1979, 721-734, and in: Politische Vierteljahresschrift, Vol. 20, 1979, 241-257. Gewerkschaften als Mitgliedsverbände: Probleme gewerkschaftlicher Mitgliederrekrutierung, in: Bergmann, Joachim, ed., 1979: Beiträge zur Soziologie der Gewerkschaften. Frankfurt am Main: Suhrkamp, 72-110. Staatliche Ordnungspolitik und industrielle Beziehungen. Zum Verhältnis von Integration und Institutionalisierung gewerkschaftlicher Interessenverbände am Beispiel des britischen Industrial Relations Act von 1971. In: Bermbach,

Udo, ed., 1978: Politische Wissenschaft und politische Praxis, Sonderheft 9 der Politischen Vierteljahresschrift, 106-139. Die organisatorische Stabilisierung der Gewerkschaften im letzten Jahrzehnt: Zur Überwindung der gewerkschaftlichen Organisationskrise der sechziger Jahre. Gewerkschaftliche Monatshefte, Vol. 29, 1978, 589-601, 632-635. Italian: Processi di razionalizzazione amministrativa nei sindacati della Germania occidentale. Studi organizzativi, Vol. 9, 1977, 141-209. Strukturdimensionen deutscher Gewerkschaften im Jahre 1914: Eine Analyse historischer Daten. Soziale Welt, 27, 1976, 399-419. Das Dilemma der Organisation. Tarifverbände zwischen Interessenvertretung und Stabilitätspolitik. In: Meissner, Werner and Lutz Unterseher, eds., 1972: Verteilungskampf und Stabilitätspolitik. Stuttgart: Kohlhammer, 130167. (13) Miscellaneous
Von der Gesellschaftssteuerung zur sozialen Kontrolle: Rückblick auf ein halbes Jahrhundert Soziologie in Theorie und Praxis. In: Blätter für deutsche und internationale Politik 1/2015, 63-80.
The Politics of Exit: On Peter Mair, Ruling the Void: The Hollowing of Western Democracy. In: New Left Review 88, July/August 2014, 121-129. Wissen als Macht, Macht als Wissen: Kapitalversteher im Krisenkapitalismus. In: Merkur: Deutsche Zeitschrift für europäisches Denken 66, 2012, No. 9/10, 776-787. Der öffentliche Auftrag der Soziologie. In: Leviathan 40, 2012, No. 1, 129-147. Doing Theory Realistically: About Dietrich Rueschemeyer, Usable Theory: Analytical Tools for Social and Political Research (Princeton/Oxford, Princeton University Press, 2009). In: European Journal of Sociology, Vol. 52, 2011, No. 3, 556-560. Man weiß es nicht genau: Vom Nutzen der Sozialwissenschaften für die Politik. In: Kraul, Margret und Peter-Tobias Stoll (Hg.), Wissenschaftliche Politikberatung. Göttingen: Wallstein 2011, 15-41. Auch als MPIfG Working Paper 09/11, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2010. Does “behavioural economics” offer an alternative to the neoclassical paradigm? In: Socio-Economic Review, Vol. 8, 2010, No. 2, 387-397. Complex, Historical, Self-reflexive: Expect the Unexpected! (mit Sandra Mitchell). MPIfG Working Paper 09/15, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2009. Von der gesteuerten Demokratie zum selbststeuernden Kapitalismus: Die Sozialwissenschaften in der Liberalisierung. In: WestEnd. Neue Zeitschrift für Sozialforschung, Jg. 6, 2009, Heft 1, 13-33. Siehe auch MPIfG Working Paper 08/7. Politik im Alter: Wahlverhalten, Beteiligung, Einfluss. Einleitung. In: Jürgen Kocka, Martin Kohli und Wolfgang Streeck (Hg.): Altern: Familie, Zivilgesellschaft, Politik. Altern in Deutschland, Bd. 8. Nova Acta Leopoldina N.F. Bd. 106, Nr. 370. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 2009, 265-271.
The Political Science of Peter J. Katzenstein (mit Peter A. Gourevitch, Robert O. Keohane, Stephen D. Krasner, David Laitin, T.J. Pempel und Sidney Tarrow). In: Political Science & Politics, Vol. 41, 2008, No. 4, 893-899. Economic Sociology and Political Economy: A Programmatic Perspective (mit Jens Beckert). MPIfG Working Paper 08/4, Köln: Max-Planck-Institut für Gesellschaftsforschung, 2008. Politik in einer alternden Gesellschaft: Vom Generationenvertrag zum Generationen-konflikt? In: Peter Gruss (Hg.), Die Zukunft des Alterns: Die Antwort der Wissenschaft. München: Verlag C.H. Beck, 2007, 279-304. Wirtschaft und Moral: Facetten eines unvermeidlichen Themas. In: Wolfgang Streeck und Jens Beckert (Hg.), Moralische Voraussetzungen und Grenzen wirtschaftlichen Handelns. Forschungsbericht aus dem MPIfG 3, Köln, 2007, 8-18. Globalisierung: Mythos und Wirklichkeit. In: Hans-Jürgen Aretz und Christian Lahusen, eds., 2005: Die Ordnung der Gesellschaft. Festschrift zum 60. Geburtstag von Richard Münch. Frankfurt am Main: Peter Lang, 355-372. * Transnationale Solidarität: Chancen und Grenzen (ed., with Jens Beckert, Julia Eckert and Martin Kohli). Frankfurt am Main: Campus, 2004. Social Science and Moral Dialogue. Critical Forum: Toward a New Socio-Economic Paradigm. Socio-Economic Review, Vol. 1, No. 1, 2003, 126-129. Wohlfahrtstaat und Markt als moralische Einrichtungen: Ein Kommentar. In: Mayer, Karl Ulrich, ed., 2001: Die beste aller Welten? Marktliberalismus versus Wohlfahrtsstaat. Frankfurt am Main: Campus, 135-167. Preface. In: Ebbinghaus, Bernhard and Philipp Manow, eds. , 2001: Comparing Welfare Capitalism: Social Policy and Political Economy in Europe, Japan and the USA, Routledge/EUI Studies in the Political Economy of Welfare, London: Routledge, xv-xx. Über Renate Mayntz, Soziologie der Organisation. In: Papcke, Sven and Georg W. Oesterdieckhoff, eds. , 2001: Schlüsselwerke der Soziologie, Wiesbaden: Westdeutscher Verlag, 320-323. Karl Polanyi: The Great Transformation. In: Kaesler, Dirk and Ludgera Voigt, eds. , 2000: Hauptwerke der Soziologie, Stuttgart: Kröner, 359-361. Die Festsetzung von Professorengehältern in den USA. Soziologie. Mitteilungsblatt der Deutschen Gesellschaft für Soziologie, No. 3, 1998, 23-30. Productive Solidarities: Economic Strategy and Left Politics (with Joel Rogers). In: David Miliband, ed., 1994: Reinventing the Left. Oxford: Polity Press, 128-145. Inclusion and Secession: Questions on the Boundaries of Associative Democracy. Politics and Society, Vol. 20, No. 4, 1992, 513-520. * Elementare Soziologie: Kommentierte Studientexte (mit Wolfgang Conrad). Hamburg: Rowohlt, 1974. Second Edition Opladen: Westdeutscher Verlag, 1982. * Parteiensystem und Status quo (mit Sylvia Streeck). Frankfurt am Main: Suhrkamp, 1972.

Academic CV Wolfgang Streeck
Professional Career

2014
Retirement

1995
Director, Max Planck Institute for the Study of Societies, Cologne, and Professor of Sociology, Faculty of Economics and Social Science, University of Köln

1988-1995
Professor of Sociology and Industrial Relations, University of Wisconsin-Madison

1980-1988
Senior Fellow, Wissenschaftszentrum Berlin

1986
Habilitation in Sociology, University of Bielefeld

1980
Dr. phil., Johann Wolfgang Goethe University, Frankfurt am Main

1974-1976
Assistant Professor in Sociology, University of Münster, Department of Economics and Social Sciences

1972-1974
Graduate Student of Sociology, Columbia University

1976-1980
Research Fellow, International Institute of Management, Berlin

1972
Diplom in Sociology, Johann Wolfgang Goethe University, Frankfurt am Main

Professional Activities and Public Service

since 2012
Research Council, European University Institute (EUI)

since 2012
International Advisory Board, The Sheffield Political Economy Research Institute, University of Sheffield

2008-2009
Member of the "Zukunftskommission" of the Land of North Rhine-Westphalia

2005-2006
Member of the Commission of the Federal Government for the Modernization of Enterprise-level Co-determination

2003-2006
Chair, Human Sciences Section, Max Planck Society

2000-2006
Advisory Committee, Deutsches Institut für Japanstudien, Tokyo (DIJ); chair since 2003

2001-2008
Member of the Council (Konzil) of the German Sociological Association (Deutsche Gesellschaft für Soziologie, DGS)

1989-2006
Executive Council, Society for the Advancement of Socio-Economics (SASE)

2000-2005
Scientific Advisory Committee, Centre Saint-Gobain pour la recherche en économie

1999-2005
Executive Board, Society for Comparative Research

1998-1999
President, Society for the Advancement of Socio-Economics (SASE)

1998-2001
Member, Arbeitsgruppe Benchmarking (the Benchmarking Working Group) of the Bündnis für Arbeit (Alliance for Jobs) as Representative of the Federal Government

1997-1999
Chair, Visiting Committee, University of Konstanz, Department of Administrative Science

1995-1998
Research Director and Member, Kommission Mitbestimmung, Bertelsmann-Stiftung and Hans-Böckler Stiftung

1995-2005
Member, Scientific Advisory Committee, Hans-Böckler-Stiftung

1990-1993
Co-Director, Center on Wisconsin Strategy, Department of Sociology, University of Wisconsin-Madison

1989-1993
Chair, Western European Area Studies, University of Wisconsin-Madison

1989-1992
Director, Center for Comparative and International Labor Studies, Industrial Relations Research Institute, University of Wisconsin-Madison

1989-1990
University Research Committee, University of Wisconsin-Madison

1987-1988
Scientific Advisory Committee, German Sports Federation

1982-1986
Coordinating Committee, European Group for Organizational Studies (EGOS)
Selected Visiting Appointments

2013/14
Theodor Heuss Chair, The New School for Social Research, New York, N.Y.

2011
Fernand Braudel Fellow, European University Institute, Florence

2007, 2009
Visiting Scholar, Russell Sage Foundation, New York, N.Y.

2000
Jean Monnet Professor, Robert Schumann Centre, European University Institution, Florence

1998
German-American Academic Council Distinguished Lecturer, Duke University, Durham, North Carolina

1996
Jean Monnet Professor, European University Institute, Florence

1996
Professeur invité, Fondation Nationale des Sciences Politiques, Institut d´Etudes Poliitiques de Paris ("Sciences Po")

1996
Visitor, European Forum, European University Institute, Florence

1993-1994
Fellow, Wissenschaftskolleg of Berlin

1989
Visiting Professor, Universita Commerciale Luigi Bocconi, Milan

1988
Visiting Professor, Centro de Estudios Avanzados en Ciencias Sociales, Instituto Juan March de Estudios e Investigaciones, Madrid

1985
Leverhulme Visiting Professor in European Industrial Relations, School of Industrial and Business Studies, University of Warwick

1983-1984
Visiting Professor, European University Institute, Florence
Honors

2012
Award for Outstanding Contribution to the Public Unterstanding of Sociology, German Sociological Association (DGS)

2011
Order of Merit, Land of North Rhine-Westphalia

2006
Honorary Fellow, Society fot the Advancement of Socio-Economics

2002
Commendatore della Republica Italiana

since 2002
Member, Academia Europaea

2000
Doctor of Science honoris causa, University of Birmingham

2000-2003
Honorary President, Association for the Study of German Politics (ASGP)

since 1998
Member, Berlin-Brandenburgische Akademie der Wissenschaften (BBAE)
Scholarly Journals

since 2009
British Journal of Industrial Relations, International Advisory Board

2006-2012
Socio-Economic Review, Chief Editor

since 2002
Comparative European Politics, Editorial Board

since 2000
Work, Employment and Society, International Advisory Board

since 1994
European Journal of Industrial Relations, International Advisory Panel

since 1992
European Sociological Review, Editorial Board

1999-2005
Kölner Zeitschrift für Soziologie, Advisory Council

1998-2005
Stato e mercato, Comitato editoriale

1995-2007
Industrielle Beziehungen, Editorial Board

1995-1999
Zeitschrift für Soziologie, Co-Editor

1988-1998
Economic and Industrial Democracy, Editorial Board

1979-1986
Organization Studies, Editorial Board

Michel Eichelbaum

I want to propose Professor Michel Eichelbaum to become professor honoris causa at SDU for his outstanding contributions to clinical pharmacology during more than 40 years.

Michel Eichelbaum was born in Leipzig on 19 May 1941. He studied medicine at the University of Heidelberg between 1960 and 1966, and he defended his doctoral thesis at this university in 1968.

During 1966 to 1968 he was an intern in Internal Medicine, Surgery and Gynaecology and Obstetrics. Between 1968- 1976 he was a resident in Internal Medicine at University Hospitals of Giessen and Bonn. From 1976-1985 he was attending physician and Associate Professor of Internal Medicine and Clinical Pharmacology at the Department of Medicine, University of Bonn. He is a specialist in both Clinical Pharmacology and in Internal Medicine.

From 1985 and 21 years onwards he was the Director of the Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart/Germany. Simultaneously he was Professor and Chairman of Clinical Pharmacology at the University of Tübingen, and in 2001 he became Adjunct Professor with the University of Adelaide, Australia.

Head of Institute, Professor ph.d. Jesper Bo Nielsen
Institute of Public Health
University of Southern Denmark

Michel Eichelbaum has obtained several Research Fellowships. Thus during 1970-1971 he worked in the Laboratory of Chemical Pharmacology, National Heart and Lung Institute, National Institutes of Health, Bethesda, USA together with Drs. B.B.Brodie and J.R.Gillette. From1973-1974 he was at the Department of Clinical Pharmacology, Karolinska Institute in Stockholm Sweden together with Prof.F. Sjöqvist, and from 1995-1996 he was a Visiting Professor Department of Clinical and Experimental Pharmacology, University of Adelaide, Australia.

Michel Eichelbaum has received numerous Awards and Honors. This year he was honoured with the Oscar B. Hunter Memorial Award in Therapeutics from the American Society of Clinical Pharmacology and Therapeutics (ASCPT). He is only the third European who has got this prize.
His primary research interest has been the pharmacogenetics of drug metabolizing enzymes and transporter proteins. He was also one of the pioneers of studying various aspects of the stereochemistry of drugs, the use of stable isotopes in clinical pharmacology and intestinal metabolism and transport of drugs.

In 1975 he discovered a genetic polymorphism in the oxidation of the antiarrhythmic and oxytocic drug, sparteine, which later became known as the cytochrome P4502D6 or CYP2D6 polymorphism. This is considered his single most important scientific discovery, and it has been an enormous inspiration for the pharmacogenetics research all over the World including at the University of Southern Denmark where more than 100 scientific studies are indebted to this discovery.

Later Michel Eichelbaum became involved in research on factors involved in the regulation of drug metabolizing enzymes and transporters with special emphasis on nuclear receptors. This basic research is supplemented by clinical studies in oncology with special emphasis on breast cancer treatment, HIV, psychiatry and organ transplantation in which the consequences of genetic polymorphisms of these proteins for drug effects and toxicity are explored.

He has published nearly 500 articles, reviews and book chapters and numerous abstracts, and his work has been cited over 25000 times by other authors and his Hirsch Index is 84 making him of course one of the most cited pharmacologists in in the World. Michel Eichelbaum is still very active and since his retirement in 2006 he has published around 40 scientific papers.
In summary Michel Eichelbaum is one of the most important scientists in clinical pharmacology and for nearly 40 years he has been a leading figure in the discipline. It would indeed be a great honor for the University of Southern Denmark to make him professor honoris causa in the year of 2015 where his major scientific discovery of the CYP2D6 oxidation polymorphism celebrates its 40 years jubilee.

Yours sincerely
Kim Brøsen, DrMSc
Professor and Chief Physician of Clinical Pharmacology

Education:
1960-1966 Medical School, University of Heidelberg
1968 M.D. thesis University of Heidelberg

Positions and Employment
1966-1968 Internships in Internal Medicine, Surgery and Gynaecology and Obstetrics

1968- 1976 Residency in Internal Medicine at University Hospitals of Giessen and
Bonn

1976-1985 Attending physician and Associate Professor of Internal Medicine and
Clinical Pharmacology at the Department of Medicine, University of Bonn

1985-2006 Director of the Dr. Margarete Fischer-Bosch-Institute of Clinical
Pharmacology, Stuttgart/Germany

1996–2006 Professor and Chairman of Clinical Pharmacology at the University of
Tübingen

2001 Adjunct Professor with the University of Adelaide, Australia
Research fellowships:

1970-1971 Laboratory of Chemical Pharmacology, National Heart and Lung Institute,
National Institutes of Health, Bethesda, USA with Drs. B.B.Brodie and
J.R.Gillette

1973-1974 Department of Clinical Pharmacology, Karolinska Institute, Stockholm,
Sweden with Prof.F. Sjöqvist

1995-1996 Visiting Professor Department of Clinical and Experimental Pharmacology,
University of Adelaide, Australia

Honors
1976 Paul-Martini Award
1979 Homburg Prize
1983 Paul-Edvard Poulsson Award of the Norwegian Society
of Pharmacology and Toxicology
1983 Paul-Martini Medal
1988 Dr. Robert-Pfleger Prize
1990 William N. Creasy Award and Visiting Professor in
Clinical Pharmacology, Burroughs Wellcome Fund,
University of Colorado, Denver
1991 Rudolf Buchheim prize lecture of the German Society
of experimental and clinical Pharmacology and
Toxicology
2001 Galenus-von-Pergamon-Prize 2001
2001 Clinical Science Lecture 2001 of Karolinska Institute,
Stockholm
2001 Börje Uvnäs Lecture, Stockholm
2001 Member of the National Academy of Sciences
Leopoldina, Germany
2003 Member of the Academy of Sciences and Arts, Mainz,
Germany
2004 1st Tennessee Visiting Professor of the University of
Tennessee, Health Science Center, USA
2006 Grant R. Wilkinson Distinguished Lectureship Award
Vanderbilt University Medical School
2008 Oswald Schmiedeberg Award of the German Society of
Experimental and Clinical Pharmacology and
Toxicology for life-long scientific achievements
2008 10th Heymans Lecture of the Royal Belgium Academy
of Medicine, Brussels
2015 Oscar B. Hunter Memorial Award in Therapeutics from
the ASCPT

I have been recognized as one of the most highly cited authors in pharmacology by ISI
Highly Cited Researchers.

Research areas:
My primary research interest and focus of my clinical research have been the
Pharmacogenetics of drug metabolizing enzymes and transporter proteins, various aspects of
the stereochemistry of drugs, use of stable isotopes in clinical pharmacology and intestinal
metabolism and transport of drugs.

In 1975, I described in my Habilitationsschrift (this is an extended PhD thesis in the German
University system which is required for the promotion to lecturer) the sparteine-type of
polymorphism of drug oxidation which later became known as CYP2D6 polymorphism.
In addition, I have been involved in studies exploring factors involved in the regulation of
drug metabolizing enzymes and transporters with special emphasis on nuclear receptors. This
basic research is supplemented by clinical studies in oncology with special emphasis on
breast cancer treatment, HIV, psychiatry and organ transplantation in which the consequences
of genetic polymorphisms of these proteins for drug effects and toxicity are explored.
I have published over four hundred and seventy five original articles, reviews and book
chapters and numerous abstracts. My work has been cited over 25000 times by other authors
and my Hirsch Index is 84.

Professional Societies
German Society of Internal Medicine
German Society of experimental and clinial Pharmacology and Toxicology
International Society for the Study of Xenobiotics

Editor:
European Editor of “Pharmacogenetics and Genomics” 1998 - 2009
Editor of “Handbook of Experimental Pharmacology” series, Springer Heidelberg from 2003
– 2007
Editor together with Bernard Testa and Andrew Somogyi of a handbook on “Stereochemical
Aspects of Drug Action and Disposition” (2003)
Editor with R.H. Levy, K.E. Thummel, W.F. Trager and P.D. Hanston “Metabolic Drug
Interactions” (2000)
Editorial Board Member:
Chirality
European Journal of Clinical Pharmacology
European Journal of Pharmaceutical Sciences
British Journal of Clinical Pharmacology
Therapeutic Drug Monitoring
Clinical Pharmacokinetics
Pharmacogenetics&Genomics
Journal of the German Medical Association
Reviewer for the following journals:
New England Journal of Medicine
Lancet
British Medical Journal
Clinical Endocrinology and Metabolism
Journal of Clinical Oncology
Nature Medicine
Chirality
Clinical Pharmacology and Therapeutics
Journal of Pharmacology and experimental Therapeutics
Biochemical Pharmacology
Therapeutic Drug Monitoring
British Journal of Clinical Pharmacology
Clinical Pharmacokinetics
European Journal of Clinical Pharmacology
Pharmacogenetics
Basic and Clinical Pharmacology
Proceedings of the National Academy of Science
Grant reviews
Canadian Foundation for Innovation
European Union
German Research Council,
German Cancer Foundation,
German Ministry of Education and Research
German Cancer Foundation
German – Israeli Foundation for Research
INSERM ,France
Ministry of Health Singapore
National Institutes of Health ( NIH ): USA,
Swedish Foundation for Strategic Research,
Swiss National Research Fund,
Wellcome Trust, UK
Professional Activities
Member of the External Scientific Panel of the NIH Pharmacogenomic Research Network
Chairman of the Scientific Advisory Board of the European Pharmacogenetic Research

Network
Chairman of the Scientific Advisory Board of the University of Liverpool, NHS Chair of
Pharmacogenetics
Member of the Scientific Advisory Board, Mayo Clinic, Pharmacogenetic Programme
Member of the EMEA Outcomes Assessment Steering Group for Innovative Medicine
Initiative of the European Commission
Member of the Steering Committee of the International Tamoxifen Pharmacogenomics
Research Network
Member of the Drug Committee of the German Medical Association
Member of the Medical Advisory Board of the Ministry of Defense, Germany
Member of the Board of the German Society of Clinical Pharmacology and Therapy
Member of the Scientific Advisory Board of the Dr. R. Pfleger Foundation
Organizer of the Cold Spring Harbor Laboratory (USA) and Wellcome Trust Sanger Institute,
Hinxton (UK) Annual Conference on Pharmacogenomics ( past )
Member of the Scientific Advisory Board of the European Network on Pharmacogenomics of
epilepsy

Former Professional Activities:
President of the German Society of Clinical Pharmacology, 1987 – 1990
Vice-President of the German Society of experimental and clinical Pharmacology and
Toxicology (2000 – 2003)
Chairman Scientific Programme Committee IV. World Congress of Clinical Pharmacology,
1989, Mammheim-Heidelberg, Germany

Schriftenverzeichnis
(Prof. Dr. M. EICHELBAUM)
1968
1. Eichelbaum M, Dengler HJ: Inhibition of 3H-noradrenaline uptake in heart tissue by
prenylamine and its mode of action. Biochem Appl 1968;XIV: 53-61.
2. Kaess H, Gugler R, Eichelbaum M: Untersuchungen über die Magensaftsekretion nach
Stimulation mit Pentagastrin (ICI 50123). Kli Wo 1968;2: 93-97.
3. Gugler R, Eichelbaum M, Kaess H: Untersuchungen über die Säuresekretion des Magens
nach Pentagastrin. Verh Dtsch Ges Inn Med 1968;74: 228-230.
1969
4. Kaess H, Gugler R, Eichelbaum M: Dosis-Wirkungsbeziehung zwischen der Säuresekretion
des Magens und Pentagastrin. Gastroenterologie 1969;2: 88-91.
1970
5. Eichelbaum M, Schomerus M, Dengler HJ: Zur Pharmakokinetik von Prenylamin
(Segontin) beim Menschen. Verh Dtsch Ges Inn Med 1970;76: 942-945
6. Eichelbaum M, Hengstmann J, Dengler HJ: Die Wirkung von Cyclohexylamin auf die
Noradrenalinaufnahme und den Noradrenalingehalt des Rattenherzens. Naunyn-Schmiedebergs
Arch Exp Pharmacol 1970;267: 353-363.
7. Eichelbaum M, Hengstmann J, Dengler HJ: Das Verteilungsmuster des Chlophentermins
2
bei der Ratte, dem Kaninchen und dem Schwein. Naunyn-Schmiedebergs Arch Exp
Pharmacol 1970;267: 446-456.
8. Dengler HJ, Eichelbaum M, Hengstmann J, Wieber J: Pharmacokinetic studies with
sparteine in man. Pharmacol Clin 1970;2: 189-195.
9. Dengler HJ, Eichelbaum M, Schomerus M: Pharmacokinetics of prenylamine in man. In:
Clin. Pharmacol. and Ther. Aspects of Prenylamine; Proc. of the 2nd Int. Symp. on
Prenylamine 1970;: 26-45.
1971
10. Eichelbaum M, Hengstmann J: Eine spezifische und empfindliche Methode zur Bestimmung
von Cyclohexylamin in biologischen Flüssigkeiten. Arch Toxikol 1971;27:
136-141.
11. Reid WD, Christie B, Eichelbaum M, Krishna G: 3-methylcholanthrene blocks hepatic
necrosis induced by administration of bromobenzene and carbon tetrachloride. Exp &
Molec Pathology 1971;15: 363-372.
1973
12. Eichelbaum M: Eine spezifische und empfindliche Methode zur Bestimmung von Prenylamin
und Prenylaminderivaten in biologischen Flüssigkeiten. Arzneim Forsch (Drug
Res) 1973; 23(1): 74-77.
13. Gugler R, Eichelbaum M, Bodem G, Schneider-Deters C, Dengler HJ: Einfluss der
Schilddrüsenfunktion auf den Arzneimittelstoffwechsel beim Menschen. Verh Dtsch Ges
Inn Med 1973; 79: 1230-1233.
1974
14. Eichelbaum M, Hengstmann J, Rost HD, Brecht T, Dengler HJ: Pharmacokinetics, cardiovascular
and metabolic actions of cyclohexylamine in man. Arch Toxikol 1974;31:
243-263.
3
15. Eichelbaum M, Bodem G, Gugler R, Schneider-Deters C, Dengler HJ: Influence of thyroid
status on plasma half-life of antipyrine in man. New Engl J Med 1974;290:
1040-1042.
16. Wieber J, Gugler R, Eichelbaum M, Witkop H: Diaplazentare Passage von Ketamin und
Diazepam beim Menschen. In: Lawin, P Morr-Strathmann (Ed): Jahrestagung Dtsch Ges
Anästh Wiederbel, Springer-Verl 1974;: 622-631.
17. Maling HM, Eichelbaum M, Saul W, Sipes IG, Brown EAB, Gillette JR: Nature of the
protection against carbon tetrachloride-induced hepatotoxicity produced by pretreatment
with dibenamine (N(2-chloroethyl)-dibenzylamine). Biochem Pharmacol 1974;23:
1479-1491.
18. Bodem G, Grieser H, Eichelbaum M, Gugler R: Pharmacokinetics of practolol in renal
failure. Europ J Clin Pharmacol 1974;7: 249-252
19. Dengler HJ, Eichelbaum M: Mechanismen der Schädigung parenchymatöser Organe. In:
Tomberg HP (Hrsg): Poisson controle / Entgiftungsprobleme, Dr. D. Steinkopff-Verlag
Darmstadt 1974; 80-86.
20. Hengstmann J, Konen W, Eichelbaum M, Dengler HJ: The physiological disposition of
p-octopamine in man. Naunyn-Schmiedebergs Arch Pharmacol 1974;283: 93-106.
1975
21. Eichelbaum M, Bertilsson L: Determination of carbamazepine and its epoxide metabolite
in plasma by high-speed liquid chromatography. J Chrom 1975;103: 135-140.
22. Eichelbaum M, Ekbom K, Bertilsson L, Ringberger VA, Rane A: Plasma kinetics of carbamazepine
and its epoxide metabolite in man after single and multiple doses. Europ J
Clin Pharmacol 1975;8: 337-341.
23. Hengstmann J, Konen C, Eichelbaum M, Dengler HJ: Bioavailability of m-octopamine in
man related to its metabolism. Europ J Clin Pharmacol 1975;8: 33-39.
1976
4
24. Eichelbaum M, Bertilsson L, Lund L, Palmer L, Sjöqvist F: Plasma levels of carbamazepine
and carbamazepine-10-11-epoxide during carbamazepine therapy in epileptic patients.
Europ J Clin Pharmacol 1976;9: 417-421.
25. Eichelbaum M, Bertilsson L, Rane A, Sjöqvist F: Untersuchungen zur Kinetik und zum
Stoffwechsel von Carbamazepin. Arzneimittelforschung 1976;26: 134-138.
26. Eichelbaum M, Bertilsson L, Rane A, Sjöqvist F: Autoinduction of carbamazepine metabolism
in man. In: Richens, Woodford (Ed): Anticonvulsant drugs and Enzyme induction.
Elsevier Excerpta Medica 1976;: 147-158.
27. Eichelbaum M: Drug metabolism in thyroid disease. Clin Pharmacokin 1976;1: 339-350.
28. Schomerus M, Stieren B, Spiegelhalder B, Eichelbaum M: Über das pharmacokinetische
Verhalten von Verapamil beim Menschen. Verh Dtsch Ges Inn Med 1976;82,II:
1697-1699.
29. Schomerus M, Spiegelhalder B, Stieren B, Eichelbaum M: Physiological disposition of
verapamil in man. Cardiovasc Res 1976;10: 605-612.
1977
30. Eichelbaum M: Die Yersiniose, eine differentialdiagnostisch wichtige Krankheit. Med
Welt 1977;28: 1591-1593.
31. Eichelbaum M, Spannbrucker N: Rapid and sensitive method for the determination of
antipyrine in biological fluids by high pressure liquid chromatography. J Chromatogr
1977;140: 288-292.
32. Eichelbaum M, Goenechea S, Klehr HU: Die Anwendung pharmakokinetischer Daten
zur Beurteilung der Effektivitaet von Entgiftungsmassnahmen bei Monoureidvergiftungen.
In: Möglichkeiten und Grenzen der Hämoperfusion 1977;: 26-31.
33. Spiegelhalder B, Eichelbaum M: Determination of verapamil in human plasma by mass
fragmentography using stabile isotope labelled verapamil as internal standard. Arzneimittelforschung
1977;27,I: 94-97.
34. Remberg G, Eichelbaum M, Spiteller G, Dengler HJ: Metabolism of C14-D, L-prenylamine
in man. Biomed Mass Spectrometry 1977;4: 297-304.
5
35. Gugler R, Fröscher W, Eichelbaum M, Hildenbrand G: The bioavailability of phenytoin.
J Neurol 1977;216: 155-162.
36. Gugler R, Schell A, Eichelbaum M, Fröscher W, Schulz HU: Disposition of valproic acid
in man. Europ J Clin Pharmacol 1977;12: 125-132.
37. Klehr HU, Goenechea S, Eichelbaum M: Der Effekt der extrakorporalen Hämoperfusion
auf die Elimination von Carbromal bei Carbromal-Intoxikationen. Verh Dtsch Ges Inn
Med 1977;: 1612-1614.
38. Dengler HJ, Eichelbaum M: Polymorphismen und Defekte des Arzneimittelstoffwechsels
als Ursache toxischer Reaktionen. Arzneimittelforschung 1977;27: 1836-1844.
1978
39. Eichelbaum M, Spannbrucker N, Dengler HJ: A probably genetic defect of the metabolism
of sparteine. In: Gorrod JW, ed. Biological Oxidation of Nitrogen. : Elsevier
N-Holland Biom.Press, 1978: 113-118.
40. Eichelbaum M, Sonntag B, v.Unruh G: Determination of monoureids in biological fluids
by high pressure-liquid-chromatography. Arch Toxicol 1978; 41: 187-193.
41. Zietz E, Dengler HJ, Eichelbaum M, Spiteller G: Zum Metabolismus von Antipyrin.
Arzneimittelforschung 1978;28: 315-319.
1979
42. Eichelbaum M, Hoffmann F, Köthe KW, v.Unruh G: Pharmacokinetics and metabolism
of carbamazepine during antiepileptic drug therapy. Clin Pharmacol Ther 1979;26:
366-371.
43. Eichelbaum M, Steincke B, Spannbrucker N, Dengler HJ: Defective N-oxidation of
sparteine in man: A new pharmacogenetic defect. Europ J Clin Pharmacol 1979;16:
183-187.
44. Eichelbaum M, Spannbrucker N, Dengler HJ: The influence of the defective metabolism
of sparteine on the pharmacokinetics of the drug. Europ J Clin Pharmacol 1979;16:
6
189-194.
45. Eichelbaum M, Hoffmann F, Koethe KW, v.Unruh G: Measurement of the metabolites of
the epoxide-diol pathway of carbamazepine to assess the extent of induction of carbamazepine
metabolism during chronic treatment. In: Johannessen, et al, eds. Antiepileptic
Therapy: Adv. in Drug Monitoring. N.Y.: Raven Press, 1979: 143-148.
46. Eichelbaum M, Ende M, Remberg G, Schomerus M, Spiteller G: Metabolism of D, L,
(C14) verapamil in man. Drug Dispos Metab 1979;7(3): 145-148.
47. Schulz HU, Fröscher W, Gugler R, Eichelbaum M: Untersuchungen zum therapeutischen
Bereich der Valproinsäure. Med Welt 1979;30: 59-61.
48. Gugler R, Eichelbaum M, Schell A, Fröscher W, Kiefer K, Schulz HU, Müller G: The
disposition of valproic acid. In: Johannessen, et al, eds. Antiepileptic Therapy. Adv. in
Drug Monitoring. N.Y.: Raven Press, 1979: 121-130.
49. Fröscher W, Eichelbaum M, Gugler R, Hildenbrand G, Penin H: Report on a controlled
trial on the significance of plasma antiepileptic drug monitoring. In: Johannessen, et al,
eds. Antiepileptic Therapy. Adv. in Drug Monitoring. N.Y.: Raven Press, 1979: 263-270.
50. Schomerus M, Eichelbaum M, Dengler HJ: Pharmakokinetik von Spartein und Verapamil.
In: Antoni, Effert, eds. Herzrhythmus-Störungen. Neue Theoret. und klinische Aspekte.:
Schattauer Verlag, 1979:.
51. Fröscher W, Eichelbaum M, Gugler R, Baur MP: Nachtabfall des Carbamazepin--
Spiegels. Der Nervenarzt 1979;50: 171-178.
52. v.Unruh G, Köthe KW, Eichelbaum M: Pharmacokinetics and metabolism of carbamazepine
during therapy studied with 15N-Carbamazepine. In: Stable Isotopes: Proceedings
of the 3rd Intern.Conf. N.Y.: Academic Press, 1979: 453-462.
1980
53. Eichelbaum M, Albrecht M, Kliems G, Schäfer K, Somogyi A: Influence of meso-caval
shunt surgery on verapamil kinetics, bioavailability and response. Br J Clin Pharmacol
1980;10: 527-529.
54. Eichelbaum M: Clinical pharmacokinetics of calcium ion antagonists. Clin Investig Med
7
1980;3: 13-17.
55. Eichelbaum M, Birkel P, Grube E, Gütgemann U, Somogyi A: Effect of verapamil on
PR-intervals in relation to verapamil plasma levels following single i.v. and oral administration
and during chronic treatment. Kli Wschr 1980 58: 919-925.
56. Eichelbaum M, Albrecht M, Kliems G, Schaefer K, Somogyi A: Einfluss von Lebererkrankungen
und mesocavalem Shunt auf die Pharmakokinetik, biologische Verfügbarkeit
und Wirkung von Verapamil. Verh Dtsch Ges Inn Med 1980: 1222-1224.
57. Bertilsson L, Dengler HJ, Eichelbaum M, Schulz HU: Pharmacogenetic covariation of
defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine. Europ J Clin
Pharmacol 1980;17: 153-155.
58. Remberg G, Ende M, Eichelbaum M, Schomerus M: Mass spectrometric identification of
D,L-verapamil metabolites. Arzneimittelforschung (Drug Res) 1980;30: 398-401.
59. Bertilsson L, Eichelbaum M, Mellström B, Säwe J, Schulz HU, Sjöqvist F: Nortriptyline
and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci
1980;6: 1673-1678.
60. Fröscher W, Eichelbaum M, Gugler R, Hildenbrand G: Medikamentöse Therapie der
Epilepsien unter Kontrolle der Antiepileptika Serumspiegel. N.Y.: Schattauer-Verlag,
1980.
61. Musch E, Eichelbaum M, Wang JK, v.Sassen W, Dengler HJ: Häufigkeit und pathophysiologische
Aspekte der INH-Hepatitis bei tuberkulostatischer Kombinationsbehandlung.
Verh Dtsch Ges Inn Med 1980;: 1201-1206.
62. Dengler HJ, Eichelbaum M, von Unruh G: The use of stable isotopes in clinical pharmacokinetics.
In: Gladtke, Heimann, eds. Pharmacokinetics. Stuttgart-N.Y.: Fischer-Verlag,
1980: 7-22.
1981
63. Eichelbaum M, Somogyi A, v.Unruh G, Dengler HJ: Simultaneous determination of the
i.v. and oral pharmacokinetic parameters of D,L-verapamil using stable labelled verapamil.
Europ J Clin Pharmacol 1981;19: 133-138.
8
64. Eichelbaum M, Dengler HJ, Somogyi A, v.Unruh G: Superiority of stable labelled techniques
in the bioavailability assessment of drugs undergoing extensive first-pass elimination.
Europ J Clin Pharmacol 1981;19: 127-132.
65. Eichelbaum M, Sonntag B, Dengler HJ: HPLC determination of antipyrine metabolites.
Pharmacology 1981;23: 192-202.
66. Eichelbaum M, Somogyi A: Verapamil disposition in health and the disease state. In:
Zanchetti, et al, eds. Calcium Antagonism in Cardiovasc. Ther.: Experience with Verapamil.:
Exc Med, 1981: 64-71.
67. Eichelbaum M: Polymorphism of drug oxidation in man.
TIPS 1981;Feb: 31-34.
68. Fröscher W, Eichelbaum M, Niesen M, Altmann D, v.Unruh G: Antiepileptic therapy
with carbamazepin and valproic acid during pregnancy and lactation period. In: Dam,
Gram, Penry, eds. Advances in Epileptology. N.Y.: Raven Press, 1981: 581-588.
69. Fröscher W, Niesen M, Altmann D, Eichelbaum M, Gugler R, Hoffmann F, Penin H:
Antiepileptika-Therapie während Schwangerschaft und Geburt. In: Remschmidt, Rentz,
Jungmann, eds. Epilepsie 1980.: Georg Thieme Verlag, 1981: 152-163.
70. Fröscher W, Eichelbaum M, Gugler R, Hildenbrand G, Penin H: A prospective randomised
trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. Neurology
1981;224: 193-201.
71. Gugler R, Eichelbaum M: Dosisanpassung von Medikamenten bei chronischen Lebererkrankungen.
Leber, Magen, Darm 1981;11: 81-87.
72. Somogyi A, Albrecht M, Kliems G, Schäfer K, Eichelbaum M: Pharmacokinetics, bioavailability
and ECG response of verapamil in patients with liver cirrhosis. Br J Clin
Pharmacol 1981;12: 51-60.
73. Musch E, Eichelbaum M, v.Sassen W, Castro-Parra M, Wang JK, Brestowski U, Baur
MP, Dengler HJ: Beziehung zwischen INH-Metabolismus und INH-Hepatotoxizität unter
tuberkulostatischer Kombinationsbehandlung. Verh Dtsch Ges Inn Med 1981;: 224-228.
74. Musch E, Eichelbaum M, Wang JK, v.Sassen W, Kaschell HJ, Dengler HJ: Häufigkeit
und pathophysiologische Aspekte der Lebertoxizität der antimykobakteriellen Behandlung
mit INH bzw. INHG-Na, RMP und EMB. Prax Klin Pneumol 1981;35: 1062-1067.
9
1982
75. Eichelbaum M: Defective oxidation of drugs: Kinetic and therapeutic implications. Clin
Pharmacokin 1982;7: 1-22.
76. Eichelbaum M, Somogyi A: Pharmacokinetics, bioavailability and ECG response of verapamil
in man. In: Kaltenbach M, Epstein SE, eds. Hypertrophic Cardiomyopathy.:
Springer Verlag, 1982: 291-297.
77. Eichelbaum M: Dosage modification in patients with hormonal dysfunction. In: Yoshida,
al et, eds. Adv. in Pharmacol. and Therap; Clin. Pharmacol.: Pergamon Press, 1982:
187-196.
78. Eichelbaum M, Bertilsson L, Saewe J, Zekorn C: Polymorphic oxidation of sparteine and
debrisoquine: Related pharmacogenetic entities. Clin Pharmacol Ther 1982;31: 184-187.
79. Eichelbaum M: Kalziumantagonisten. Begriff und therapeutische Anwendungen. Med
Welt 1982;33: 1079-1082.
80. Eichelbaum M, Ochs HR, Robertz G, Somogyi A: Pharmacokinetics and metabolism of
antipyrine after intravenous and oral administration. Arzneimittelforschung (Drug Res.)
1982;32: 575-578.
81. Eichelbaum M, Köthe KW, Hoffmann F, v.Unruh G: Use of stable labelled carbamazepine
to study its kinetic during chronic carbamazepine treatment.
Europ J Clin Pharmacol 1982;23: 241-244.
82. Somogyi A, Eichelbaum M, Gugler R: Prediction of bioavailability for drugs with a high
first-pass effect using oral clearance data. Eur J Clin Pharmacol 1982;22: 85-90.
83. Musch E, Eichelbaum M, Wang J, v.Sassen W, Castro-Parra M, Dengler HJ: Die Häufigkeit
hepatotoxischer Nebenwirkungen der tuberkulostatischen Kombinationstherapie
(INH, RMP, EMB) in Abhängigkeit vom Azetyliererphänotyp. Kli Wo 1982;60:
513-519.
84. Fröscher W, Eichelbaum M, Hildenbrand G, Hildenbrand K, Penin H: Prospektive Untersuchungen
zur Epilepsietherapie mit Carbamazepin. Fortschr Neurol Psychiat
1982;50: 396-408.
10
85. Musch E, Loos U, Mackes KG, Reetz P, Glaeser R, v.Sassen W, Schwabe KH, Hengstmann
J: Eichelbaum, M. Klinische Verlaufsstudie bei intravenöser Rifamicinapplikation
in der Tuberkulosetherapie. Verh Dtsch Ges Inn Med 1982;: 638-644.
86. Musch E, Eichelbaum M, Wang JK, v.Sassen W, Ochs HR, Castro-Parra M, Dengler HJ:
Hepatotoxizität der tuberkulostatischen Kombination INH + RMP + EMB in Beziehung
zum Arzneistoffwechsel der Leber. Med Welt 1982;33: 911-914.
87. Park K, Eichelbaum M, Ohnhaus EE: 6-beta-hydroxycortisol excretion in relation to polymorphic
N-oxidation of sparteine. Br J Clin Pharmacol 1982; 13: 737-740.
88. Eichelbaum M, v.Unruh G, Somogyi A: Application of stable labelled drugs in clinical
pharmacokinetic investigations. Clin Pharmacokin 1982;7: 490-507.
1983
89. Eichelbaum M, Bertilsson L, Saewe J: Antipyrine metabolism in relation to polymorphic
oxidation of sparteine and debrisoquine. Br J Clin Pharmacol 1983;15: 317-321.
90. Eichelbaum M: Genetische Polymorphismen des oxidativen Arzneimittelstoffwechsel.
Therapeutische und toxikologische Implikationen. Internist 1983;24: 117-127.
91. Eichelbaum M: Arzneimitteldosierung bei Lebererkrankungen. In: Kliems, Schulz, eds.
Portale Hypertension. Diagnostik und Therapie. Weinheim: Edition Medizin, 1983:
13-17.
92. Eichelbaum M: Pharmakokinetik von Diltiazem, Nifedipin und Verapamil. In: Kalziumantagonisten
in der Therapie der arteriellen und pulmonalen Hypertonie: Uhlen-
Verlag, 1983: 18-21.
93. Eichelbaum M: Drug metabolism in thyroid disease. In: Gibaldi et al, eds. Handbook of
Clin. Pharmacokinetics. N.Y.: ADIS Health Science Press, 1983: 169-181.
94. Eichelbaum M: Polymorphism of drug oxidation in man. In: Lamble, ed. Drug Metabolism
and Distribution. Current Reviews in Biomed.: Elsevier Biomd. Press, 1983:
115-121.
95. Loos U, Musch E, Mackes KG, Reetz KP, Glaeser R, v.Sassen W, Labedzki L, Schwabe
HK: Hengstmann, J. Vergleich oraler und intravenöser RifampicinGabe bei der Behand11
lung offener Lungentuberkulosen. Prax Klin Pneumol 1983; 37: 482-484.
96. Eichelbaum M: Arzneimittel-Nebenwirkungen unter Therapie mit Calcium-Antagonisten.
In: Olsen et al, eds. Medikamentöse Behandlung ausgewählter kardiovaskulärer
Erkrankungen.: Klett-Verlag, 1983: 408-413.
97. Loos U, Musch E, Mackes KG, Reetz P, Glaeser R, Schwabe KH, Hengstmann J, Eichelbaum
M: Intravenöse Rifampicin-Therapie offener Lungentuberkulosen. Med Welt
1983;34: 701-703.
1984
98. Eichelbaum M, Jensen C, v.Sassen W, Bertilsson L, Tomson T: The in vivo and in vitro
biotransformation of carbamazepine in man and rat. In: Levy RH et al, eds. Metabolism
of Antiepileptic Drugs. N.Y.: Raven Press, 1984: 27-34.
99. Musch E, Eichelbaum M, v.Sassen W, Castro-Parra M, Wang JK, Dengler HJ: Isoniazidhepatitis.
Verh Dtsch Ges Inn Med 1984;: 1305-1321.
100. Eichelbaum M: Genetische Determinanten der Arzneimittelwirkung. Verh Dtsch Ges Inn
Med 1984;: 138-143.
101. Eichelbaum M, Somogyi A: Inter- and intra-subject variation in the first-pass elimination
of highly cleared drugs during chronic dosing. Eur J Clin Pharmacol 1984;26: 47-53.
102. Eichelbaum M: Clinical pharmacology of calcium channel blockers. In: Lemberger L,
Reidenberg MM, eds. Proc. of the Second World Conf on Clinical Pharmacol and
Therap. Bethesda: Am Soc Pharmacol Exp Ther, 1984: 774-787.
103. Ochs HR, Eichelbaum M, Vogelgesang B, Kumm D, Knuechel M: Diltiazem, Verapamil
und Chinidin bei chronischem Vorhofflimmern. Med Welt 1984;35: 383-387.
104. Eichelbaum M: Polymorphic drug oxidation in humans. Fed Proc 1984;43: 98-102.
105. Eichelbaum M: Drug toxicity and hormonal dysfunction. Arch Toxicol Suppl 1984;7:
39-47.
106. Dahlqvist R, Bertilsson L, Birkett DJ, Eichelbaum M, Säwe J, Sjöqvist F: Metabolism of
theophylline in the relation of metabolism of antipyrine, debrisoquine and sparteine in
12
healthy subjects. Clin Pharmacol Ther 1984;35: 815-821.
107. Fröscher W, Eichelbaum M, Niesen M, Dieterich K, Rausch P: Carbamazepine levels in
breast milk. Ther Drug Mon 1984;6: 266-271.
108. Eichelbaum M: Elimination von Fremdstoffen aus dem Organismus bei Intoxikationen.
In: Deutsch E, Kleinberger G, Ritz R, Schuster HP, eds. Diagnose, Verlaufskontrolle und
Therapie schwerer exogener Vergiftungen. New York: Schattauer Verlag Stuttgart, 1984:
69-78.
109. Eichelbaum M: Pharmakokinetik und Metabolismus von Verapamil. In: Gross F, ed. Die
Bedeutung der Kalzium-Antagonisten für die Hochdrucktherapie. München: MMW
Medizin Verlag, 1984: 67-77.
110. Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M: Stereoselective first-pass metabolism
of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined
with a stable isotope technique. Br J Clin Pharmac 1984;18: 733-740.
111. Eichelbaum M, Echizen H: Clinical pharmacology of calcium antagonists: A critical review.
J Cardiovas Pharmacol 1984;6: 963-967.
112. v.Unruh GE, Eichelbaum M, Dengler HJ: Stable isotopes in pharmacokinetic studies. In:
Reid E, Wilson ID, eds. Drug determination in therapeutic and forensic contexts.: Plenum
Publishing Corporation, 1984: 27-37.
113. Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA: Characterization
of a common genetic defect of cytochrome P-450 function (debrisoquine-
sparteine type polymorphism) - Increased Michaelis constant and loss of stereo-
selectivity of bufuralol l-hydroxylation in poor metabolizers. Biochem Biophys Res
Comm 1984; 125: 374-380.
114. Eichelbaum M, Mikus G, Vogelgesang B: Pharmacokinetics of (+), (-) and (+/-) verapamil
after intravenous administration. Br J Clin Pharmacol 1984;17: 453-458.
1985
115. Eichelbaum M, Woolhouse NM: Inter-ethnic difference in sparteine oxidation among
Ghanaians und Germans. Eur J Clin Pharmacol 1985;28: 79-83.
13
116. Eichelbaum M, Tomson T, Tybring G, Bertilsson L: Carbamazepine metabolism in man -
Induction and pharmacogenetic aspects. Clin Pharmacokin 1985; 10: 80-90.
117. Echizen H, Brecht T, Niedergesaess S, Vogelgesang B, Eichelbaum M: The effect of
dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am
Heart J 1985;109: 210-217.
118. Echizen H, Vogelgesang B, Eichelbaum M: The effect of D, L-Verapamil on atrioventricular
conduction in relation to its stereoselective first pass metabolism. Clin Pharmacol
Ther 1985; 38: 71-76.
119. Woolhouse NM, Eichelbaum M, Oates NS, Idle JR, Smith RL: Dissociation of coregulatory
control of debrisoquine / phenformin and sparteine oxidations in Ghanaians. Clin
Pharmacol Ther 1985; 37: 512-521.
120. v.Sassen W, Castro-Parra M, Musch E, Eichelbaum M: Determination of isoniazid,
acetylisoniazid, acetylhydrazine and diacetylhydrazine in biological fluids by
high-performance liquid chromatography. J Chromatogr 1985;338: 113-122.
121. Ochs HR, Anda M, Eichelbaum M, Greenblatt DJ: Diltiazem, Verapamil, and Quinidine
in Patients with chronic atrial fibrillation. J Clin Pharmacol 1985;25: 204-209.
122. Musch E, Loos U, Schwabe HK, Eichelbaum M: Bioverfuegbarkeit und klinischer Effekt
von Rifampicin unter Dauertherapie. Kongr Ber Wiss Tag Norddtsch Ges Lungen- und
Bronchialheilk 1985;18: 359-362.
123. Kirch W, Ohnhaus EE, Zekorn C, Eichelbaum M, Spahn H, Mutschler E: Pharmakokinetics
of metoprolol in relation to polymorphic sparteine oxidation. Arch Toxicol 1985;8:
401-402.
124. Zekorn C, Achtert G, Hausleiter HJ, Moon CH, Eichelbaum M: Pharmacokinetics of
N-propylajmaline in relation to polymorphic sparteine oxidation. Klin Wochenschr
1985;63: 1180-1186.
125. Loos U, Musch E, Jensen JC, Mikus G, Schwabe HK, Eichelbaum M: Pharmacokinetics
of oral and intravenous rifampicin during chronic administration. Klin Wochenschr
1985;63: 1205-1211.
126. Eichelbaum M: The application of drugs labelled with stable isotopes in pharmacokinetics
and clinical pharmacokinetics. In: Breimer DD, Speiser P, eds. Topics in pharmaceutical
sciences 1985. Elsevier Science Publishers, 1985: 237-248.
14
1986
127 Eichelbaum M, Echizen H, Vogelgesang B: Einfluss der Applikationsart auf die Plasmakonzentrations-
Wirkungsbeziehung von Pharmaka. In: Frölich JC, ed. Plasmaspiegel -
Wirkungsbeziehungen von Pharmaka. Stuttgart: Fischer-Verlag, 1986: 7-13.
128 Eichelbaum M: Pharmakogenetische Aspekte der Arzneimitteltherapie. In: Doelle W,
Müller-Oerlinghausen B, Schwabe U, eds. Grundlagen der Arzneimitteltherapie. Entwicklung,
Beurteilung und Anwendung von Arzneimitteln. : B.I.-Wissenschaftsverlag,
1986: 438-448.
129 Eichelbaum M: Polymorphic oxidation of debrisoquine and sparteine. In: Kalow W, ed.
Ethnic differences in reaction to drugs and other xenobiotics. New York: R.Liss, Inc,
1986: 157-167.
130 Eichelbaum M, Reetz P, Schmidt EK, Zekorn C: Polymorphism of sparteine metabolism.
Xenobiotica 1986;16: 465-481.
131 Eichelbaum M, Mineshita S, Ohnhaus EE, Zekorn C: The influence of enzyme induction
on polymorphic sparteine oxidation. Br J Clin Pharmacol 1986;22: 49-53.
132 Osikowska-Evers BA, Eichelbaum M: A sensitive capillary GC assay for the determination
of sparteine oxidation products in microsomal fractions of human liver. Life Sci
1986;38: 1775-1782.
133 Eichelbaum M, Fischer C, Heuer B, Mikus G: Pharmakokinetik und Metabolismus von
Nitrendipin. In: Distler A, ed. Calcium-Antagonisten in der Hochdrucktherapie. Stuttgart-
New York: Schattauer Verlag, 1986: 35-43.
134 Eichelbaum M: Pharmakokinetik in Abhängigkeit vom Lebensalter. In: Besonderheiten
von Arzneimittelwirkungen in verschiedenen Lebensphasen. Frankfurt/Main: Bundesapothekerkammer,
1986: 193-204.
135 Eichelbaum M: Klinische Pharmakologie der Mukolytika. In: Rauchen und Atemwege.
Prävention und therapeutische Aspekte. München: Verlag angewandte Wissenschaften,
1986: 103-111.
136 Eichelbaum M: Pharmacokinetic drug interactions. J Clin Pharmacol 1986;26: 469-473.
15
137 Mikus G, Ha HR, Vozeh S, Zekorn C, Follath F, Eichelbaum M: Pharmacokinetics and
metabolism of quinidine in extensive and poor metabolisers of sparteine. Eur J Clin
Pharmacol 1986; 31: 69-72.
138 Klotz U, Mikus G, Zekorn C, Eichelbaum M: Pharmacokinetics of midazolam in relation
to polymorphic sparteine oxidation. Br J Clin Pharmac (1986); 22; 618-620.
139 Krämer G, Theisohn M, vonUnruh GE, Eichelbaum M: Carbamazepine-danazol drug
interaction: Its mechanism examined by a stable isotope technique. Ther Drug Mon
(1986); 8: 387-392.
140 Echizen H, Eichelbaum M: Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.
Clin Pharmacokin (1986); 11: 425-449.
141 Fischer C, Heuer B, Heuck K, Eichelbaum M: Quantification of nitrendipine by stable
isotope dilution and electron-capture negative ion chemical ionization. Biom Environm
Mass Spectrom, 1986: 645-650.
1987
142 Eichelbaum M: Pharmakokinetische Besonderheiten im Alter. Hospitalis 57:74-78, 1987
143 Eichelbaum M: Arzneimittelstoffwechsel der Leber: Genetische Faktoren als Ursache der
individuellen Variabilität. S. 145-160. In: Seidel, D. und Lang, H. (Hrsg) Funktion und
Funktionsdiagnostik der Leber. Springer Verlag Berlin / Heidelberg / New York / London
/ Paris / Tokyo, 1987
144 Eichelbaum M, Baur MP, Dengler HJ, Osikowska-Evers BO, Tieves G, Zekorn C,
Rittner C: Chromosomal assignment of human cytochrome P-450 (debrisoquine / sparteine
type) to chromosome 22. Br J Clin Pharmac 23: 455-458, 1987
145 Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ: Evidence for
polymorphic oxidation of sparteine in Japanese subjects. Br J clin Pharmac: 482-485,
1987
146 Osikowska-Evers B, Dayer P, Meyer UA, Robertz GM, Eichelbaum M: Evidence for
altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in
poor metabolizers. Clin Pharmacol Ther:320-325, 1987
16
147 Eichelbaum M, von Unruh GE, Hoffmann F: Pharmakokinetik des Tegretal retard. In:
Carbamazepin in der Neurologie (Hrsg.: G. Krämer, H.Chr. Hopf), Georg Thieme Verlag
Stuttgart, pp. 222-224, 1987
148 Wagner F, Jähnchen E, Trenk D, Eichelbaum M, Harnasch P, Hauf G, Roskamm H: Severe
complications of antianigal drug therapy in a patient identified as a poor metabolizer
of metoprolol, propafenone, diltiazem and sparteine. Klin. Wochenschr. 65: 1164-1168,
1987
149 Mikus G, Fischer C, Heuer B, Langen C, Eichelbaum M: Application of stable isotope
methodology to study the pharmacokinetics, bioavailability and metabolism of
nitrendipine after i.v. and p.o. administration. Br. J. Clin. Pharmacol. 24: 561-570, 1987
150 Dayer P, Kronbach T, Eichelbaum M, Meyer U: Enzymatic basis of the debrisoquine
/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1`-
hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Biochem Pharmacol 36: 4145-4152, 1987
151 Loos U, Musch E, Jensen JC, Schwabe HK, Eichelbaum M: Influence of the enzyme
induction by rifampicin on its presystemic metabolism. Pharmac Ther 33:201-204, 1987
152 Meese CO, Thalheimer P, Eichelbaum M: High-performance liquid chromatographic
mthod for the analysis of debrisoquine and its S-(+) and R-(-)-hydroxy metabolites in
urine. J. Chromatogr. 423: 344-350, 1987
153 Mikus G, Eichelbaum M: Pharmacokinetics, bioavailability, metabolism and hemodynamic
effects of the calcium channel antagonist nitrendipine. J. Cardiovasc. Pharmacol. 9:
140-141, 1987
1988
154 Meese CO, Fischer C,Eichelbaum M: Stereoselectivity of the 4-hydroxylation of debrisoquine
in man - detected by gas chromatography / mass spectrometry. Biomed. Environ.
Mass Spectrom. 15: 63-66, 1988
155 Eichelbaum M: Pharmacokinetic and Pharmacodynamic Consequences of Stereoselective
Drug Metabolism in Man. Biochemical Pharmacology 37: 93-96, 1988
156 Eichelbaum M: Enantioselective drug metabolism and its pharmacokinetic and pharma17
codynamics consequences. In: Metabolism of Xenobiotics (Ed. J.W. Gorrod, H.
Oelschläger, J. Caldwell), Taylor & Francis London / New York / Philadelphia, pp. 345-
352, 1988
157 Lennard MS, Tucker GT, Woods HF, Iyun AO, Eichelbaum M: Stereoselective 4-
hydroxylation of debrisoquine in Nigerians. Biochem. Pharmacol. 37: 97-98, 1988
158 Eichelbaum M, Bertilsson L, Küpfer A, Steiner E, Meese CO: Enantioselectivity of 4-
hydroxylation in extensive and poor metabolizers of debrisoquine. Br J Clin Pharmac 25:
505-508, 1988
159 Eichelbaum M: Genetic polymorphisms in oxidative drug metabolism of man. Jpn. J.
Clin. Pharmacol. Ther. 19: 331-336, 1988
160 Fröscher W, Stoll K-D, Hildenbrand G, Eichelbaum M: Investigations on the intraindividual
constancy of the ratio of carbamazepine to carbamazepine-10.11-epoxide in
man. Arzneim.-Forsch./Drug Res. 38: 724-726, 1988
161 Eichelbaum M: Stereoselective drug metabolism: its pharmacokinetic and pharmacodynamic
consequences. The Keio Journal of Medicine 37: 209-210, 1988
162 Echizen H, Manz M, Eichelbaum M: Electrophysiologic effects of dextro- and levoverapamil
on sinus node and av node function in humans. J. Cardiovasc. Pharmacol. 12:
543-546, 1988
163 Eichelbaum M, Mikus G, Mast V, Fischer C, Kuhlmann U, Machleidt C: Pharmacokinetics
and Pharmacodynamics of nitrendipine in healthy subjects and patients with kidney
and liver disease. J. Cardiovasc. Pharmacol. 12: S6-S10, 1988
164 Beckmann J, Hertrampf R, Gundert-Remy U, Mikus G, Gross AS, Eichelbaum M: Is
there a genetic factor in flecainide toxicity? Br. Med. J. 297: 1316, 1988
165 Walter-Sack I, Eichelbaum M, deVries JX, Weber E: Benzbromarone biotransformation
is not related to polymorphic oxidation of sparteine. Klin. Wschr. 66: 1097-1098, 1988
166 Kassai A, Toth G, Eichelbaum M, Klotz U: No evidence of a genetic polymorphism in
the oxidative metabolism of midazolam. Clin. Pharmacok. 15: 319-325, 1988
167 Horai Y, Ishizaki T, Eichelbaum M, Hashimoto K, Chiba K, Dengler HJ: Further analysis
of sparteine oxidation in a Japanese population and comparison with data observed in different
ethnic populations. Xenobiotica 18: 1077-1084, 1988
18
168 Eichelbaum M: Genetic polymorphism of sparteine / debrisoquine oxidation. ISI Atlas
Sci Pharm. 2: 243-251, 1988
169 Gross AS, Heuer B, Eichelbaum M: Stereoselective protein binding of verapamil enantiomers.
Biochem. Pharmacol. 37: 4623-4627, 1988
1989
170 Meese CO, Eichelbaum M: Stereoselective drug metabolism and pharmacodynamic consequences.
In: Xenobiotic Metabolism and Disposition (Ed. R. Kato, R.W. Estabrook and
M.N. Cayen), Taylor & Francis London / New York / Philadelphia, pp. 179-184, 1989
171 Ebner T, Meese CO, Eichelbaum M: Thin-layer chromatographic screening test for polymyorphic
sparteine oxidation. Therap. Drug Monit. 11: 214-216, 1989
172 Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M: In vitro characterization
of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin.
Pharmacol. Ther. 45: 28-33, 1989
173 Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood A, Eichelbaum M, Woosley R,
Roden D: Stereoselective disposition and pharmacologic activity of propafenone enantiomers.
Circulation 79: 1068-1076, 1989
174 Mikus G, Gross AS, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M: The
influence of the sparteine / debrisoquin phenotype on the disposition of flecainide. Clin.
Pharmacol. Ther. 45: 562-567, 1989
175 Ebner T, Eichelbaum M, Fischer P, Meese CO: Über die stereospezifische Hydroxylierung
von (+)-Spartein (Pachycarpin) bei der Ratte. Arch. Pharm. 322: 399-403, 1989
176 Eichelbaum M, Mikus G: Arzneimittelinteraktionen - was gibt es Neues? Pharmakotherapie
39: 2610-2616, 1989
177 Seyffer R, Eichelbaum M, Jensen JC, Klotz U: Antipyrine metabolism is not affected by
terbinafine, a new antifungal agent. Eur. J. Clin. Pharmacol. 37: 231-233, 1989
178 Gross AS, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M: Stereoselective
disposition of flecainide in relation to the sparteine / debrisoquine metaboliser
19
phenotype. Br. J. Clin. Pharmac. 28: 555-566, 1989
179 Eichelbaum M: Pharmakokinetik und Metabolismus von Gallopamil. Kardiologie 78:
20-24, 1989
1990
180 Eichelbaum M: Zur Problematik genetischer Polymorphismen im oxidativen Arzneimittelstoffwechsel
des Menschen. In: Toxikologische und klinisch-pharmakologische Prüfungen
(Hrsg. P. Grosdanoff, O. Kraupp, W. Schütz, R. Schulte-Hermann) Verlag Walter
de Gruyter Berlin/New York, pp. 555-565, 1990
181 Gross A S , Borstel B,Eichelbaum M : Determination of gallopamil in serum by gas
chromatography - mass spectrometry. J. Chromatogr. 525: 183-192, 1990
182 Eichelbaum M, Gross A S: The genetic polymorphism of debrisoquine / sparteine metabolism
- Clinical aspects. Pharmac. Ther. 46: 377-394, 1990
183 Eichelbaum M, Hardtmann E, Kroemer HK, Mörike K: Pharmakokinetik und Pharmakogenetik
der Antiarrhythmika Encainid, Flecainid, N-Propylajmalin und Propafenon. In:
Arrhythmie-behandlung und Hämodynamik (Hrsg. B. Lüderitz) Springer-Verlag, pp. 24-
37, 1990
184 Grant DM, Mörike K, Eichelbaum M,Meyer UA: Acetylation pharmacogenetics. The
slow acetylater phenotype is caused by decreased or absent arylamine N-acetyltransferase
in human liver. J. Clin. Invest.85: 968-972, 1990
185 Specht D, Meese CO, Ratge D, Eichelbaum M: The metabolic pattern of Scarboxymethyl-
L-cysteine. A new study with HPLC and a novel ex vivo carbon-13-
NMR-method. Fresenius J. Anal. Chem. 337: 63-64, 1990
186 Eichelbaum M: Genetische Polymorphismen des Arzneimittelmetabolismus - Konsequenzen
für die neurologische Therapie. In: Verhandlungen der Deutschen Gesellschaft
für Neurologie 5 (Hrsg. O.-A. Fischer, H. Baas und W. Enzensberger), Springer Verlag,
pp. 781-788, 1990
187 Mikus G, Eichelbaum M, Fischer C, Gumulka S, Klotz U, Kroemer HK: Interaction of
verapamil and cimetidine: stereochemical aspects of drug metabolism, drug disposition
and drug action. J. Pharmacol. & Exper. Ther. 253: 1042-1048, 1990
20
188 Ebner T, Meese CO, Eichelbaum M: Stable isotope studies on the stereochemistry of the
polymorphic oxidation of sparteine and debrisoquine in man. Chirality and Biological
Activity; 191-198, 1990
189 Fischer C, Schönberger F, Meese CO, Eichelbaum M: Determination of the enantiomers
of flecainide and two major metabolites in man by gas chromatography/mass spectrometry
using negative ion chemical ionization and stable isotope labelled internal
standards. Biom. & Environm. Mass Spectr. 19: 256-266, 1990
190 Meese CO, Hofmann U, Eichelbaum M: Polymorphic sulphoxidation of carbocysteine.
Lancet 336: 693-694, 1990
191 Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Büschenfelde K-H, Eichelbaum
M: Patients with type II autoimmuno hepatitis express functionally intact cytochrome
P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo.
Hepatology 12: 127-132, 1990
192 Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR: Identification
of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:
773-776, 1990
1991
193 Häußermann K, Benz B, Gekeler V, Schumacher K, Eichelbaum M: Effects of verapamil
enantiomers and major metabolites on the cytotoxicity of vincristine and daunomycin in
human lymphoma cell lines. Eur. J. Clin. Pharmacol. 40: 53-59, 1991
194 Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA: Deletion of the entire cytochrome
P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers
of the debrisoquine / sparteine polymorphism. Amer. J. Hum. Gen. 48: 943-950, 1991
195 Hofmann U, Eichelbaum M, Seefried S, Meese CO: Identification of thiodiglycolic acid,
thiodiglycolic acid sulfoxide and (3-darboxymethylthio)lactic acid as major human biotransformation
products of S-carboxymethyl-L-cysteine. Drug Metab. Dispos. 19: 222-
226, 1991
196 Gross AS, Mikus G, Fischer C, Eichelbaum M: Polymorphic flecainide disposition under
conditions of uncontrolled urine flow and pH. Eur. J. Clin. Pharmacol 40: 155-162, 1991
21
197 Mikus G, Mast V, Fischer C, Machleidt C, Kuhlmann U, Eichelbaum M: Pharmacokinetics,
bioavailability, metabolism and acute and chronic antihypertensive effects of
nitrendipine in patients with chronic renal failure and moderate to severe hypertension.
Br J Clin Pharmac 31: 313-322, 1991
198 Mikus G, Somogyi AA, Bochner F, Eichelbaum M: Codeine O-demethylation: rat strain
differences and the effects of inhibitors. Biochem Pharmacol 41: 757-762, 1991
199 Balant JP, Benet LZ, Blume H, Bozler G, Breimer DD, Eichelbaum M, Gundert-Remy
U, HIrtz JL, Mutschler E, Midha KK, Rauws AG, Ritschel WA, Sansom LN, Skelly JP,
Vollmer K-O: Is there a need for more precise difinitions ofbioavailability? Eur J Clin
Pharmacol 40:123-126, 1991
200 Gross AS, Kroemer HK, Eichelbaum M: Genetic polymorphism of drug metabolism in
humans. In: Biolog. React. Intermed. IV (Ed. C.M. Witmer et al.), Plenum Press, New
York, pp. 627-640, 1991
201 Eichelbaum M, Kroemer HK: Drug metabolism as a source of variability in drug response.
In: Hepatic Metabolism and Disposition of Endo- and Xenobiotics. (ed. K.W.
Bock, W. Gerok, S. Matern, R. Schmid), Kluwer Academic Publishers, Dordrecht / Boston
/ London, pp. 61-74, 1991
202 Ayesh R, Kroemer HK, Eichelbaum M, Smith RL: Metabolism of verapamil in a family
pedigree with deficient N-oxidation of trimethylamine. Br. J. clin. Pharmac. 31: 693-696,
1991
203 Mikus G, Zekorn C, Brecht T, Eichelbaum M: Acute haedomynamic effects of i.v.
nitrendipine in healthy subjects. Eur. J. Clin. Pharmacol. 41: 99-103, 1991
204 Kroemer HK, Fischer C, Meese CO, Eichelbaum M: Enantiomer / Enantiomer interaction
of (S)- and (R)-propafenone for cytochrome P450IID6-catalyzed 5-hydroxylation: in
vitro evaluation of the mechanism. Molecular Pharmacol. 40: 135-142, 1991
205 Ebner T, Meese CO, Eichelbaum M: Regioselectivity and stereoselectivity of the metabolism
of the chiral quinolizidine alkaloids sparteine and pachycarpine in the rat. Xenobiotica
21: 847-857, 1991
206 Ebner T, Meese CO, Fischer P, Eichelbaum M: A nuclear magneticresonance study of
sparteine delta metabolite structure. Drug Metab. Dispos. 19: 955-959, 1991
22
207 Broly F, Gaedigk A, Heim M, Eichelbaum, M, Mörike K, Meyer UA: Debrisoquine/
sparteine hydroxylation genotype and phenotype: analysis of common mutations and
alleles of CYP2D6 in a European population. DNA and Cell Biology 10: 545-558, 1991
208 Meese CO, Fischer C, Küpfer A, Wisser H, Eichelbaum M: Identification of the "major"
polymorphic carbocysteine metabolite as S-(carboxymethylthio)-L-cysteine. Biochem.
Pharmacol. 42: R13-R16, 1991
209 Mikus G, Somogyi AA, Bochner F, Eichelbaum M: Thebaine O-demethylation to oripavine:
genetic differences between two rat strains. Xenobiotica 21: 1501-1509, 1991
210 Mikus G, Mast V, Fischer C, Machleidt C, Kuhlmann U, Eichelbaum M: Farmacocinéta,
biodisponibilidad, metabolismo y efectos antihipertensivos agudos y crónicos del
nitrendipino en los pacientes con insuficiencia renal crónica e hipertensión de grado
moderado a grave. Pharmacy Digest 2: 3-5, 1991
211 Turgeon J, Fiset C, Giguere R, Gilbert M, Mörike K, Rouleau JR, Kroemer HK, Eichelbaum
M, Grech-Belanger O, Belanger PM: Influence of debrisoquine phenotype and of
quinidine on mexiletine disposition in man. J. Pharmacol. Exp. Ther. 259: 789-798, 1991
212 Eichelbaum M, Gross AS: Implications of stereoselectivity in clinical pharmacokinetics.
In: New Trends in Pharmacokinetics (Ed. by A. Rescigno and A.K. Thakur) Plenum
Press, New York, pp. 271-279, 1991
213 Balant LP, Balant-Gorgia AE, Gex-Fabry M, Eichelbaum M: Genetic polymorphism
human drug metabolism. In: New Trends in Pharmacokinetics (Ed. by A. Rescigno and
A.K. Thakur) Plenum Press, New York, pp. 271-279, 1991
214 Meese CO, Fischer C, Eichelbaum M, Wisser H:Identification of an urinary disulphide
human metabolite of carbocysteine by 13C nuclear magnetic resonance spectroscopy and
gas chromatography/mass spectrometry. Eur. J. Clin. Chem. Clin. Biochem. 29: 594-595,
1991
1992
215 Mast V, Fischer C, Mikus G, Eichelbaum M: Use of pseudoracemic nitrendipine to elucidate
the metabolic steps responsible for stereoselective disposition of nitrendipine enantiomers.
Br J clin Pharmac. 33: 51-59, 1992
23
216 Roller E, Benz B, Eichelbaum M, Gekeler V, Häußermann K, Klumpp B, Schumacher
K: Reversal of Multridrug Resistance with a New Calcium/Calmodulin Antagonist.
Haematology and Blood Transfusion 34: 40-43, 1992
217 Eichelbaum M, Gross AS, Kroemer HK: Genetic polymorphism in drug metabolism and
its role in patient medication. In: Topics in pharmaceutical sciences 1991 (Ed. by D.J.A.
Crommelin, K.K. Midha) Medpharm Scientific Publishers Stuttgart, pp. 473-484, 1992
218 Kroemer HK, Echizen H, Heidemann H, Eichelbaum M: Predictabilty of the in Vivo Metabolism
of Verapamil from in Vitro Data: Contribution of Individual Metabolic Pathways
and Stereoselective Aspects. J.Pharmacol Exp. Ther. 260: 1052-1057, 1992
219 Meese CO, Eichelbaum M, Ebner T, Heinkele G, Krimmer S, Fischer P: 13C and 2H
NMR as ex-vivo probe for monitoring human drug metabolism. In: Synthesis and Applications
of Isotopically Labelled Compounds (ed E. Buncel and G.W. Kabalka) Elsevier
Science Publishers B. V. 291-296, 1992
220 Mateblowski M, Topfmeier P, Kuhn D, Eichelbaum M, Mikus G: Bioäquivalenz von
Verapamil-Retardzubereitungen. Vergleich einer Verapamil-Retardkapsel mit Isoptin
RR240. Arzneimitteltherapie 1992; 10: 44-47
221 Eichelbaum M, Kroemer HK, Mikus G: Genetically determined differences in drug metabolism
as a risk factor in drug toxicity. Toxicology Letters 64/65: 115-122, 1992
1993
222 Eichelbaum M: Leberzirrhose und steroselektiver First-pass Metabolismus razemischer
Arzneimittel: Konsequenzen für die Interpretation von pharmakokinetischen und pharmakodynamischen
Daten. In: Konzepte in der Humanpharmakologie; Pharmakodynamische
Modelle für die Arzneimittelentwicklung (Hrsg. Lange D, Jaeger H, Seifert W,
Klingmann I), Springer Verlag, pp. 45-54, 1993
223 Eichelbaum M, Bühl K, Engel G, Ladda E, Schumacher K, Weimer A: Phase I Studie mit
R-Verapamil zur Aufhebung der Multidrug-Resistenz bei Chemotherapie. In: Dexverapamil
- circumventor of multidrug resistance (ed. by M. Eichelbaum, H.-P. Hirth, K.
Schumacher, U. Traugott), Kluwer Academic Publishers: 51-56, 1993
224 Schumacher K, Ladda E, Bühl K, Weimer A, Eser C, Traugott U, Roller E, Löffler B,
Eichelbaum M: Reversal of multidrug resistance by R-Verapamil. In. Dexverapamil -
24
circumventor of multidrug resistance (ed. by M. Eichelbaum, H.-P. Hirth, K. Schumacher,
U. Traugott), Kluwer Academic Publishers: 57-64, 1993
225 Botsch S, Gautier J-C, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization
of the cytochrome P450 enzymes involved in N-dealkylation of propafenone:
Molecular base for interaction potential and variable disposition of active metabolites.
Molecular Pharmacology, 43: 120-126, 1993
226 Ebner T, Eichelbaum M: The metabolism of aprinidine in relation to the sparteine / debrisoquine
polymorphism. Br. J. clin. Pharmac. 35:426-430, 1993
227 Bertilsson L, Meese CO, Yue QY, Dahl ML, Engelman-Sundberg M, Johansson I, Säwe
J, Eichelbaum M: Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in
Chinese of different CYP2D6 genotypes. Pharmacogenetics 3:94-100, 1993
228 Roller E, Klumpp B, Krause J, Eichelbaum M, Schumacher K: Influence of sequential
exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid
cell lines. Cancer Chemotherapy and Pharmacology, 32: 151-155, 1993
229 Eichelbaum M: Enantiomers: Implications and complications in developmental pharmacology.
Developmental Pharmacology and Therapeutics S. 131-134, 1993
230 Meese CO, Specht D, Ratge D, Eichelbaum M, Wisser H: High-performance liquid
chromatographic and carbon-13 nuclear megnetic resonance spectrometric determination
of S-carboxymethyl-L-cysteine and its metabolites in human urine. Fresenius J Anal
Chem, 346: 837-840, 1993
231 Fritz P, Behrle E, Beaune P, Eichelbaum M, Kroemer HK: Differential expression of
drug metabolizing enzymes in primary and secondary liver neoplasm: immunohistochemical
characterization of cytochrome P4503A and glutathione-S-transferase. Histochemistry
99: 443-451, 1993
232 Fischer C, Schönberger F, Mück W, Heuck K, Eichelbaum M: Simultaneaous assessment
of the intravenous and oral disposition of the enantiomers of racemic nimodipine by chiral
stationary-phase high-performance liquid chramatography and gas chromatography/
mass spectroscopy combined with a stable isotope technique. J Pharmac Sci 82: 244-
250, 1993
233 Kroemer HK, Gautier J-C, Beaune P, Henderson C, Wolf CR, Eichelbaum M: Identification
of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-
Schmiedeberg's Arch. Pharmacol. 348: 332-337, 1993
25
234 Mikus G, Eichelbaum M: Application of subject phenotyping in bioequivalence Studies.
In: Bio International Bioavailability, Bioequivalence and Pharmacokinetics (ed. by K.K.
Midha and H.H. Blume) Medpharm Scientific Publishers Stuttgart, 1993
235 Gross AS Eser C, Mikus G, Eichelbaum M: Enantioselective gallopamil protein binding.
Chirality 5: 414-418, 1993
236 Jorgé LF, Tomás DA, Griese U, Nebert DW, Eichelbaum M: Evolutionary pharmacogenetics
of CYP2D6 in Ngawbe guaymi of Panama: allele-specific PCR detection of the
CYP2D66B allele and RFLP analysis. Pharmacogenetics 3: 231-238, 1993
237 Roller E, Eichelbaum M, Klumpp B, Krause J, Schumacher K: Circumvention of multidrug
resestance by addition of calcium/calmodulin antagonists to cytostatic drugs. In:
Drug Resistancen in Leukemia and Lymphoma (eds. Kaspers, G., Pieters, R., Twentyman,
P., Weisenthal, L., Veerman, A.) Harwood academic publishers. 189-194, 1993
238 Arias TD, Jorgé LF, Griese E-U, Inaba T, Eichelbaum M: Polymorphic N-acetyltransferase
(NAT2) in Amerindian populations of Panama and Colombia: high frequencies of
point mutation 857A as found in allele S3/M3. Pharmacogenetics 3: 328-331, 1993
1994
239 Mikus G, Bochner F, Eichelbaum M, Horak P, Somogyi AA, Spector SL: Endogenous
codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/
sparteine) polymorphism1 J. Pharmacol. exp. Ther. 268: 546-551, 1994
240 Mikus G, Kroemer HK, Eichelbaum M: Clinical implications of genetic polymorphisms
in human drug metabolism. In: Frontiers in Biotransformation, Volume 9, Chapter 7:
Regulation and Control of Complex Biological Processes by Biotransformation (ed. By
Klaus Ruckpaul and Horst Rein, Akademie Verlag): 215-245, 1994
241 Roller E, Bürkle D, Eichelbaum M, Klumpp B, Krause J, Schumacher K: Combinations
of cytostatic drugs with calcium/ calmodulin antagonists for reversal of multidrug resistance.
In: Acute Leukemias IV, Prognostic Factors (ed. by Büchner et al, Springer
Verlag Berlin/Heidelberg): 254-257, 1994
242 Botsch S, Heinkele G, Meese CO, Eichelbaum M, Kroemer HK: Rapid determination of
CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of
26
propafenone glucuronides. Eur. J. Clin. Pharmacol, 46: 133-135, 1994
243 Bühl K, Eichelbaum M: Besonderheiten der Arzneimitteltherapie im Alter. In: Der geriatrische
Tumorpatient; Beitr. Onkologie Vol. 45 (Hrgs. Neises, M., Wischnik, A., Melchert,
F.) Karger Verlag Basel): pp 81-94, 1994
244 Funck-Brentano C, Becquemont L, Kroemer HK, Bühl K, Knebel NG, Eichelbaum M,
Jaillon P: Variable disposition kinetics and electrocardiographic effects of fecainide during
repeated dosing in humans: Contribution of genetic factors, dose-dependent clearance,
and interaction with amiodarone. Clin. Pharmacol. Ther. 55: 256-269, 1994
245 Kroemer HK, Mikus G, Eichelbaum M: Clinical Relevance of Pharmacogenetics. In.
Pharmacokinetics of Drug (Hrgs. P.G. Welling and L.P. Balant, Springer Verlagt Berlin/
Heidelberg): 265-288, 1994
246 Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M: An enantiomer-
enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic
drug therapy. Circulation, 89 (5): 2396-2400, 1994
247 Kroemer HK, Gross A, Eichelbaum M: Enantioselectivity in drug action and drug metabolism:
Influence on dynamics. In: Pharmacodynamics and drug development - Perspectives
in clinical pharmacology (ed. by Cutler, N.R. et al., Joh Wiley & Sons, Chichester):
103- 114, 1994
248 Mörike K, Mikus G, Prawirohardjono W, Eichelbaum M: Potency of the i- and Npropylajmaline
in experimental reperfusion arrhythmia. Pharmacology Communications,
4 (3): 225-232, 1994
249 Evers J, Eichelbaum M, Kroemer HK: Unpredictabilitiy of flecainide plasma concentrations
in patients with renal failure: relationship to side effects and sudden death. Therapeutic
Drug Monitoring 16: 349-351, 1994
250 Bock KW, Schrenk D, Forster A, Griese E-U, Mörike K, Brockmeier D, Eichelbaum M:
The influence of environmental and genetic factors on CYP2D6, CYP2A1 and UDPglucuronosyltransferases
in man using sparteine, caffeine, and paracetamol as probes.
Pharmacogenetics 4: 209-218, 1994
251 Evert B, Griese E-U, Eichelbaum M: A missense mutation in exon 6 of the CYP2D6
gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer
phenotype of sparteine. Naunyn-Schmiedeberg's Arch. Pharmacol. 350: 434-439, 1994
27
252 Evert B, Griese E-U, Eichelbaum M: Cloning and sequencing of a new non-functional
CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics,
4: 271-274, 1994
253 Eichelbaum M, Botsch S, Kroemer HK: Prädiktion des humanen in vivo Metabolismus
durch in vitro Untersuchungen. In: Fremdstoffmetabolismus und Klinsiche Pharmakologie
(ed. by Hans J. Dengler und Ernst Mutschler, Gustav Fischer Verlag Stuttgart), 111-
122, 1994
254 Eichelbaum M, Kroemer HK: Genetische Polymophismen des Arzneimittelstoffwechsels
und Therapeutisches Drug Monitoring. In: Therapeutisches Drug Monitoring (ed. by G.
Hitzenberger, Blackwell MZV 1994), 29-35, 1994
255 Eichelbaum M; Side effects and toxic reaction of chiral drugs: A clinical perspective.
In. Toxicology in Transition (ed. By G.H. Degen et al., Springer Verlag Berlin), 514-521,
1994
1995
256 Mikus G, Mast V, Ratge D, Wisser H, Eichelbaum M: Stereoselectitvity in cardiovascular
and biochemical action of calcium antagonists: Studies with the enantiomers of the
dihydropyridine nitrendipine. Clin. Pharmacol. Ther. 57: 52-61, 1995
257 Engel G, Hofmann U, Eichelbaum M: Highly sensitive and specific gas chromatographic-
tandem mass spectrometric method for the determination of trace amounts of antipyrine
metabolites in biological material. J. Chromatogr. B 666: 111-116, 1995
258 Firkusny L, Kroemer HK, Eichelbaum M: In vitro characterization of cytochrome P450
catalysed metabolism of the antiemetic tropiestron. Biochem. Pharmacol. 49: 1777-1784,
1995
259 Kroemer HK, Eichelbaum M: "It's the genes, stupid". Molecular bases and clinical Consequences
of Genetic Cytochrom P450 2D6 polymorphism. Life Sci. 56: 2285-2298,
1995
260 Eichelbaum M, Kroemer HK: Klinisch-pharmakologische Grundlagen der Arzneimitteltherapie.
In: Therapie-Handbuch (Hrsg. Bünte H., et al., Urban & Schwarzenberg München-
Wien-Baltimore), 1-24, 1995
28
261 Eichelbaum M, Kroemer HK: Besonderheiten der Arzneimitteltherapie bei Patienten mit
Niereninsuffizienz. In: Therapie-Handbuch (Hrsg. Bünte H., et al., Urban & Schwarzenberg
München-Wien-Baltimore), 1-2, 1995
262 Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M: Cytochromes of the P450 2C
subfamily are the major enzymes involved in the O-demethylation of verapamil in humans.
Naunyn-Schmiedeberg's Arch. Pharmacol. 353: 116-121, 1995
263 Bohnenstengel F, Johnson S, Hofmann U, Eichelbaum M, Kroemer HK: Direct gas
chromatographic determination of dechloroethylclophosphamide following microsomal
incubation of cyclophosphamide. J. Chromatogr. B 672: 271-276, 1995
264 Ebner T, Meese CO, Eichelbaum M: Mechanism of cytochrome P450 2D6-catalyzed
sparteine metabolism in humans. Mol. Pharmacol. 48: 1078-1986, 1995
265 Kivistö KT, Kroemer HK, Eichelbaum M: The role of human cytochrome P450 enzymes
in the metabolism of anticancer agents: implications for drug interactions. Br. J. Clin.
Pharmacol. 40: 523-530, 1995
1996
266 Eichelbaum M, Gross AS: Stereochemical aspects of drug action and disposition.
Advances in Drugs Research 28:1-64, 1996
267 Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzales FJ, Huang J-D,
Idle JR, Ingelmann-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW,
Steen VM, Wolf CR, Zanger UM: Nomenclature for human CYP2D6 alleles. Pharmacogenetics
6:193-201, 1996
268 Kévorkian J-P, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi M-N,
Eichelbaum M, Jaillon P, Funck-Brentano C: Assessment of individual CYP2D6 activity
in extensive metabolizers with renal failure: Comparison of sparteine and dextromethorphan.
Clinical Pharmacology and Therapeutics 59(5):583-592, 1996
269 Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M: Antipyrine as a probe for
human oxidative drug metabolism: Indentification of the cytochrome P450 enzymes catalyzing
4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Clinical Pharmacology and Therapeutics 59:613-623, 1996
29
270 Kroemer HK, Fromm MF, Eichelbaum M: Stereoselectivity in drug metabolism and action:
effects of enzyme inhibition and induction. Therapeutic Drug Monitoring 18:388-
392, 1996
271 Mörike K, Koch M, Fritz P, Urban W, Eichelbaum M: Identification of N2 as a metabolite
of acetylhydrazine in the rat. Arch toxicol 70:300-305, 1996
272 Fromm MF, Busse D, Kroemer HK, Eichelbaum M: Differential induction of prehepatic
and hepatic metabolism of verapamil by rifampin. Hepatology 24:796-801, 1996
273 Eichelbaum M, Evert B: Influence of pharmacogenetics on drug disposition and response.
Proceedings of the Australien Society of Clinical and Experimental Pharmacologists
and Toxicologists. Clinical and Experimental Pharmacology and Physiology
23:983-985, 1996
274 Stüven T, Griese E-U, Kroemer HK, Eichelbaum M, Zanger UM: Rapid detection of
CYP2D6 null alleles by long distance and multiplex-polymerase chain reaction. Pharmacogenet
6:417-421, 1996
275 Eichelbaum M: Pharmakokinetik von Calciumantagonisten (insbesondere von Gallopamil).
In: Forschung und Klinik, Vergangenheit, Gegenwart und Zukunft. Kübler W. und
Tritthart H.A. (Hrsg), Steinkopf Verlag Darmstatt 43-55, 1996
276 Bohnenstengel F, Hofmann U, Eichelbaum M, Kroemer HK: Characterization of the cytochrome
P450 involved in side-chain oxidation of cyclophosphamide in humans. European
Journal of Clinical Pharmacology 51:297-301, 1996
1997
277 Evert B, Eichelbaum, M, Haubruck H, Zanger UM: Functional properties of CYP2D6 1
(wild-type) and CYP2D6 7 (His324Pro) expressed by recombinant baculovirus in insect
cells. Naunyn-Schmiedeberg‘s Arch Pharmacol 355:309-318, 1997
278 Mikus G, Trausch B, Rodewald C, Hofmann U, Richter K, Gramatté T, Eichelbaum M:
Effect of codeine on gastrointestinal motility in relation to CYP2D6 phenotype. Clin
Pharmcol Ther 61:459-466, 1997
279 Bohnenstengel F, Eichelbaum M, Golbs E, Kroemer HK: High-performance liquid
chromatographic determination of acrolein as a marker for cyclophosphamide bioactiva30
tion in human liver microsomes. J Chromatogr Biomed Appl 692:163-168, 1997
280 Gross AS, Mikus G, Ratge D, Wisser H, Eichelbaum M: Pharmacokinetics and pharmacodynamics
of the enantiomer of gallopamil. J Pharmacol Exp Ther 281(3):1102-1112,
1997
281 Busse D, Busch FW, Bohnenstengel F, Eichelbaum M, Fischer P, Opalinska J, Schumacher
K, Schweizer E, Kroemer HK: Dose escalation of cyclophosphamide in patients
with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol
15(5):1885-1896, 1997
282 Fromm MF, Eckhardt K, Li S, Schänzle G, Hofmann U, Mikus G, Eichelbaum M: Loss
of analgesic effect of morphine due to coadministration of rifampin. Pain 72:261-267,
1997
283. Fromm MF, Kroemer HK, Eichelbaum M: Impact of P450 genetic polymorphism on the
first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Del Rev 27:171-
199, 1997
1998
284 Schrenk D, Brockmeier D, Mörike K, Bock KW, Eichelbaum: A distribution study of
CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy caucasian
volunteers. Eur J Clin Pharmacol 53: 361-367, 1998
285 Eckhardt K, Li S, Ammon S, Schänzle G, Mikus G, Eichelbaum M: Same incidence of
adverse drug events after codeine administration irrespective of the genetically determined
differences in morphine formation. Pain 76:27-33, 1998
286. Griese U, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T,
Eichelbaum M: Assessment of the predictive power of genotypes for the in-vivo catalytic
function of CYP2D6 in a German population. Pharmacogenetics 8:15-26, 1998
287. Ettl A, Hofmann U, Daxer A, Dietrich H, Schmid E, Eichelbaum M: Ocular pharmacokinetics
of verapamil in rabbits. Naunyn-Schmiedeberg’s Arch Pharmacol 357:331-335,
1998
288. Fromm MF, Dilger K, Busse D, Kroemer HK, Eichelbaum M, Klotz U: Gut wall metabolism
of verpamil in older people: effects of rifampicin-mediated enzyme induction. Br J
31
Clin Pharmacol 45:247-255, 1998
289. Eichelbaum M: Correlations between in vivo and in vitro studies in human drug metabolism.
In: Molecular and applied aspects of oxidative drug metabolizing enzymes, E.
Arinç, J.B. Schenkman, and E. Hodgson (eds); Plenum Press, pp 81-90 (1998) NATO
Advanced Study Institute on Molecular and Applied Aspects of Oxidative Drug Metabolizing
Enzymes, August 31 - September 11, 1997, in Antalya, Turkey
290. Eichelbaum M: Clinical aspects of polymorphic drug metabolism in humans. In: E.
Arinç, J.B. Schenkman, E. Hodgson (eds.) Molecular ans Applied Aspects of Oxidadative
Drug Metabolizing Enzymes. Plenum Press New York pp 111-126 (1998) NATO
Advanced Study Institute on Molecular and Applied Aspects of Oxidative Drug Metabolizing
Enzymes, August 31 - September 11, 1997, in Antalya, Turkey
291. Pauli-Magnus C, Eichelbaum M: Arzneimittelinteraktionen bei der Therapie mit CSEHemmern.
Arzneimitteltherapie 11:343-350, 1998
292. Darbar D, Fromm MF, Dell’Orto S, Kim RB, Kroemer HK, Eichelbaum M, Roden DM:
Modulation by dietary salt of verapamil disposition in humans. Circulation 98: 2702-
2708, 1998
1999
293. Busse D, Busch FW, Schweizer E, Bohnenstengel F, Eichelbaum M, Fischer P, Schumacher
K, Aulitzky WE, Koemer HK: Fractionated administration of high-dose cyclophosphamide:
influence on dose-dependent changes in pharmacokinetics and metabolism.
Cancer Chemother Pharmacol 43: 263-268, 1999
294. Dilger K, Eckhardt K, Hofmann U, Kucher K, Mikus G, Eichelbaum M: Chronopharmacology
of intravenous and oral modified release verapamil. Br J Clin Pharmacol 47: 413-
419, 1999
295. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD: Comparative evolutionary
pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia:
role of selection versus drift in world populations. Pharmacogenetics 9:217-228,
1999
296. Griese EU, Läpple F, Eichelbaum M: Detection of CYP2C19 alleles *1, *2 and *3 by
multiplex polymerase chain reaction. Pharmacogenetics 9:389-391, 1999
32
297. Waldegger S, Niemeyer G, Mörike K, Wagner CA, Suessbrich H, Busch AE, Lang F,
Eichelbaum M. Effect of verapamil enantiomers and metabolites on cardiac K+ channels
expressed in Xenopus oocytes. Cell Physiol Biochem 9:81-89, 1999
298. Tugnait M, Hawes EM, McKay G, Eichelbaum M, Midha KK: Characterization of the
human hepatic cytochromes P450 involved in the in vitro oxidation of clozapine. Chem
Biol Interact 118:171-89, 1999
299. Griese E-U, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M: Analysis of the
CYP2D6 gene mutations and their consequences for enzyme function in a west African
population. Pharmacogenetics 9: 715-723, 1999
300. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer
HK: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J
Clin Invest 104:147-53, 1999
301. Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M: Consequences
of rifampicin treatment on propafenone disposition in extensive and poor metabolizers
of CYP2D6. Pharmacogenetics 9:551-9, 1999
302. Fritz P, Sperker B, Mürdter TE, Spath M, Schwarzmann P, Kroemer HK, Eichelbaum M,
Kivisto KT. Quantitative immunohistochemical analysis of the glutathione S-transferase
GSTM1: in situ phenotyping in archival material. Xenobiotica 29:693-702, 1999
303. Hofmann U, Seefried S, Schweizer E, Ebner T, Mikus G, Eichelbaum M: Highly sensitive
gas chromatographic-tandem mass spectrometric method for the determination of
morphine and codeine in serum and urine in the femtomolar range. J Chromatogr B Biomed
Sci Appl 727:81-88, 1999
304. Dalen P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR: Disposition of debrisoquine
in Caucasians with different CYP2D6-genotypes including those with multiple
genes. Pharmacogenetics 9:697-706, 1999
305. Schwab M, Eichelbaum M. Pharmakokinetische Aspekte der Arzneimitteltherapie. Arzneiverordnung
in der Praxis 2: 2-5, 1999
2000
33
306. Richter von O., Eichelbaum M, Schönberger F, Hofmann U: Rapid and highly sensitive
method for determination of verapamil,[2H7] verapamil and metabolites in biological fluids
by liquid chromarography-mass spectrometry. J Chromatogr Biomed Appl 738: 137-
147, 2000
307. Gross AS, Eichelbaum M, Mörike K, Mikus G: Pharmakokinetics and pharmacodynamics
of R- and S-gallopamil during multiple dosing. Br J Clin Pharmacol 49:132-138, 2000
308. Schwab M., Zanger U., Eichelbaum M: Pharmakogenetische Aspekte der Arzneimitteltherapie.
J Lab Med 24: 182-188, 2000
309. Hoffmeyer S, Burk O, Richter von O, Arnold HP, Brockmöller J, Johne A, Cascorbi I,
Gerloff T, Roots I, Eichelbaum M, Brinkmann U: Functional polymorphisms of the human
multidrug-resistance gene: multiple sequence variations and correlation of one allele
with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97: 3473-
3478, 2000
310. Busse D, Eichelbaum M: Calcium channel blockers. In: Metabolic Drug Interaction . R.
H. Levy, K.E. Tummel, W.F. Trager, P.D. Hansten, M. Eichelbaum (eds.), Lippincott
Williams & Wilkins Verlag Philadelphia pp 591-602, 2000
311. Fromm MF, Eichelbaum M: Antiarrhythmics. In: Metabolic Drug Interaction . R. H.
Levy, K.E. Tummel, W.F. Trager, P.D. Hansten, M. Eichelbaum (eds.), Lippincott Williams
& Wilkins Verlag Philadelphia pp 391-401, 2000
312. Zanger UM, Eichelbaum M: CYP2D6. In: Metabolic Drug Interaction . R. H. Levy, K.E.
Tummel, W.F. Trager, P.D. Hansten, M. Eichelbaum (eds.), Lippincott Williams & Wilkins
Verlag Philadelphia pp 87-94, 2000
313. Mörike K, Eichelbaum M: Grundlagen der Arzneimitteltherapie und pharmakokinetische
Grundbegriffe. Internist 41:328-31, 2000
314. Pauli-Magnus C, Eichelbaum M: Arzneimittelinteraktionen bei der Therapie mit Statinen.
Arzneiverordnung in der Praxis 2:9-10, 2000
315. Ammon S, von Richter O, Hofmann U, Thon KP, Eichelbaum M, Mikus G: In vitro interaction
of codeine and diclofenac. Drug Metab Dispos 28:1149-1152, 2000
316. Dilger K, Meisel P, Hofmann U, Eichelbaum M: Disposition of propafenone in a poor
metabolizer of CYP2D6 with Gilbert’s syndrome. Ther Drug Monit 22:366-368, 2000
34
317. Bohnenstengel F, Friedel G, Ritter CA, McClellan M, Fritz P, Eichelbaum M, Linder A,
Toomes H, Dierkesmann R, Kroemer HK: Variability of cyclophosphamide uptake into
human bronchial carcinoma: consequences for local bioactivation. Cancer Chemother
Pharmacol 45:63-68, 2000
318. Fromm MF, Kauffmann HM, Fritz P, Burk O, Kroemer HK, Warzok RW, Eichelbaum
M, Siegmund W, Schrenk D: The effect of rifampin treatment on intestinal expression of
human MRP transporters. Am J Pathol 157:1575-1580, 2000
319. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, Fromm
MF: Characterization of the major metabolites of verapamil as substrates and inhibitors
of P-glycoprotein. J Pharmacol Exp Ther 293:376-382, 2000
320. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM: Elucidation
of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation
by CYP2D6. Pharmacogenetics 10: 577-581, 2000
321. Schwab M, Röder F, Aleker T, Ammon S, Thon KP, Eichelbaum M, Klotz U: Psychotropic
drug use, falls and hip fracture in the elderly. Aging 12: 234-239, 2000
322. Hofmann U, Pecia M, Heinkele G, Dilger K, Kroemer HK, Eichelbaum M: Determination
of propafenone and its phase I and phase II metabolites in plasma and urine by highperformance
liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr
B Biomed Sci Appl 748:113-123, 2000
323. Eichelbaum M, Schwab M: Inter- und intraindividuelle Unterschiede im Arzneimittelmetabolismus.
In: Arzneiverordnungen, 19. Auflage. Arzneimittelkommission der deutschen
Ärzteschaft (Hrsg.) Dt. Ärzte-Verlag Köln, S. 847-865, 2000
324. Garaedts M, Selbmann HK, Barczok M, Brech W, Dettweiler W, Dierkesmann R, Eichelbaum
M, Lorenz G, Mangold W, Mörike K, Schülen E: Leitlinie zur Versorgung von
erwachsenen Patienten mit Asthma bronchiale in der Region Neckar-Alb. Z ärztl Fortbild
Qual. Sich. (ZaeFQ) Urban & Fischer Verlag 94:359-364, 2000
325. Eckhardt K, Nevo I, Levy R, Mikus G, Eichelbaum M, Vogel Z: Morphine-related metabolites
differentially activate adenylyl cyclase isozymes after acut and chronic administration.
FEBS Lett 470:309-14, 2000
2001
35
326. Fritz P, Mürdter TE, Eichelbaum M, Siegle I, Weissert M, Zanger UM: Microsomal
epoxide hydrolase expression as a predictor of tamoxifen response in primary breast cancer:
a retrospective exploratory study with long-term follow-up. J Clin Oncol 19:3-9,
2001
327. Griese EU, Ilett KF, Kitteringham NR, Eichelbaum M, Powell H, Spargo RM, LeSouef
PN, Musk AW, Minchin RF: Allele and genotype frequencies of polymorphic cytochromes
P4502D6, 2C19 and 2E1 in aborigines from Western Australia. Pharmacogenetics
11:69-76, 2001
328. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M: Cellular localization and regional
distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics
11:237-245, 2001
329. Pauli-Magnus C, Mürdter T, Godel A, Mettang T, Eichelbaum M, Klotz U, Fromm MF:
P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and betaacetyldigoxin.
Naunyn Schmiedebergs Arch Pharmacol 363:337-343, 2001
330. Eichelbaum M, Burk O: CYP3A genetics in drug metabolism. Nat Med 7:285-288, 2001
331. Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J, Schwab M, Eichelbaum M,
Fromm MF: The C3435T mutation in the human MDR1 gene is associated with altered
efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells.
Pharmacogenetics 11:293-298, 2001
332. Schaeffeler E, Lang T, Zanger UM, Eichelbaum M, Schwab M: High-throughput genotyping
of thiopurine S-methyltransferase by denaturing HPLC. Clin Chem 47:548-555,
2001
333. Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E,
Eichelbaum M, Brinkmann U, Roots I: Frequency of single nucleotide polymorphisms in
the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther
69:169-174, 2001
334. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction
of intestinal MDR1 by rifampin. J Biol Chem 276:14581-14587, 2001
335. Brinkmann U, Eichelbaum M: Polymorphisms in the ABC drug transporter gene MDR 1.
Pharmacogenomics J 1:59-64, 2001
36
336. Busse D, Fromm MF, Mörike K, Drescher S, Kühlkamp V, Eichelbaum M: Disposition
and pharmacologic effects of R/S-verapamil in patients with chronic atrial fibrillation: an
investigation comparing single and multiple dosing. Clin Pharmacol Ther 69:324-332,
2001
337. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM,
Schwab M: Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet
358:383-384, 2001
338. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M,
Schwab M, Zanger UM: Extensive genetic polymorphism in the human CYP2B6 gene
with impact on expression and function in human liver. Pharmacogenetics 11:399-415,
2001
339. Brinkmann U, Roots I, Eichelbaum M: Pharmacogenetics of the human drug-transporter
gene MDR1: impact of polymorphisms on pharmacotherapy. Drug Discov Today
15:835-839, 2001
340. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, Fuss C, Brehm I, Brinkmann
U, Eichelbaum M, Wojnowski L, Burk O: Natural protein variants of pregnane X receptor
with altered transactivation activity towards CYP3A4. Drug Metab Dispos
29:1454-1459, 2001
341. Eichelbaum M, Evans W, Yamazoe Y: A tribute to Frank Gonzalez. Pharmacogenetics
11:371, 2001
342. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M:
Comprehensive analysis of the genetic factors determining expression and function of
hepatic CYP2D6. Pharmacogenetics 11:573-585, 2001
343. von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, Dent J, Somogyi
A, Eichelbaum M: Determination of in vivo absorption, metabolism, and transport of
drugs by the human intestinal wall and liver with a novel perfusion technique. Clin
Pharmacol Ther 70:217-227, 2001
344. Coller JK, Fritz P, Zanger UM, Siegle I, Eichelbaum M, Kroemer HK, Mürdter TE: Distribution
of microsomal epoxide hydrolase in humans: an immunohistochemical study in
normal tissues, and benign and malignant tumours. Histochem J 33:329-336, 2001
37
345. Marx C, Schwab M, Zanger UM, Eichelbaum M: Pharmakogenetische Aspekte der Arzneimitteltherapie
gastrointestinaler Erkrankungen. Verdauungskrankheiten 19:260-271,
2001
346. Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M: Shortcoming
in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping
only. Gastroenterology 121:498-9, 2001
347. Eichelbaum M, Schwab M. Elimination von Pharmaka und Metabolismus und durch Exkretion
(1.3.4. und 1.3.5.). In: Forth W, Henschler D, Rummel W, Förstermann U, Starke
K (Hrsg.). Allgemeine und spezielle Pharmakologie und Toxikologie. 8. Auflage. München:
Urban & Fischer Verlag, 2001:39-56
2002
348. Lutz M, Schwab M, Griese EU, Marx C, Müller-Oerlinghausen B, Schönhöfer PS, Meisner
C, Gleiter CH, Eichelbaum M, Mörike K: Visual disorders associated with omeprazole
and their relation to CYP2C19 polymorphism. Pharmacogenetics 12:73-75, 2002
349. Schwab M, Marx C, Zanger UM, Eichelbaum M: Pharmakogenetik der Cytochrom P-450
Enzyme: Bedeutung für Wirkung und Nebenwirkung von Medikamenten. Deutsches
Ärzteblatt 99, 8:497-504, 2002
350. Gläser H, Drescher S, van der Kuip H, Behrens C, Geick A, Burk O, Dent J, Somogyi A,
von Richter O, Griese EU, Eichelbaum M, Fromm M: Shed human enterocytes as a tool
for the study of expression and fuction of intestinal drug-metabolizing enzymes and
transporters. Clin Pharmacol Ther 71:131-140, 2002
351. Endrizzi K, Fischer J, Klein K, Schwab M, Nüssler A, Neuhaus P, Eichelbaum M,
Zanger UM: Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene
expression by TaqMan Real-Time reverse transcriptase polymerase chain reaction.
Anal Biochem 300:121-131, 2002
352. Schwab M, Schaeffeler E, Brinkmann U, Zanger UM, Eichelbaum M: Pharmacokinetic
differences between ethnic groups. Lancet 359:78-79, 2002
353. Jorge-Nebert LF, Eichelbaum M, Griese EU, Inaba T, Arias TD: Analysis of six SNPs of
NAT2 in Ngawbe and Embera Amerindians of Panama and determination of the
Embera acetylation phenotype using caffeine.Pharmacogenetics 12:39-48, 2002
354. Fromm MF, Eichelbaum M: The Pharmacogenomics of Human P-Glycoprotein. In: Phar
macogenomics: The Search for Individualized Therapeutics. Licinio J, Wong ML
38
(Hrsg.), Wiley-Vch S. 159-178, 2002
355. Siegsmund M, Brinkmann U, Schaeffeler E, Weirich G, Schwab M, Eichelbaum M, Fritz
P, Burk O, Decker J, Alken P, Rothenpieler U, Kerb R, Hoffmeyer S, Brauch H: Association
of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility
to renal epithelial tumors. J Am Soc Nephrol 13:1847-54, 2002
356. Bredschneider M, Klein K, Muerdter TE, Marx C, Eichelbaum M, Nuessler AK, Neuhaus
P, Zanger UM, Schwab M: Genetic polymorphisms of glutathione S-transferase
A1, the major glutathione S-transferase in human liver: consequences for enzyme
expression and busulfan conjugation. Clin Pharmacol Ther 71:479-87, 2002
357. Schwab M, Oetzel C, Moerike K, Jaegle C, Gleiter CH, Eichelbaum M: Using trade
names: a risk factor for accidental drug overdose. Arch Intern Med 162:1065-6, 2002
358. Eichelbaum M, Evans WE, Yamazoe Y: From the Editors: progress and the way forward.
Pharmacogenetics 12:273-4, 2002
359. Bock KW, Bock-Hennig BS, Munzel PA, Brandenburg JO, Kohle CT, Soars MG, Riley
RJ, Burchell B, Richter O, Eichelbaum MF, Swedmark S, Orzechowski A: Tissuespecific
regulation of canine intestinal and hepatic phenol and morphine UDPglucuronosyltransferases
by beta-naphthoflavone in comparison with humans. Biochem
Pharmacol 63:1683-90, 2002
360. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Eichelbaum
M, Fromm MF: MDR1 gene polymorphisms and disposition of the P-glycoprotein
substrate fexofenadine. Br J Clin Pharmacol 53:526-34, 2002
361. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF,
Nuessler AK, Neuhaus P, Zanger UM, Eichelbaum M, Wojnowski L: Molecular
mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine.
J Biol Chem 277:24280-8, 2002
362. Schwab M, Schaeffeler E, Marx C, Fischer C, Lang T, Behrens C, Gregor M, Eichelbaum
M, Zanger UM, Kaskas BA: Azathioprine therapy and adverse drug reactions in
patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.
Pharmacogenetics 12:429-36, 2002
363. Johne A, Köpke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R,
Fromm MF, Brinkmann U, Eichelbaum M, Brockmöller J, Cascorbi I, Roots I: Modulation
of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.
Clin Pharmacol Ther 584-94, 2002
39
364. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, Keil A,
Eichelbaum M, Koepsell H: Identification of genetic variations of the human organic cation
transporter hOCT1 and their functional consequences. Pharmacogenetics 12:591-5,
2002
365. Busse D, Würthwein G, Hinske C, Hempel G, Fromm MF, Eichelbaum M, Kroemer HK,
Busch FW: Pharmacokinetics of intravenous etopside in patients with breast cancer: influence
of dose escalation and cyclophosphamide and doxorubicin coadministration.
Naunyn-Schmiedeberg’s Arch Pharmacol 366:218-225, 2002
366. Coller JK, Krebsfaenger N, Klein K, Endrizzi K, Wolbold R, Nüssler A, Neuhaus P,
Zanger UM, Eichelbaum M, Mürdter TE: The influence of CYP2B6, CYP2C9 and
CYP2D6 genotypes on the to formation of the potent antioestrogen Z-4-hydroxytamoxifen
in human liver. Br J Clin Pharmacol 54:157-67, 2002
367. Furuno T, Landi MT, Ceroni M, Caporaso N, Bernucci I, Nappi G, Martignoni E,
Schaeffeler E, Eichelbaum M, Schwab M, Zanger UM: Expression polymorphism of the
blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease
Pharmacogenetics, 12:529-34, 2002
368. Koch I, Weil R, Wolbold R, Brockmöller J, Hustert E, Burk O, Nuessler A, Neuhaus P,
Eichelbaum M, Zanger U, Wojnowski L: Interindividual variability and tissue-specificity
in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 30:1108-14, 2002
369. Michalski C, Cui Y, Nies AT, Nuessler AK, Neuhaus P, Zanger UM, Klein K, Eichelbaum
M, Keppler D, König J: A naturally occurring mutation in the SLC21A6 gene causing
impaired membrane localization of the hepatocyte uptake transporter. J Biol Chem,
277:43058-63, 2002
370. Geisel J, Kivistö KT, Griese EU, Eichelbaum M: The efficacy of simvastatin is not influenced
by CYP2D6 polymorphism. Clin Pharmacol Ther 72:595-6, 2002
2003
371. Kaskas B, Louis E, Hindorf U, Schaeffeler E, Deflandre J, Graepler F, Schmiegelow K,
Gregor M, Eichelbaum M, Zanger UM, Schwab M: Safe treatment of thiopurine Smethyltransferase
deficient Crohn's disease patients with azathioprine. Gut 52:140-2,
2003
372. Schwab M, Eichelbaum M, Fromm M: Genetic polymorphisms of the human MDR1
40
drug transporter. Annu Rev Pharmacol Toxicol 43:285-307, 2003
373. Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, Stange E, Herfarth
H, Schoelmerich J, Gregor M, Walker S, Cascorbi I, Roots I, Brinkmann U, Zanger UM,
Eichelbaum M: Association between the C3435T MDR1 gene polymorphism and susceptibility
for ulcerative colitis. Gastroenterology 124:26-33, 2003
374. Eichelbaum M, Schwab M: Inter- und intraindividuelle Unterschiede im Arzneimetabolismus
und Arzneimitteltransport. Arzneiverordnungen: Empfehlungen zur rationalen
Pharmakotherapie / hrsg. Von der Arzneimittelkommission der Deutschen Ärzteschaft
- 20. Aufl. - Köln: Dt. Ärzte-Verlag, Kap. 62:1006-1024, 2003
375. Drescher S, Glaeser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF: P-glycoproteinmediated
intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73:223-
231, 2003
376. Zanger UM, Eichelbaum M. Cytochrome P4502D6. In: Pharmacogenetics, Handbook of
Experimental Pharmacology (Eds: Roots I, Gonzalez FJ, Brockmöller J.). Springer, Heidelberg
705-712 (2003)
377. Eichelbaum M. Progress in clinical pharmacology over the last 20 years. Britisch Journal
of Clinical Pharmacology 55:458-9, 2003
378. Fischer J, Schwab M, Eichelbaum M, Zanger UM. Mutational Analysis of the Human
Dihydropyrimidine Dehydrogenase Gene by Denaturing High-Performance Liquid
Chromatography. Genetic Testing 7:97-105
379. Hofmann U, Schwab M, Seefried S, Marx C, Zanger UM, Eichelbaum M, Mürdter TE:
Sensitive method for the quantification of urinary pyrimidine metabolites in healthy
adults by gas chromatography-tandem mass spectrometry. Journal of Chromatography B,
791:371-380, 2003
380. Dalen P, Dahl ML, Roh HK, Tybring G, Eichelbaum M, Wilkinson GR, Bertilsson L:
Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6
genotypes, and comparison with Caucasians.Br J Clion Pharmacol 55:630-634, 2003
381. Eichelbaum M: In search of endogenous CYP2D6 substrates.Pharmacogenetics 13:305-6,
2003
382. Schaeffeler E, Stanulla M, Greil J, Schrappe M, Eichelbaum M, Zanger UM: A novel
TPMT missense mutation associated with TPMT deficiency in a 5-jear-old boy with
ALL. Leukemia 17:1422-4, 2003-07-29
41
383. Gross AS, Somogyi A, Eichelbaum M: Stereoselective Drug Metabolism and Drug Interactions.
In: Stereochemical Aspects of Drug Action and Disposition. Handbook of Experimental
Pharmacology (ed. Starke K, Springer Verlag Berlin) Vol. 153:313-339, 2003
384. Eichelbaum M: Drug Input Rate and its Consequences for Absorption and Presystemic
Elimination. In: Optimization of Oral Drug Delivery Systems: Getting the Best from your
Drugs. Basel Dec 12, 2002. Capsugel Library: 41-53, 2003
385. Klotz U, Eichelbaum M: „Spieglein, Spieglein an der Wand, wer ist der beste Protonenpumpeninhibitor
im Land?“ Z Gastroenterol 2003; 41:885-887
386.Wolbold R, Klein K, Burk O, Nüssler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger
UM: Sex Is a Major Determinant of CYP3A4 Expression in Human Liver. Hepatology 38,
2003; 978-988
387.Fromm MF, Schwab M, Eichelbaum M: Pharmakogenetik zur Optimierung der Therapie bei
HIV-Infektionen. Bundesgesundheitsbl 10, 2003: 851-854
388.Läpple F, Richter v. O, Fromm MF, Richter T, Thon KP, Wisser H, Griese E-U, Eichelbaum
M, Kivistö K: Differential expression and function of CYP2C isoforms in human intestine
and liver. Pharmacogenetics 13:565-575, 2003
389.Schaeffeler E, Schwab M, Eichelbaum M, Zanger U: CYP2D6 Genotyping Strategy Based
on Gene Copy Number Determination by TaqMan Real-Time PCR. Human Mutation 22:
476-485 (2003)
2004
390.Richter T, Mürdter T.E., Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger
U: Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine.
Journal of Pharmacology and Experimental Therapeutics 308: 189-197 (2004)
391.Zanger UM, Raimundo S, Eichelbaum M: Cytochrome P450 2D6: overview and update on
pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg’s Arch Pharmacol 369: 23-37
(2004)
42
392.Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, Klein K, Zanger UM, Eichelbaum
M, Fromm MF: Genetic polymorphisms in the multidrug resistance-associated protein
3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver.
Pharmacogenetics 14: 155-164 (2004)
393.Eichelbaum M, Fromm MF, Schwab M: Clinical Aspects of the MDR1 (ABCB1) Gene Polymorphism.
Ther Drug Monit 2: 180-184 (2004)
394.Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, Kaufmann P, Fritz
P, Fromm MF, Schwab M: Variable expression of P-glycoprotein in the human placenta and
its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics
14: 1-10 (2004)
395.Arnold KA, Eichelbaum M, Burk O: Alternative splicing affects the function and tissuespecific
expression of the human constitutive androstane receptor. Nuclear Receptor 2: ??
(2004)
396. Zanger UM, Eichelbaum M: Cytochrome P450 Mono-oxygenase System. Encyclopedic
Reference of Molecular Pharmacology (Eds: S. Offermanns, W. Rosenthal); Springer, Heidelberg
705-712 (2004)
397. Schaeffeler E, Fischer C, Brockmeier D, Wernet D, Moerike K, Eichelbaum M, Zanger
UM, Schwab M: Comprehensive analysis of thiopurine kS-methyltrasnferase phenotypegenotype
correlation in a large population of German-Caucasians and identification of novel
TPMT variants. Pharmacogenetics 14: 407-417 (2004)
398.Raimundo S, Toscano C, Klein K, Fischer J, Griese EU, Eichelbaum M, Schwab M, Zanger
UM: A novel intronic mutation, 2988G>A, with high predictivity for impaired function of
cytochrome P450 2D6 in white subjects. Clinical Pharmacology & Therapeutics 76: 128-138
(2004)
399.Eichelbaum M, Schwab M: Inter- und intraindividuelle Unterschiede im Arzneimittelmetabolismus
und Arzneimitteltransport. In: Arzneiverordnungen, 21. Auflage. Arzneimittelkommission
der deutschen Ärzteschaft (Hrsg.) Dt. Ärzte-Verlag Köln, 62: 1479-1498 (2006)
400.Kivisto KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Eichelbaum
M, Strandberg T: Lipid-lowering response to statins is affected by CAP3A5 polymorphism.
Pharmacogenetics 14: 523-525 (2004)
401.Eichelbaum M, Schwab M: Pharmacogenomics. In: Encyclopedic Reference of Genomics
and Proteomics. (Book chapter, in press)
402.Fichtl B, Eichelbaum M, Schwab M: Wirkungen des Organismus auf Pharmaka: Allgemeine
43
Pharmakokinetik. In: Allgemeine und spezielle Pharmakologie und Toxikologie, 9. Auflage.
Aktories Försterman Hofmann Starke. (Hrsg) Urban & Fischer Verlag, 36-64 (2004)
403.Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivistö KT: Cytochrome
P450 3A4 and P-glycoprotein expression in human small intenstinal enterocytes and hepatocytes:
A comparative analysis in paired tissue specimens. Clinical Pharmacology & Therapeutics
75 (3): 172-83(2004)
404.Glaeser H, Drescher S, Hofmann U, Heinkele G, Somogyi AA, Eichelbaum M, Fromm MF:
Impact of concentration an drate of intraluminal drug delivery on absorption and gut wall
metabolism of verapamil in humans. Clin Pharmacol Ther 76: 230-238 (2004)
405.Kivisto KT, Zukunft J, Hofmann U, Niemi M, Rekersbrink S, Schneider S, Luippold G,
Schwab M, Eichelbaum M, Fromm MF: Characterisation of cerivastatin as a P-glycoprotein
substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out
mice. Naunyn Schmiedebergs Arch Pharmacol 370: 124-130 (2004)
406.Burk O, Koch I, Raucy J, Hustert E, Eichelbaum M, Brockmoller J, Zanger UM, Wojnowski
L: The induction of cyotcohrome P450 3A5 (CYP3A5) in the human liver and intestine is
mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutevly activated
receptor (CAR). J Biol Chem 279: 38379-38385 (2004)
407.Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb
R, Schwab M, Neuvonen PJ, Eichelbaum M, Kivistö KT: High plasma pravastatin concentrations
are associated with single nucleotide polymorphisms and haplotoypes of organic anion
transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14: 429-440
(2004)
408.Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M, Schwab M, Zanger UM: Multiple
novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of
phenotypic null alleles. J Pharmacol Exp Ther 311: 34-43 (2004)
409.Coller JK, Krebsfaenger N, Klein K, Wolbold R, Nüssler A, Neuhaus P, Zanger UM,
Eichelbaum M, Mürdter TE: Large interindividual variability in the in vitro formation of tamoxifen
metabolites related to the development of genotoxicity. Br J Clin Pharmacol 57:
105-111 (2004)
410.Eichelbaum M: Stereoselective first-pass metabolism of highly cleared drugs: studies of the
bioavailability of L- and D-verapamil examined with a stable isotope technique. Author’s
commentary. Br J Clin Pharmacol 58: 804-805 (2004)
44
2005
411.Gläser H, Drescher S, Eichelbaum M, Fromm MF: Influence of rifampicin on the expression
and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 59: 199-
206 (2005)
412.Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann
H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M: ABCB1 genotype
of the donor but not of the recipient is a major risk factor for cyclosporine related nephrotoxicity
after renal transplantation. J Am Soc Nephrol. May;16(5):1501-11 (2005)
413.Niemi M, Backman JT, Kajosaari LI, Leathart JB, MPhil, Neuvonen M, Daly AK, Eichelbaum
M, Kivistö KT, Neuvonen PJ: Polymorphic organic anion transporting polypeptide
1B1 (OATP1B1) is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology
& Therapeutics 77: 468-78 (2005)
414.Richter T, Schwab M, Eichelbaum M, Zanger UM: Inhibition of human CYP2B6 by N, N’,
N’’-triethylenethiophosphoramide is irreversible and mechanism-based. Biochemical Pharmacology
69: 517-524 (2005)
415.Zukunft J, Lang T, Richter T, Hirsch-Ernst KI, Nussler AK, Klein K, Schwab M, Eichelbaum
M, Zanger UM: A natural CYP2B6 TATA box-polymorphism (-82T>C) leading to
enhanced transcription and relocation of the transcriptional start site. Mol Pharmacol 67:
1772-1782 (2005)
416. Kivistö KT, Niemi M, Schaeffeler E, Pitkälä K, Tilvis R, Fromm MF, Schwab M, Lang F,
Eichelbaum M, Strandberg T: CYP3A5 genotype is associated with diagnosis of hypertension
in elderly patients: data from the DEBATE study. American Journal of Pharmacogenomics
5: 191-195 (2005)
417.Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, Welte K, Ludwig
W-D, Bartram CR, Zanger UM, Eichelbaum M, Schrappe M, Schwab M: Thiopurine
methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in
childhood acute lymphoblastic leukemia. JAMA 293: 1485-1489 (2005)
418. Stanulla M, Schäffeler E, Arens S, Rathmann A, Schrauder A, Welte K, Eichelbaum M,
Zanger UM, Schrappe M, Schwab M: GSTP1 and MDR1 genotypes and central nervous
system relapse in childhood acute lymphoblastic leukaemia. Int J Hematol 81: 39-44 (2005)
419. Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm
MF, Eichelbaum M: Antimalarial Artemisinin Drugs Induce Cytochrome P450 and MDR1
Expression by Activation of Xenosensors Pregnane X Receptor and Constitutive Androstane
Receptor. Mol Pharmacol 67: 1954-1965 (2005)
45
420.Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lütjohann D, von Bergmann
K, Eichelbaum M, Kivistö KT: Acute effects of pravastatin on cholesterol synthesis are associated
with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics
15: 303-309 (2005)
421.Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF: Characterisation of
(R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn
Schmiedeberg’s Arch Pharmacol 371: 195-201 (2005)
422.Niemi M, Kivistö KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF: Fexofenadine
pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding
OATP1B1). Br J Clin Pharmacol 59: 602-604 (2005)
423.Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M: A role for constitutive androstane
receptor in the regulation of human intestinal MDR1 expression. Biol Chem 386: 503-513
(2005)
424.Fux R, Mörike K, Pröhmer AMT, Delabar U, Schwab M, Schäffeler E, Lorenz G, Gleiter
CH, Eichelbaum M, Kivistö KT: Impact of CYP2D6 genotype on adverse effects during
treatment with metoprolol: a prospective clinical study. CPT 78: 378-387 (2005)
425. Eichelbaum M, Ingelman-Sundberg M, Evans WE: Pharmacogenomics and individualized
drug therapy. Annu. Rev. Med. 57: 119-137 (2006)
426.Eichelbaum M, Schwab M: Pharmakogenetik. Monatsschrift Kinderheilk 153: 741-750
(2005)
427.Kivisto KT, Grisk O, Hofmann U, Meissner K, Moritz KU, Ritter C, Arnold K, Lutjohann
D, von Bergmann K, Kloting I, Eichlbaum M, Kroemer HK: Disposition of oral and intravenous
pravstatin in MRP2-deficient TR-rats. Drug Metab Dispos. 33: 1593-1596 (2005)
428.Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck W-H, Eichelbaum M, Schwab M,
Zanger UM: Genetic variability of CYP2B6 in populations of African and Asian origin: allele
frequencies, novel functional variants and possible implications for anti-HIV therapy
with efivarenz. Pharmacogenetics and Genomics 15: 861-873 (2005)
429. Neurath MF, Kiesslich R, Teichgräber U, Fischer C, Hofmann U, Eichelbaum M, Galle PR,
Schwab M: 6-Thioguanosine diphosphate and trihosphate levels in red blood cells and response
to azathioprine therapy in Crohn`s disease. Clinical Gastroenterology and Hepatology
3: 1007-1014 (2005)
46
2006
430. Toscano C, Raimundo S, Klein K, Eichelbaum M, Schwab M, Zanger UM: A silent mutation
(2936G<A, exon 6) causally responsible for impaired expression and function of
CYP2D6. Pharmacogenetics and Genomics 16: 767-70 (2006)
431.Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K,
Eichelbaum M, Kivistö KT: Impact of SLCO1B1 (Encoding OATP1B1) polymorphism on
the pharmacokinetics and lipid-lowering effects of multiple-dose pravastatin. Clin Pharmacol
Ther 79: 419-426 (2006)
432.Becquemont L, Glaeser H, Drescher S, Hitzl M, Simon N, Murdter TE, Heinkele G, Hofmann
U, Schaefer C, Burk O, Vestuyft C, Eichelbaum M, Fromm MF: Effects of ursodexycholic
acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics
in humans. Clin Pharmacol Ther 79: 449-460 (2006)
433.Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Nüssler AK, Nüsserl N, Eichelbaum M,
Meier PJ, Stieger B: Interindividual variability of canalicular ATP-binding-cassette (ABC)-
Transporter expression in human liver. Hepatology 44: 62-74 (2006)
434.Niemi M, Kivistö KT, Dicfalusy U, Bodin K, Bertilsson L, Fromm MF, Eichelbaum M: Effect
of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. Pharmacogenetics
and Genomics 16: 565-568 (2006)
435.Niemi M, Arnold KA, Backmann JT, Pasanan MK, Gödtel-Armbrust U, Wojnowski L,
Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T: Association of genetic polymorphism
in ABCC2with hepatic MRP2 expression and pravastatin pharmacokinetics.
Pharmacogenetics and Genomics 11: 801-808 (2006)
436.Toscano C, Klein K, Blievernicht J, Schaeffeler E, Saussele T, Raimundo S, Eichelbaum M,
Schwab M, Zanger UM: Impaired expression of CYP2D6 in intermediate metabolizers carrying
the *41 allele caused by the intronic SNP2988G>A: evidence for modulation of splicing
events. Pharmacogenetics and Genomics 16: 755-66 (2006)
437.Busse D, Templin S, Mikus G, Schwab M, Hofmann U, Eichelbaum M, Kivistö KT: Cardi47
ovascular effects of (R )- and (S)-verapamil and racemic verapamil in humans: a placebocontrolled
study. European Journal of Clinical Pharmacology 62: 613-9 (2006)
438.Hedman M, Antikainen M, Holmberg C, Neuvonen M, Eichelbaum M, Kivisto KT, Neuvonen
PJ, Niemi M: Pharmacokinetics and response to pravastatin in paediatric patients with
familial hypercholesterolaemia and in paediatric cardicac transplant recipients in relation to
polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 61: 706-715
(2006)
439.Schaeffeler E, Eichelbaum M, Reinisch W, Zanger UM, Schwab M: Three Novel Thiopurine
S-Methyltransferase Allelic Variants (TPMT*20, *21, *22) – Association with decreased
enzyme function. Human Mutation 27: 976 (2006)
440.Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA: Transcriptional
profiling of genes induced in the livers of patients treated with carbamazepine. Clinical
Pharmacology & Therapeutics 80 (5): 440-56 (2006)
2007
441.Blievernicht JK, Schaeffeler E, Klein K, Eichlbaum M, Schwab M, Zanger UM: MALDITOF
mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms.
Clinical Chemistry 53: 24-33 (2007)
442.Gradhand U, Tegude H, Burk O Eichelbaum M, Fromm MF, König J: Functional analysis of
the polymorphism – 211C>T in the regulatory region of the human ABCC3 gene. Life Science
80: 1490-4 (2007)
443.Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Décosterd L, Blievernicht J,
SausseleT, Günthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM: Predictive value
of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIVinfected
individuals. CPT 81(4):557-66 (2007).
444. Saussele T, Burk O, Blievernicht JK, Klein K, Nussler A, Nussler N, Hengstler JG, Eichelbaum
M, Schwab M, Zanger UM: Selective induction of human hepatic cytochromes P450
2B6 and 3A4 by metamizole. CPT82(3):265-74 (2007).
445.Tegude H, Schnabel A, Zanger UM, Klein K, Eichelbaum M, Burk O: Molecular mechanism
of basal CYP3A4 regulation in the intestine. Drug Metab Dispos. 35(6):946-54 (2007).
48
446.Gradhand U, Lang T, Schaefefler E, Glaseser H, Tegude H, Klein K, Fritz P, Jedlitschky G,
Kroemer HK, Bachmakov I, Anwald B, Kerb R, Zanger UM, Eichelbaum M, Schwab M,
Fromm MF: Variability in human hepatic MRP4 expression: influence of cholestasis and
genotype. Pharmacogenomics J 8(1):42-52 (2008)
447.Klein K, Tatzel S, Raimundo S, Saussele T, Hustert E, Pleiss J, Eichelbaum M, Zanger UM:
A natural variant of heme-binding signature (R441C) resulting in complete loss of function
of CYP2D6. Drug Metab Dispo. 35(8):1247-50 (2007)
448.Gicaomini KM, Krauss RM, Roden DM, Eichelbaum M, Hayden MR, Nakamura Y: When
good drugs go bad. Nature 26; 446 (7139): 975-7 (2007)
449.Igel S, Drescher S, Mürdter T, Hofmann U, Heinkele G, Tegude H, Glaeser H, Brenner S,
Somogyi A, Omari T, Schaefer C, Eichelbaum M, Fromm MF: Increased absorption of digoxin
from the human jejunum due to inhibition of intestinal transporter-mediated efflux.
Clin Pharmacokinet 46: 777-785 (2007)
450.Oscarson M, Burk O, Winter S, Schwab M, Wolbold R, Dippon J, Eichelbaum M, Meyer
UA: Effects of rifampicin on global gene expression in human small intestine. Pharmacogenetics
and Genomics 17: 907-918 (2007)
451.Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum
M, Brauch H: Breast cancer treatment outcome with adjuvant tamoxifen relative to patient
CYP2D6 and CYP2C19 genotypes. Journal of Clinical Oncology 25: 5187-5193 (2007)
2008
452. Buck MB, Coller JK, Muerdter TE, Eichelbaum M, Knabbe C: TGFbeta2 and TbetaRII are
valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites
in breast cancer cells.Breast Cancer Res Treat 107: 15-24 (2008)
453. Mörike K, Kivistö K, Schäffeler E, Jägle C, Igel S, Drescher S, Fux R, Marxc C, Hofmann
U, Engel C, Wagner F, Delabar U, Meisner C, Bail D, Böhm J, Gleiter C, Ziemer G, Rein J,
49
Hellberg K, Eichelbaum M, Schwab M: Propafenone for the prevention of atrial tachyarrhythmias
after cardiac surgery: a randomized, double-blind placebo-controlled trial. Clin
Pharmacol Ther 84: 104-10 (2008)
454. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Kerb R, Blievernicht J, Fischer J,
Hofmann U, Bokemeyer C, Eichelbaum M: Role of genetic and nongenetic factors for
fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-
FU toxicity study group. J Clin Oncol 26: 2131-8 (2008)
455. Ji Y, Olson J, Zhang J, Hildebrandt M, Wang L, Ingle J, Fredericksen Z, Sellers T, Miller
W, Dixon JM, Brauch H, Eichelbaum M, Justenhoven C, Hamann U, Ko Y, Brüning ,
Chang-Claude J, Wang-Gohrke S, Schaid D, Weinshilboum R: Breast cancer risk reduction
and membrane-bound catechol O-methyltransferase genetic polymorphisms. Cancer Res 15:
5997-6005 (2008)
456. Schaeffeler E, Zanger UM, Eichelbaum M, Asante-Poku S, Shin JG, Schwab M: Highly
multiplexed genotyping of thiopurine S-methyltransferase variants using MALDI-TOF mass
spectrometry: reliable genotyping in different ethnic groups. Clin Chem 54: 10 (2008)
457. Brauch H, Schroth W, Eichelbaum M, Schwab M, Harbeck N in cooperation with the AGO
TRAFO Comission. Clinical Relevance of CYP2D6 Genetics for Tamoxifen Response in
Breast Cancer. Breast Care 3: 43-50 (2008)
458. Rokavec M, Schroth W, Amaral SMC, Fritz P, Antoniadou L, Glavac D, Simon W, Schwab
M, Eichelbaum M, Brauch H: A polymorphism in the TC21 promoter associates with an unfavourable
tamoxifen treatment outcome in breast cancer. Cancer Res 68: 9799-9804 (2008)
50
2009
459. Eichelbaum M, Altman RB, Ratain M, Klein TE: New feature: pathways and important
genes from PharmGKB. Pharmacogenet Genomics 19: 403 (2009)
460. Stanulla M, Schaeffeler E, Moricke A, Coulthard SA, Cario G, Schrauder A, Kaatsch P,
Dordelmann M, Welte K, Zimmermann M, Reiter A, Eichelbaum M, Riehm H, Schrappe
M, Schwab M: Thiopurine methyltransferase genetics is not a major risk factor for secondary
malignant neoplasms after treatment of childhood acute lymphoblastic leukemia
on Berlin-Frankfurt-Munster protocols. Blood 114: 1314 (2009)
461. Brauch H, Muerdter TE, Eichelbaum M, Schwab M: Pharmacogenomics of Tamoxifen
Therapy. Clin Chem 55: 1770-1782 (2009)
462. Schroth W, Goeth MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon
W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R,
Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M,
Brauch H: Association between CYP2D6 polymorphisms and outcomes among women
with early stage breast cancer treated with tamoxifen. JAMA 302, 1429-1436 (2009)
463. Birkenfeld AL, Jordan J, Hofmann U, Busjahn A, Franke G, Krüger N, Igel S, Mürdter
T, Drescher S, Shi S, Engeli S, Schwab M, Eichelbaum M, Luft FC, Fromm MF: Genetic
influences on the pharmacokinetics of orally and intravenously administered digoxin as
exhibited by monozygotic twins. Clin Pharmacol & Ther 86, 605-608 (2009)
2010
464. Istrate MA, Nussler AK, Eichelbaum M, Burk O: Regulation of CYP3A4 by pregnane X
receptor: The role of nuclear receptors competing for response element binding. Biochem
Biophys Res Comm 19: 393 (4):688-93 (2010)
465. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA,
Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D,
Haas DW: Effect of CYP2B6, ABCB1 and CYP3A5 polymorphisms on efavirenz pharmacokinetics
and treatment response: an AIDS clinical trials group study. J Infect Dis
202:717-22 (2010)
51
466. Eichelbaum M, Brauch H, Schwab W, Schroth W: Pharmacogenomics and individualized
drug therapy. Symposium: “Clinical Pharmacology Anno 2008”; 10th Heymans Memorial
Lecture 25 October 2008, Brussels, pp 322-334 (2008)
467. Burk O, Brenner SS, Hofmann U, Tegude H, Igel S, Schwab M, Eichelbaum M, Alscher
MD: The impact of thyroid disease on the regulation, expression and function of ABCB1
(MDR1/P-Glycoprotein) and consequences for the disposition of digoxin. CPT 88: 685-
94 (2010)
468. Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M,
Schroth W: Automated extraction of DANN and RNA from a single formalin-fixed paraffin-
embedded tissue section for analysis of both sigle-nucleotide polymorphisms and
mRNA expression. Clinical Chemistry 56: 1845-53 (2010)
469. Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M,
Brauch H: CYP2D6 polymorphisms as predictors of outcome in breast cancer patients
treated with tamoxifen: expanded polymorphism coverage improves risk stratification.
Clin Cancer Res 16: 4468-77 (2010).
2011
470. Muerdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W,
Fasching PA, Fehm T, The German Tamoxifen and AI clinicans group, Eichelbaum M,
Schwab M, Brauch H: Activities of tamoxifen metabolites at the estrogen receptor and the
impact of genetic polymorphisms of phase I and II enzymes on their plasma levels. Clin
Pharmacol Ther 89: 708-17 (2011).
471. Song X, Varker H, Eichelbaum M, Stopfer P, Shahidi M, Wilson K, Kaiser R, Finnern
HW: Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome
P450 isoenzymes. Lung Cancer 74:103-11 (2011)
472. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-
Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM,
Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal
A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon
JF, Nelson MR, Watkins PB, Daly AK; Spanish DILI Registry, EUDRAGENE, DILIN,
DILIGEN, and International SAEC: Susceptibility to Amoxicillin-Clavulanate-Induced
Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology 141:
52
338-47 (2011)
473. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A,
Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann
M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett
R, Gehrmann M, Gnant M, EP Investigators: A new molecular predictor of distant
recurrence in ER-positive, HER2-negative breast cancer adds independent information to
conventional clinical risk factors. Clin Cancer Res 17: 6012-6020 (2011)
Collaborators: Bachleitner-Hofmann T, Taucher S, Pluschnig U, Bartsch R, Steger G,
Zielinski C, Horvath S, Seifert M, Dadak C, Obwegeser R, Kubista E, Asseryanis E,
Möoslinger-Gehmayr R, Hanzal E, Sam C, Mayer P, Moik M, Menzel C, Menzel B, Rass
C, Reitsamer R, Russ G, Haider K, Kwasny W, Markis E, Stiglbauer W, Grill R, Nader
A, Stierer M, Medl M, Redtenbacher S, Ulrich W, Reiner G, Hofbauer F, Lang M,
Horvath W, Kier P, Reiner-Concin A, Renner K, Balcke P, Salem G, Sedivy R, Nessler
E, Neunteufel W, Haid A, Lang A, Jasarevic Z, Offner F, Gruber C, Kugler F, Michlmayer
G, Pöstlberger S, Schildberger R, Sega W, Fridrik F, Greul R, Hochreiner G, Syré G,
Tausch C, Tausch G, Chott A, Hartleb H, Ludwig H, Salzer H, Kocher R, Leitner G,
Stangl F, Stering R, Rabl H, Forsthuber E, Omann J, Urbania A, Holzmüller K, Rogatsch
H, Feichtinger H, Rottmann M, Schüller J, Burger F, Braun O, Bayer-Tiefenbach G,
Böhm G, Mach K, Gebhard B, Rausch W, Punzengruber R, Ohlinger W, Döller W, Mel
binger E, Brustmann H, Naudé S, Riss P, Eichelbaum M, Simon W, Poremba C.
2012
474. Eichelbaum M. Cardiovascular Pharmacogenetics: Much Ado About Nothing? Dialogues
in Cardiovascular Medicine 17(4):243-249 (2012)
475. Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum
M. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol
31(2):176-80 (2012)
2013
475. Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum
M. Reply to A.-S. Dieudonne et al and J.M. Rae et al. J Clin Oncol 31:2755-2756
(2013)
476. Actis-Goretta L, Leveques A, Rein M, Teml A, Schafer C, Hofmann U, Li H, Schwab M,
53
Eichelbaum M, Williamson G. Intestinal absorption, metabolism, and excretion of (-)-
epicatechin in healthy humans assessed by using an intestinal perfusion technique. Am J
Clin Nutr 98:924-933 (2013)
477. Brauch H, Schroth W, Goetz MP, Murdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum
M. Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters. J Clin
Oncol 31:176-180 (2013)
478. Eichelbaum M. Wo steht die Pharmakogenetik nach 30 Jahren Forschung? Dtsch Med
Wochenschr 138:659-661 (2013)
479. Eichelbaum M Schwab M. 1.4 Wirkungen des Organismus auf Pharmaka: allgemeine
Pharmakokinetik In: Aktories, Förstermann, Hofmann, and Starke (eds.). Allgemeine
und spezielle Pharmakologie und Toxikologie 11 Auflage ed Urban & Fischer 36-62
(2013)
480. Eichelbaum M Schwab M. 1.5 Arzneistoffkonzentration im Organismus in Abhängigkeit
von der Zeit: Pharmakokinetik im engeren Sinn. In: Aktories, Förstermann, Hofmann,
and Starke (eds.). Allgemeine und spezielle Pharmakologie und Toxikologie 11 Auflage
ed Urban & Fischer Verlag 63-77 (2013)
2014
481. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ,
Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone
CB, Beckmann MW, Choi JY, Dieudonne AS, Fasching PA, Ferraldeschi R, Gong L,
Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts
D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA,
Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren
S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB,
Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE. CYP2D6 Genotype
and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations. Clin
Pharmacol Ther 95:216-227 (2014)
482. Saladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles
B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ,
Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H. Tamoxifen metabolism
predicts drug concentrations and outcome in premenopausal patients with early breast
cancer. Pharmacogenomics J (2014), Epub
54

Vladimir M. Shalaev

Hereby I would like to nominate for the Honorary Doctor of SDU:
Prof. Vladimir M. Shalaev
Scientific Director of Nanophotonics
Bob and Anne Burnett Distinguished Professor of Electrical and Computer Engineering
Professor of Biomedical Engineering and Professor of Physics
Purdue University & Birck Nanotechnology Center
West Lafayette, IN 47907-2057 (USA)

Prof. V. M. Shalaev is a world leading scientist in several modern branches of electrodynamics,
including metamaterials, transformation optics, nanophotonics and plasmonics.1 He made
pioneering contributions to the optics of metal nanostructures and nanostructured materials,
enabling the development of novel technologies for biophysical and biomedical sensing and
molecular identification, and to the field of optical metamaterials (i.e., artificial materials with
unique properties that cannot be found in nature), enabling the development of innovative
technologies for realization of optical cloaks (which render objects invisible) in the optical range
with very important inferences ranging from design industry to military applications. Overall, this
research has opened exciting perspectives for future developments of optical metamaterials and was
ranked in the top 50 innovations in nanotechnology in 2006. Later on, Prof. Shalaev and co-workers
have demonstrated the world smallest (nano) laser, which constitutes a major breakthrough in the
field of quantum electronics with far reaching implications ranging from quantum cryptography to
laser-based cancer treatment.

Prof. V. M. Shalaev received several awards for his pioneering and ground-breaking research in the
field of nanophotonics and metamaterials, including the prestigious Willis E. Lamb Award for
Laser Science and Quantum Optics (2010), the highest distinction awarded by the Optical Society
of America – the Max Born Award (2010) and the 2012 Nanotechnology Award from UNESCO.
1 http://en.wikipedia.org/wiki/Vladimir_Shalaev

The citation for the Max Born Award given to Prof. Shalaev in 2010: “For seminal contributions
to both the theoretical framework and the experimental realization of optical metamaterials”.
Prof. Shalaev is a Fellow of the American Physical Society (APS), of The International Society for
Optical Engineering (SPIE), and of the Optical Society of America (OSA). He is a Co-/Editor for
five books in the area of nano-optics, an Editorial Board Member for a number of research journals
and, in general, has an extremely impressive publication record reflected in his CV. In the context
of this nomination, it is important to emphasize that his ground-breaking research in optical
metamaterials has many aspects in common with the research conducted in our Centre for Nano
Optics. Thus, very recent developments led to the realization of optical metasurfaces, which
represent surface nanostructures that are specially designed and engineered to implement key
optical functionalities, such as beam steering, polarization splitting, extreme light focusing, and
wide-angle holography. Both our research groups contributed significantly to the progress in their
development, publishing several key papers in high-ranking journals and earning the reputation of
pioneers and world leaders in this field.
With respect to the quantitative evaluation of the quantity and quality of Shalaev’s scientific
research and achievements it should be emphasized that his > 300 publications resulted in a very
high h-index of 57 as registered by Web of Science with the number of citations exceeding 13.600
(March, 2015), reflecting a very high impact on overall research and developments in science and a
significant importance of his work for a broad scientific community.

Prof. V. M. Shalaev has a long history of research collaboration with our group, which has started
20 years ago with investigations of electromagnetic properties of metal surface nanostructures near
the percolation threshold conducted by near-field microscopy (our group) and theoretically analysed
by Prof. Shalaev and his group. Since then, the collaboration between our Centre for Nano Optics
and Nanophotonics Center at Purdue University (understandingly limited due to long distances) was
conducted mostly via e-mail and discussions during encounters at international conferences.
Currently, our research on optical metamaterials and metasurfaces (supported by the FNU project
“Optical metmaterials using detuned electrical dipoles”, project number 12-124690) is, in many
aspects, closely related to the investigations conducted in Nanophotonics Center led by Prof.
Shalaev, which have recently been supported with a prestigious AFOSR-MURI grant “Active
Metasurfaces for Advanced Wavefront Engineering and Waveguiding”. These investigations and
common research interests, specifically in the area of phase-gradient gap-plasmon based reflective
metasurfaces, form a solid background for establishing strong and fruitful collaboration, mutually
beneficial for both our groups.

We intend to further develop the cooperation with Prof. Shalaev by arranging his 6-month
sabbatical stay at our Centre for Nano Optics in 2016 via his nomination for the HCA Academy
visiting professorship. There is no doubt that, given the success of both nominations (Honorary
Doctor and HCA Academy visiting professorship), Prof. Shalaev would be able of significantly
strengthening our research and inspiring all members of our Centre via participation in Centre
seminars, joint research and publications, and other activities listed in his nomination for the HCA
Academy visiting professorship. The collaborative research on optical metamaterials and
metasurfaces initiated during his visit would definitely extend well beyond 2016, as this subject is
one of the hottest topics of modern electrodynamics with wide potential applications ranging from
optical cloaking (invisibility) to quantum optics and supercomputers. Furthermore, the visit of Prof.
Shalaev would initiate further steps in our collaboration, including preparation of a joint research
application to US National Science Foundation (NSF) on fundamental limiting factors in plasmonbased
nanophotonics and establishing the framework for future exchange visits of MSc and PhD
students between our centres.

Overall, as an appreciation of the significant contribution of Professor Vladimir M. Shalaev to the
modern nanoscience and nanotechnology and his continuing active involvement into the scientific
research at SDU, I believe that it would be most appropriate to award him the title of a Honorary
Doctor. SDU and the Faculty of Engineering will certainly take large benefit from such nomination
in view of Professor Shalaev’s public profile and scientific expertise.

Education:
Ph.D. Krasnoyarsk State University (Russia), physics and mathematics (with honors), 1983
M.S. Krasnoyarsk State University (Russia), physics (with highest distinction), 1979

Professional Career:
Scientific Director for Nanophotonics, Birck Nanotechnology Center, Purdue, 2011-
Bob and Anne Burnett Distinguished Professor of Electrical and
Computer Engineering 2011-pres
Robert and Anne Burnett Professor of Electrical and Computer Engineering, 2004-2011.
Professor of Biomedical Engineering 2005-
Professor of Physics 2011-pres
Professor of ECE Department, Purdue University 2001-pres.
George W. Gardiner Professor of Physics, New Mexico State University 1997–2001
Associate Professor, New Mexico State University 1993–1997
Research Associate Professor, University of Toronto (Canada) 1991–1993
Humboldt Foundation Fellow, University of Heidelberg (Germany) 1990–1991
Assistant Professor, Krasnoyarsk State University (Russia) 1983–1990
Research Fellow, Institute of Physics, Krasnoyarsk (Russia) 1983–1990
Professional Recognitions, Honors, and Awards
Selected to the Purdue Innovator Hall of Fame (2014)
The 2014 Goodman Book Award from OSA and SPIE
The 2012 Nanotechnology Award from UNESCO
The 2010 Optical Society of America Max Born Award
The 2010 Willis E. Lamb Award for Laser Science and Quantum Optics
The 2006 Top 50 Nano Technology Award Winner for “Nanorod Material”
The 2009 McCoy Award, Purdue's highest honor for scientific achievement
The 2006 College of Engineering Research Award
The Acorn Award: Seed for Success, 2007
Fellow of the Institute of Electrical and Electronics Engineers (IEEE), 2010-
Fellow of the American Physical Society (APS), 2002-
Fellow of the Optical Society of America (OSA), 2003-
Fellow of The International Society for Optical Engineering (SPIE), 2005-
Robert and Anne Burnett Professor of Electrical and Computer Engineering, 2004-pres
George W. Gardiner Endowed Professorship, New Mexico State University, 1997–2001
Member of the Steering Committee for MIT-Skolkovo Tech, 2011-2013
2
Member of the Scientific Advisory Council for Skolkovo Innovation Center (“Russian Silicon
Valley”)
Member of the Scientific Advisory Board for the Russian Quantum Center
Member of the Executive Committee for the Russian Quantum Center
General co-Chair for the 2011 CLEO/QELS conference
Program co-Chair for the 2009 CLEO/IQEC conference
Chair of the OSA Technical Group “Photonic Metamaterials”, 2008-2010
Chair of the OSA Topical Group: Photonic Metamaterials: from Random to Periodic, 2004-2007
Vice-Chair of the OSA Topical Group: Waves in Random and Periodic Media, 2002-2004
Reviewing Editor for Science
Co-Editor of Applied Physics B – Lasers and Optics, 2006-2013
Co-Editor for Advances in Nano-Optics and Nanophotonics book series (Elsevier), 2006-2008
Co-Editor for Series in Nanooptics and Nanophotonics, Taylor & Francis Books, Inc.2008-
Topical Editor for J. of Optical Society of America B, 2005-2011
Editorial Board for “Nanophotonics” journal, 2012-
Editorial Advisory Board Member for Laser and Photonics Reviews, 2008-
Editorial Advisory Board Member for Laser Physics Letters, 2006-
Editorial Board Member for “Metamaterials” Journal, 2006-
Editorial Board Member for Journal of Nanotechnology, 2008-
Editorial Advisory Board Member for International Journal of Theoretical Physics, Group Theory,
and Nonlinear Optics
Editorial Advisory Board Member for The J. Nonlinear Optical Physics and Materials (JNOPM)
Editor for Special Issue “Optics on the Nanoscale: Pronciples, Instrumentation and Applications” of
Applied Physics B, v. 84, ##1 and 2, July/Aug. 2006.
Guest Editor for IEEE's Journal of Selected Topics in Quantum Electronics (JSTQE) on Negative
Index and Metamaterials, 2009
Guest Co-Editor for J. of Optics B: Quantum and Semiclassical Optics special issue on
Metamaterials, 2005.
Associate Guest Editor for IEEE's Journal of Selected Topics in Quantum Electronics (JSTQE) on
Nonlinear Optics, 2005
Guest Editor/Coordinator for Journal of Optical Society of America B (JOSA-B) Focus Issue on
Metamaterials, 2005
Editor for Feature Issue of J. of the Optical Society of America A and B on “Photonic
Metamaterials”, v. 24, #10, 2007
OSA Max Born Award Committee, Member, 2005, 2006
Organizer of a number of symposia for ACS, OSA, APS, and CLEO/QELS Annual Meetings, 1997-
2005
Chair and Member of Program Committees and International Advisory Committees for a number of
International Conferences, Symposia, and Schools
Visiting Professorships (1999-2000; sabbatical year) at:
Ecole Superieure de Physique et de Chimie Industrielles, Paris
University of Science and Technology, Hong Kong
Ludwig-Maximilians Universitat, Munich
The Associated Western Universities Faculty Fellowship (Sandia National Laboratories), 1995
International Humboldt Foundation Scholar (Paris-Sud Universite, France), 1991
3
Humboldt Foundation Fellow (Heidelberg, Germany, and Paris, France), 1990-1991
USSR Academy of Science Grant for Young Investigators, 1988-1990
2nd Prize in the USSR Academy of Science Competition on Fundamental Studies, 1983
Publication Summary (h-factor is 74, as of Jan. 2015 according to Google Scholar): One
monograph and two co-authored books, 5 edited/co-edited books, 26 invited book chapters and a
number of invited review articles; over 400 publications, in total, including 255 research papers in
refereed journals. Co-inventor of 11 patents. Over 300 invited presentations at International
Conferences and leading research centers, including a number of plenary and keynote talks.
The OPTICS category in the ISI Web of Science contains 80 journals, which in total publish over
40,000 papers each year. Out of about 480,000 papers published in these journals from January
2005 to January 2015, three papers from the Shalaev group are among the top dozen most cited
publications and they are ranked (as of January, 2015), in terms of the number of citations, as #6
(V. M. Shalaev, “Optical negative-index metamaterials,” Nature Photonics 1, 41 (2007) - 1,679
citations (Google Scholar)), #8 (V. M. Shalaev et al, “Negative index of refraction in optical
metamaterials,” Optics Letts 30, 3356 (2005) – 1,347 citations), and #12 (W. Cai, U. K. Chettiar, A.
V. Kildishev, and V. M. Shalaev, “Optical cloaking with metamaterials,” Nature Photonics 1, 224
(2007) – 1,098 citations). According to Google Scholar, there are more than 22,000 citations in
total to Shalaev’s papers.
25 Most Cited papers and books (as of Jan 2015 according to Google Scholar)
1. Shalaev, V. M. Optical Negative-Index Metamaterials. Nature photonics 1, 41-48, (2007). -1679
citations
2. Shalaev, V. M. et al. Negative Index of Refraction in Optical Metamaterials. Optics Letters 30,
3356-3358, (2005). -1347 citations
3. Cai, W., Chettiar, U. K., Kildishev, A. V. & Shalaev, V. M. Optical Cloaking with Metamaterials.
Nature photonics 1, 224-227, (2007). -1098 citations
4. Noginov, M. et al. Demonstration of a Spaser-Based Nanolaser. Nature 460, 1110-1112, (2009). -
1015 citations
5. Cai, W. & Shalaev, V. M. Optical Metamaterials. Vol. 10 (Springer, 2010). -570 citations
6. Xiao, S. et al. Loss-Free and Active Optical Negative-Index Metamaterials. Nature 466, 735-738,
(2010). -420 citations
7. West, P. R. et al. Searching for Better Plasmonic Materials. Laser & Photonics Reviews 4, 795-808,
(2010). -380 citations
8. Shalaev, V. M. Nonlinear Optics of Random Media: Fractal Composites and Metal-Dielectric
Films. (Springer, 2000). -372 citations
9. Shalaev, V. M. Electromagnetic Properties of Small-Particle Composites. Physics Reports 272, 61-
137, (1996). -354 citations
10. Genov, D. A., Sarychev, A. K., Shalaev, V. M. & Wei, A. Resonant Field Enhancements from
Metal Nanoparticle Arrays. Nano Letters 4, 153-158, (2004). -338 citations
4
11. Markel, V. et al. Near-Field Optical Spectroscopy of Individual Surface-Plasmon Modes in Colloid
Clusters. Physical Review B 59, 10903, (1999). -310 citations
12. Gresillon, S. et al. Experimental Observation of Localized Optical Excitations in Random Metal-
Dielectric Films. Physical review letters 82, 4520, (1999). -305 citations
13. Podolskiy, V., Sarychev, A. & Shalaev, V. Plasmon Modes and Negative Refraction in Metal
Nanowire Composites. Optics Express 11, 735-745, (2003). -293 citations
14. Sarychev, A. K. & Shalaev, V. M. Electromagnetic Field Fluctuations and Optical Nonlinearities in
Metal-Dielectric Composites. Physics Reports 335, 275-371, (2000). -287 citations
15. Cai, W., Chettiar, U. K., Kildishev, A. V., Shalaev, V. M. & Milton, G. W. Nonmagnetic Cloak
with Minimized Scattering. Applied Physics Letters 91, 111105, (2007). -284 citations
16. Podolskiy, V. A., Sarychev, A. K. & Shalaev, V. M. Plasmon Modes in Metal Nanowires and Left-
Handed Materials. Journal of Nonlinear Optical Physics & Materials 11, 65-74, (2002). -273
citations
17. Stockman, M. I., Shalaev, V. M., Moskovits, M., Botet, R. & George, T. F. Enhanced Raman
Scattering by Fractal Clusters: Scale-Invariant Theory. Physical Review B 46, 2821, (1992). -267
citations
18. Tsai, D. et al. Photon Scanning Tunneling Microscopy Images of Optical Excitations of Fractal
Metal Colloid Clusters. Physical review letters 72, 4149, (1994). -259 citations
19. Ni, X., Emani, N. K., Kildishev, A. V., Boltasseva, A. & Shalaev, V. M. Broadband Light Bending
with Plasmonic Nanoantennas. Science 335, 427-427, (2012). -244 citations
20. Markel, V., Shalaev, V. M., Stechel, E., Kim, W. & Armstrong, R. Small-Particle Composites. I.
Linear Optical Properties. Physical Review B 53, 2425, (1996). -236 citations
21. Shalaev, V. M. & Sarychev, A. K. Nonlinear Optics of Random Metal-Dielectric Films. Physical
Review B 57, 13265, (1998). -229 citations
22. Brongersma, M. & Shalaev, V. The Case for Plasmonics. Science 328, (2010). -206 citations
23. Sarychev, A. K. & Shalaev, V. M. Electrodynamics of Metamaterials. (World Scientific, 2007). -
201 citations
24. Shalaev, V. M. Optical Properties of Nanostructured Random Media. Vol. 82 (Springer, 2002). -
198 citations
25. Shalaev, V. M. & Kawata, S. Nanophotonics with Surface Plasmons. (Elsevier, 2006). -195
citations
Consulting Activities:
Member of the Scientific Advisory Council for Skolkovo Innovation Center (“Russian Silicon
Valley”)
Member of the Steering Committee for SkolTech-MIT (2012-2013)
Exucitive Committee member for the Russian Quantum Center (2012-2013)
5
International Advisory Board member for the Russian Quantum Center
Co-Founder and scientific director for Nano-Meta Technologies, Inc. (NMTI), 2012-
Member of Scientific Advisory Board for SOLARIS Nanoscieces Inc., 2004-2011
Member of Scientific Advisory Board for Array Bioscience Inc. (Berkley, CA) 1999-2001
Consultant for Lasys Inc. (Las Cruces, NM) 2000-2003
Consultant for Battelle Scientific Services Program, ARO, 1999-2009
Consultant for Tienta Sciences Inc., 2006-2010
Consultant for Science and Technology Corporation, 2009-2011
Research Grants and Contracts Received at Purdue University
(since Fall 2001):
[1] “Plasmonic Nanophotonics and Optoelectronics” National Science Foundation,
Nanoscale Interdisciplinary Research Team (NIRT), PI, NIRT#0210445, 07/01/02-
06/30/06, $1,300,000
[2] “Surface-Enhanced Optical Detection of Proteins”, Indiana Proteomics Consortium
(co-funded by Eli Lilly Company, Inidiana University, and Purdue University), co-PI
(with Dor Ben-Amotz), 04/01/02-08/31/05, $2,100,101.
[3] “Development of Novel Composite and Random Materials for Nonlinear Optics and
Lasers”, NASA/Norfolk State University, PI (for Purdue) #: NCC5-514, 9/15/00-9/14/04.
Total award $2,000,000; PI for Purdue subcontract; Shalaev’s subcontract part: $200,000.
[4] “Nanooptics with Plasmonic Nanomaterials," National Science Foundation, PI, Grant
No. DMR-0121814, Nov. 2001 – Nov. 2005, $234,321.
[5] “Fractal Surface Enhanced Chemical and Biological Sensors” National Science
Foundation, PI, DMR-0227473, 8/1/02-7/31/03, $100,000
[6] “Instrumentation for Research on Plasmonic Nanomaterials and their Applications in
Photonics”, DoD: Defense University Research Instrumentation Program (DURIP), PI,
DAAD19-02-1-0124, $206,994
[7] “Nanostructured Metal-Dielectric Films: New Avenues for Photonics and
Spectroscopy,” Army Research Office/New Mexico State University, PI, DAAD19-01-
1-0682, 10/1/01-6/30/04. Toral award - $330,000; Purdue part -$120,000.
[8] “Nonlinear Optics of Nanocomposites in Microcavities”, NSF/New Mexico State
University, PI (for Purdue) DMR-0071901, 10/01/01-09/30/04. Total award - $285,000;
Purdue part - $50,000.
6
[9] “Nanometer Laser Spectroscopy Using Fractal Template”, PI (for Purdue)
NASA/New Mexico State University, NAG8-1710, 9/1/01-3/31/03. Total award -
$300,000; Purdue Part - $40,000.
[10] “Plasmonic Nano-Photonics”, Purdue Research Foundation, PI, 4/7/01-4/7/03,
$26,000. PI
[11] “Systematic Study of Eelectromagnetic Absorption and Scattering by Fractal
Aggregates,” Battelle Research Triangle/ARO, PI, 03/01/02-07/01/03, $38,775.
[12] “Metal-Dielectric Composite Filters with Spectral Windows of Transperancy,”
Battelle Research Triangle/ARO, PI, 05/01/02-04/30/03, $48,681. PI
[13] “Center for Research and Education in Advanced Materials,” NASA NRA 02
OEOP-01 (University Research Centers), with Norfolk State University; $6,000,000 total
for 5 years; PI for Purdue subcontract; the Purdue part is $300K.
[14] “Center for Photonic Materials Research: Engineering basic physical and
spectroscopic principals of random lasers and other nano-composite photonic materials”,
NSF-CREST, 9/1/03-02/28/09, with Norfolk State University, $4,000,000 total for 5
years; PI (at Purdue); the Purdue part is $300K.
[15] “Acquisition and Customization of a Facility for the In-situ X-ray Structural Analysis
of Nanomaterials”, NSF, co-PI, $613,822, 10/01/03-09/30/06.
[16] “Innovative Nanotechnology Research at Purdue”, DARPA (co-PI); Total
$2,000,000; Shalaev’s part is $500,000.
[17] Negative Refraction in the Optical Range and Left-Handed Photonics, ARO, 08/01/04-
12/31/06, total costs: $320,000. PI
[18] Engineering Basis Physical and Spectroscopic Principles of Random Lasers and other
Nano-Composition Photonic Materials, 09/01/03-08/30/08; total $4,000,000. With
Norfolk State University. PI for Purdue subcontract. Shalaev’s subcontract is $300,000.
[19] Plasmonic Filters with Infrared Windows Transparency, ARO via Battelle
Operations, 01/12/05-01/11/07, $277,000. PI.
[20] Spectral Properties of Negative-Index Materials in Optics, ARO, DEFENSE
UNIVERSITY RESEARCH INSTRUMENTATION PROGRAM (DURIP), $200K.
04/01/2005/03/31/06. PI
[21] Tunable Super-Lens for Nanoscale Optical Bio-Imaging, Phase I STTR/ARO project
with Tienta Inc., $100,000; Sept 1., 2005- Aug. 31, 2006
7
[22] MURI-ARO Award “Tunable and Reconfigurable Optical Negative-Index Materials
with Low Losses, $5.4M. PI (May 1, 2006 to Apr 30, 2011).
[23] NSF-PREM Award for PREM Center “Photonic Metamaterials” (Aug. 2006-Aug
2011). PI for Purdue University subcontract. Total $2M; Purdue’s part $500K.
[24] STTR-ARO Phase II Award “Super-Lens for Bio-Sensing”(with Tienta Sciences
Inc.; Oct. 2006-Oct. 2008); $800K. PI for Purdue; the Purdue part $400K.
[25] MURI-ARO Award “Passive All-Optical Switching” (Aug. 2006-Aug. 2011). Total
$5M. PI for Purdue subcontract; the Purdue budget $750K.
[26] ARO-Battelle Research Triangle Park Office “Long Pass Plasmonic-Molecular
Filters for Mid-Ifrared”, 03/09/07-03/08/09, PI, $111,000
[27] ARO, “Spectroscopic Ellipsometry of Optical Metamaterials”, co-PI, 06/02/2009 –
02/01/2010, $145K
[28] ARO-MURI, “Transformation Optical Metamaterials”, co-PI (PI for Purdue),
09/28/2009 – 01/27/2011, $2,153,250
[29] ARO, “Searching for Better Plasmonic Materials,” co-PI, 09/15/2009 – 06/14/2010,
$50K
[30] Science and Technology Corp., “Bi-spectral Plasmonic onscurants,” PI, 04/01/2009 –
12/31/2010, $150K
[31] ARO-DURIP, “Glancing Angle Deposition System for Transformation-Optics
Devices”, co-PI, 08/10/2010-09/09/2011, $150K
[32] CIA, “A Planar Magnifying Hyperlens”, PI, 07/12/2010-07/11/2012, $240K.
[33] The Boeing Company, “Hyperbolic Metamaterials for Controlling Thermal
Radiation: Feasibility Study”, co-PI, $50K, 07/01/2010-12/17/2010
[34] MURI-ONR, “Large-Area, 3D Optical Metamaterials with Tunability and Low
Loss”, co-PI, $1.3M (Shalaev’s part), 08/01/2010-07/31/2015
[35] ARO, “Unlocking New Physics with Improved Plasmonic Materials”, co-PI, $100K
(Shalaev’s part), 08/01/2011-07/30/2014
[36] MURI-AFOSR, “Intergrated Hybrid Nanophotonic Circuits”, co-PI, $750K
(Shalaev’s part), 06/01/2011-05/31/2016
8
[37] NSF-MRSEC “Center for Photonic Materials (C-PHOM)”, co-PI, $1M (Shalaev’s
part), 8/01/2011-07/30/2016
[38] NSF-PREM Award for PREM Center “META-PREM” (Aug. 2012-Aug 2017). PI
for Purdue University subcontract. Total $3.4M; Purdue’s part $900K; Shalaev’s part
$450K.
[39] University of York, “Advnaced Transformation Optical Methods,” PI, $31K,
06/15/2013-06/14/2015.
[39] ARO, “Flat Photonics with Metasurfaces”, PI, total $1.4M; Shalaev’s part $0.7M,
01/01/13-12/31/16
[40] ONR-MURI, “Novel Nonlinear Optical Processes in Active, Random, and
Nanostructured Systems” co-PI, total $6M; Shalaev’s part $1.2M, 07/01/2013-06/30/2018
[41] AFOSR-MURI, “Active Metasurfaces for Advanced Wavefront Engineering and
Waveguiding” co-PI, total $6M; Shalaev’s part $800K, July 2014 – July 2019
Professional Society Activities:
Organizations:
IEEE (Institute of Electrical and Electronics Engineers), Fellow: 2010-present
APS (American Physical Society). Fellow: 2002—present
OSA (Optical Society of America). Fellow: 2003-present
The International Society for Optical Engineering (SPIE) Fellow: 2005-present
OSA Max Born Award Committee, Member, 2005, 2006
APS (American Physical Society). Member: 1992—present
OSA (Optical Society of America). Member: 1995-present
Vice-Chair for OSA Topical Group “Waves in random and periodic structures”, 2002-
2004
Chair of the OSA Topical Group: Photonic Metamaterials: from Random to Periodic,
2004-2006
ACS (American Chemical Society). Member: 1997-99
MRS (Materials Research Society). Member: 1996-99, 2002-
SPIE (International Society for Optical Engineers). Member 2002-
IEEE-Senior Member, 2005-
IEEE LEOS Nanophotonics Member Committee, 2004-2007
Chair of OSA Technical Group “Photonic Metamaterials”, 2008-2010
9

Activities:
Conference Committees and Chair Positions
[1] Session Organizer and Chair, "Nanostructured Materials: Clusters, Composites,
and Thin Films," at the 213th American Chemical Society Meeting, San
Francisco, CA, April 13-17, 1997.

• Editor of a book developed from this session (with the same title),
published by the ACS Symposium Series, Vol. 679, ACS
Books, 1997.
[2] Member of the Program Committee and Chair of a session at XI International
Vavilov Conference on Nonlinear Optics, Novosibirsk, Russia, June 24-28,
1997.
[3] Member of the International Advisory Committee and Chair of a Session at the
Fifth International Conference on Electrical Transport and Optical Properties of
Inhomogeneous Media (ETOPIM5), Hong Kong, June 1999
[4] Organizer and Chair, "Nonlinear Optics of Random Media," Symposia at the
Annual Optical Society of America meetings in Baltimore, October 1998 and
California in 1999

• Editor of a book based on the 1999 symposia (with the same title)
in the Springer Verlag series Topics in Applied Physics, to be
published 2001.
[5] Member of the Program Committee, Sixth International Conference n Electrical
Transport and Optical Properties of Inhomogeneous Media (ETOPIM6), Salt
Lake City, UT, July 2002.
[6] Member of the International Program Committee for VIII International
Conference “Laser and Laser-Information Technology”, Sept. 27-Oct. 1, 2003,
Plovdiv, Bulgaria.
[7] Member of the International Program Committee for The 4th Asia-Pacific
Conference on Near-Field Optics, Taipei, Taiwan, October 14 -17, 2003.
[8] Chair of Sub-Committee “Fundamental Optics in Periodic and Random Media”
for Quantum Electronics and Laser Science 2003 Conference, Baltimore
[9] Co-Chair for Symposium “Waves in Random and Periodic Media” for 2002
Annual OSA Meeting in Orlando, FL.
10
[10] Co-Chair for Symposium “Waves in Random and Periodic Media” for 2004
Annual OSA Meeting in Rochester
[11] Program Committee Member for Symposium “Plasmonics: Metallic
Nanostructures and Their Optical Properties” at SPIE 48th Annual Meeting,
August 2003, San Diego, Ca.
[12] Co-Chair for Technical Group “Waves in Random and Periodic Media” for
2004 “Frontiers in Optics” OSA Meeting in Rochester, NY.
[13] Program Committee Member for Symposium “Complex Mediums IV” at SPIE
48th Annual Meeting, August 2003, San Diego, Ca.
[14] Program Committee Member for Symposium “Complex Mediums V: Light and
Complexity” at SPIE 49th Annual Meeting, 4-5August 2004, Denver, Co.
[15] Chair for Technical Group “Photonic Metamaterilas: from Random to
Periodic,” for 2005 “Frontiers in Optics” OSA Meeting in Tucson, AZ
[16] Member of International Advisory Board for Asia-Pacific Conference on Near-
Field Optics (AP-NFO05), Niigata City, Japan, Nov. 15-17, 2005.
[17] Program Committee Member for Symposium “Complex Mediums V: Light and
Complexity” at SPIE 50th Annual Meeting, 2005, San Diego, CA
[18] Co-Chair for Symposium “Plasmonic Nano-imaging and Nanofabrication” at
SPIE 50th Annual Meeting
[19] Co-Chair for OSA Topical Meeting “Photonic Metamaterials: from Random to
Periodic” held on Bahamas, June 2006
[20] Member of the Program Committee, Seventh International Conference n
Electrical Transport and Optical Properties of Inhomogeneous Media
(ETOPIM7), Sydney, Australia, July 2006.
[21] Co-Chair and Member of the Program Committee for MRS Symposium
“Plasmonics – Nanoscale Optics and Photonics Based on Metals”, Materials
Research Society Fall Meeting, Nov. 28-Dec. 2, 2005, Boston, MA (2005).
[22] Member of the Advisory and Program Committee of The Annual International
Workshop Laser Physics, LPHYS’06.
[23] Program Committee Member for International Conference on Nanophotonics
and Matamaterials (NanoMeta 2007) held in Seefeld in Austria in January 2007.
11
[24] Co-Chair for Symposium “Plasmonic Nano-imaging and Nanofabrication” at
SPIE Annual Meeting in August, 2006, San Diego, CA
[25] Co-Chair of a Symposium on Metamaterials at the American Physical Society
March Meeting in 2006.
[26] International Program Committee Member for a conference “Laser and Laser-
Informational Technologies: Fundamental Problems and Applications” 2004,
Bulgaria, and 2006, Smolian, October 4-7, 2006, Bulgaria.
[27] International Program and Steering Committee Member for 1-st International
Congress “Metamaterials” October 2007, Rome, Italy
[28] Program Committee Member for Symposium “Complex Mediums V: Light and
Complexity” at SPIE Annual Meeting, 2006, San Diego, CA
[29] Co-Chair for Symposium “Plasmonic Nano-imaging and Nanofabrication” at
SPIE Annual Meeting, 2007, San Diego, CA
[30] Program Committee Member for Symposium “Plasmonics: Metallic
Nanostructures and their Optical Properties IV” at SPIE Annual Meeting, 2006,
San Diego, CA
[31] Chair of OSA Topical Group “Photonic Metamaterials: from Random to
Periodic”, Division of Optical Sciences, 2006.
[32] Program Committee Member for Symposium “Plasmonics: Metallic
Nanostructures and their Optical Properties IV” at SPIE Annual Meeting, 2007,
San Diego, CA
[33] Program Committee Member for Symposium “Complex Mediums V: Light and
Complexity” at SPIE Annual Meeting, 2006, San Diego, CA
[34] Co-Chair for Symposium “Plasmonic Nano-imaging and Nanofabrication” at
SPIE Annual Meeting, 2008, San Diego, CA
[35] Program Committee Member for Symposium “Complex Mediums VII: Light
and Complexity” at SPIE Annual Meeting, 2008, San Diego, CA
[36] Program Committee Member for Symposium “Plasmonics: Metallic
Nanostructures and their Optical Properties VI” at SPIE Annual Meeting, 2008,
San Diego, CA
[37] International Steering Committee Member for the 2-nd International Congress
“Metamaterials” 2008, Pamplona, Spain
12
[38] Program Chair of OSA Topical Meeting: Photonic Metamaterials: from
Random to Periodic, Jackson Hole, Wy, June 4-7, 2007.
[39] Co-Chair for Symposium “Plasmonic Nano-imaging and Nanofabrica-tion” at
SPIE Annual Meeting, 2009, San Diego, CA
[40] Program Committee Member for Symposium “Complex Mediums VIII: Light
and Complexity” at SPIE Annual Meeting, 2009, San Diego, CA
[41] Program Committee Member for Symposium “Plasmonics: Metallic
Nanostructures and their Optical Properties VII” at SPIE Annual Meeting, 2009,
San Diego, CA
[42] Program Committee Member for International Conference on Nanophotonics
and Matamaterials (NanoMeta 2009) held in Seefeld, Austria, in January 2009.
[43] International Steering Committee Member for the 3-nd International Congress
“Metamaterials” 2009, London, UK.
[44] Program Committee Member of 5th International Conference on Materials for
Advanced Technologies 2009, Singapore, 28 June – 3 July, 2009.
[45] Member of the Advisory and Program Committee for Laser Physics Workshop,
Trondheim, Norway. June 30 - July 4, 2008.
[46] Member of the Advisory and Program Committee for Laser Physics Workshop,
Barcelona, Spain, July 13-17, 2009.
[47] Electrical Transport and Optical Properties of Inhomogeneous Media
(ETOPIM) Association Committee Member; the eighth International
Conference. Crete, Greece, June 8-12, 2009.
[48] Member of the Program Committee for The 8th Pacific Rim Conference on
Lasers and Electro-Optics (CLEO / Pacific Rim); Aug. 30 – Sep. 3, 2009,
Shanghai, China.
[49] Program co-Chair for the 2009 CLEO/IQEC conference
[50] Symposium Organizer, 2009 MRS Fall Meeting.
[51] Sub-committee co-chair for the program topic “Nanophotonics and Plasmonics”
of ICONO-2010 conference (International Conferences on Coherent and
Nonlinear Optics); August 23-27, 2010, Kazan, Russia
[52] Program Committee Member for Symposium “Thin Films” at SPIE Annual
Meeting, 2010, San Diego, CA
13
[53] Program Committee Member for Symposium “Metamterials” at SPIE Annual
Meeting, 2010, San Diego, CA
[54] Program Committee Member for Symposium “Plasmonics VIII” at SPIE
Annual Meeting, 2010, San Diego, CA
[55] Member of the Advisory and Program Committee for Laser Physics Workshop,
Foz do Iguacu, Brazil, July 5 - 9, 2010
[56] Co-Chair of International conference ICMAT 2011, Singapore
[57] A member of the International Program Committee (IPC) for the IASTED
International Conference on Antennas, Radar and Wave Propagation (ARP
2009)
[58] A member of the International Program Committee (IPC) for the IASTED
International Conference on Antennas, Radar and Wave Propagation (ARP
2010; Cambridge, Massachusetts, USA from November 01, 2010 to November
03, 2010)
[59] A member of Technical Program Committee of CLEO Europe-EQEC 2011
(Munich)
[60] General co-Chair for the 2011 CLEO/QELS conference
[61] International Adviser Board Member for Symposium “Smart & Adaptive
Optics” at 4th CIMTEC Conference (Montecatini Therme, Italy, 2012)
[62] Program Committee Member for the SPIE conference LA112 on Synthesis and
Photonics of Nanoscale Materials IX (21-26 January 2012, San Francisco, CA)
[63] International Program and Steering Committee Member for International
Congress “Metamaterials” in 2012 (St. Petersburg)
[64] International Program and Steering Committee Member for International
Congress “Metamaterials” in 2013 (Bordeaux, France)
[65] Member of the International Advisory Committee for a conference Modern
Problems of Laser Physics, MPLP-21013 to be held in Novosobirsk, Russia,
Aug. 25-31, 2013
[66] International Program and Steering Committee Member for International
Congress “Metamaterials” in 2014 (Copemhagen, Denmark)
[67] International Adviser Board Member for Symposium “Smart & Adaptive
Optics” at 4th CIMTEC Conference (Montecatini Therme, Italy, 2013)
14
[68] International Advisory Committee member for META’14, Singapore, May 20-
23, 2014
[69] Program Committee Member for the SPIE conference 9163 Plasmonics:
Metallic Nanostructures and Optical Properties XII (17-21 August 2014, San
Diego, CA)
[70] Advisory Board Member for the 9-th International Congress “Metamaterials”
2014, 25-30 August, Copenhagen, Denmark
[71] Gordon Conference on Plasmonics, July 6-11, 2014. Discussion leader.

PhD Thesis Supervision Completed at Purdue University:
[1] Dentcho Genov, “Electromagnetic Properties of Complex Media: Nano-
Structured Semicontinuous Films and Fractal Aggregates, 2005
[2] Eldar Khaliullin, “Quantum Size and Nonlinesr Effects in Metal Nanostructures
and Bio-Applications with SERS, 2005
[3] Wenshan Cai, “ Optical Metamaterials: Basic Structures and Potential
Applications” May 2008
[4] Hsiao-Kuan Yuan, “Optical metamaterials, July 2008
[5] Uday Chettiar, “Simulation, modeling, and design of optical metamaterials”,
December 2008.
[6] Reuben Bakker, “Optical Nanoantennae: Enhanced Electromagnetic Fields and
Enhanced Fluorescence”, August 2008.
[7] Piotr Nyga, “Plasmonic Nanomaterials for Midinfrared and their
Photomodification”, December 2008.
[8] Mark Thoreson, “Metal-Dielectric Composite Plasmonic Films and their
Applkications”, December 2009
[9] Shumin Xiao, Tunable and Active Optical Negative Index Metamaterials, August
2010
[10] Zhengtong Liu, Modeling and Characterization of Plasmon Nanostructures,
August 2010
[11] Joshua Borneman, Optical Metamterials: Linear and Nonlinear Charaterization
and Applications to Optical Limiting, May 2010
15
[12] Ji Young Kim, Near-field Optical Microscopy and Spontaneous Emission
Engineering with Plasmonic Metamaterials, December 2010
[13] Kuo Ping Chen, December 2010
[14] Xingjie Ni, October, 2012
[15] Satoshi Ishii, November, 2012
[16] Guru Naik, summer 2013 (co-advisor)
[17] Urcan Guler, December 2013
Courses Developed:
Phys. 573/673 Optics of Advanced Nanomaterials (Spring 1999; at New Mexico State)
ECE 695S “Nanophotonics and Metamaterials” (Fall 2004, Fall 2006, Spring 2008, Fall 2009,
Fall 2011, Fall 2013)
Courses "In Charge Of":
Phys. 472/572 Nonlinear Optics (Spring 1994-2001; at New Mexico State)
ECE 695S Nanophotonics and Metamaterials
ECE552 Introduction to Lasers
ECE 615 Nonlinear Optics

Research Books and Book Contributions:
a. Authored and Edited Books
[1] V. M. Shalaev, Nonlinear Optics of Random Media: Fractal Composites and Metal-
Dielectric Films, Springer Tracts in Modern Physics, v.158, Springer, Berlin
Heidelberg 2000.
[2] A. K. Sarychev and V. M. Shalaev, Electrodynamics of Metamaterials, World
Scientific, Singapore, 2007.
[3] V. M. Shalaev (Editor), Optical Properties of Random Nanostructures, Springer
Verlag, Topics in Applied Physics, Berlin Heidelberg 2002.
[4] V. M. Shalaev and M. Moskovits (Editors), Nanostructured Materials: Clusters,
Composites, and Thin Films, ACS Symposium Series v. 679, ACS Books, 1997.
16
[5] S. Kawata and V. M. Shalaev (Editors), Advances in Nano-Optics and Nanophotonics
(Elsevier), 2006
[6] S. Kawata and V. M. Shalaev (Editors), Tip Enhancement (Advances in Nano-Optics
and Nano-Photonics), Elsevier, 2007.
[7] V. M. Shalaev and S. Kawata (Editors), Nanophotonics with Surface Plasmons
(Advances in Nano-Optics and Nano-Photonics), Elsevier, 2007.
[8] W. Cai and Vladimir M. Shalaev, Optical Metamaterials: Fundamentals and
Applications, Springer, 2009
b. Book Chapters
[1] Vladimir M. Shalaev, "Optical Properties of Fractal Composites," Chapter in:
Optical Propertiesof Random Nanostructures, Ed: Vladimir M. Shalaev, Springer
Verlag, Topics in Applied Physics, Berlin Heidelberg 2002.
[2] W.T. Kim, V. P.Safonov, V. P. Drachev,V. A.Podolskiy, V. M. Shalaev, and
R.L.Armstrong, "Fractal-Microcavity Composites: Giant Optical Responses,"
Chapter in: Optical Properties of Random Nanostructures, Ed: Vladimir M. Shalaev,
Springer Verlag, Topics in Applied Physics, Berlin Heidelberg 2002.
[3] A. K. Sarychev and V. M. Shalaev, "Theory of Nonlinear Optical Responses in
Metal-Dielectric Composites," Chapter in: Optical Properties of Random
Nanostructures, Ed: Vladimir M. Shalaev, Springer Verlag, Topics in Applied
Physics, Berlin Heidelberg 2002.
[4] V. M. Shalaev, "Fractal Nano-Composites: Giant Local-Field Enhancement of
OpticalResponses," Chapter in: Nanoscale Linear and Nonlinear Optics, eds: M.
Bertolotti and C. Sibilia, AIP, 2001.
[5] V. A. Markel, V. M. Shalaev, and T. F. George, "Some Theoretical and Numerical
Approaches to the Optics of Fractal Smoke," Chapter in: Optics of Nanostructured
Materials, Eds:V.A.Markel and T.F. George, Wiley, 2000.
[6] A. K. Sarychev and V. M. Shalaev, "Field Distribution, Anderson localization, and
optical phenomena in random metal-dielectric films," Chapter in: Optics of
Nanostructured Materials, Eds: V.A. Markel and T.F. George, Wiley, 2001.
[7] V.M. Shalaev," Surface-Enhanced Optical Phenomena in Nanostructured Fractal
Materials," Chapter in: Handbook of Nanostructured Materials and
Nanotechnology, Volume 4: Optical Properties, Edited by H. S. Nalwa, Academic
Press, 1999.
17
[8] V. A. Markel and V. M. Shalaev, "Computational Approaches in Optics of Fractal
Clusters," Chapter in Computational Studies of New Materials, edited by D.A. Jelski
and T. F. George (World Scientific, Singapore, 1999)
[9] V. M. Shalaev, V. P. Safonov, E.Y. Poliakov, V. A. Markel, and A. K. Sarychev,
"Fractal Surface Enhanced Optical Nonlinearities", Chapter 8: Nanostructured
Materials: Clusters, Composites, and Thin Films, Eds; V. M. Shalaev and M.
Moskovits, ACS Symposium Series v. 679, ACS Books, 1997.
[10] Dentcho A. Genov, Andrey K. Sarychev and Vladimir M. Shalaev, Local Field
Statistic and Plasmon Localization in Random Metal-Dielectric Films, in: Wave
Scattering in Complex Media: From Theory to Applications, Eds: Sergey Skipetrov
or Bart van Tiggelen, Publisher: Kluwer Academic Publishers, Dordrecht,
Netherlands (2003)
[11] Andrey K. Sarychev and Vladimir M. Shalaev, Optical Properties of Metal-
Dielectric Films, in Introduction to Complex Mediums for Optics and
Electromagnetics, Editors: Werner S. Weiglhofer and Akhlesh Lakhtakia, SPIE
PRESS Vol. PM123 * October 2003, pp. 397-420
[12] Andrey K. Sarychev and Vladimir M. Shalaev, Negative Refraction in the Optical
Range, in: Negative Refraction Metamaterials: Fundamental Properties and
Applications, edited by G. V. Eleftheriades and K. G. Balmain, John Wiley & Sons,
Inc., 2005.
[13] Dentcho A. Genov, Andrey K. Sarychev and Vladimir M. Shalaev, Surface
Plasmons Excitation in Semicontinuous Metal Films, in: Progress in Condensed
Matter Physics, ed. F. Columbus, Nova Science Publishers, Inc., Hauppauge NY,
2004.
[14] V.P. Drachev, M. D. Thoreson, and V.M. Shalaev, SENSING PROTEINS WITH
ADAPTIVE METAL NANOSTRUCTURES, a chapter in a "Surface Plasmon
Nanophotonics, Kluwer, editors: M. Brongersma and P. Kik, 2006.
[15] A. K. Sarychev, G. Shvets, and V. M. Shalaev, Magnetic Plasmon Resonance,
chapter 1 in Nanoplamonics: From Fundamanetals to Applications, Handai
Nanophotonics, volume 2, pp3-13, Eds: S. Kawata and H. Masuhara, Elsevier
(2006).
[16] V.P. Drachev and V.M. Shalaev, Biomolecule sensing with adaptive plasmonic
nanostructures, Surface Enhanced Raman Scattering - Physics and Applications, ed.
by K. Kneipp, M. Moskovits, and H. Kneipp, Springer Verlag, Topics in applied
physics, 2006.
18
[17] A.V. Kildishev, T.A. Klar, V.P. Drachev, and V.M. Shalaev, Thin metal-dielectric
nanocomposites with a negative index of refraction, Chapter 9 in: Nanophotonics
with Surface Plasmons, ed. by V.M. Shalaev and S. Kawata, Elsevier, 2007.
[18] M.A. Noginov, G. Zhu, V.P. Drachev, and V.M. Shalaev, Surface plasmons and
gain media, Chapter 5 in: Nanophotonics with Surface Plasmons, ed. by V.M.
Shalaev and S. Kawata, Elsevier, 2007.
[19] N. M. Litchinitser and V. M. Shalaev, Negative refraction, The McGraw-Hill 2008
Yearbook of Science & Technology, pp. 230-233.
[20] N. M. Litchintser, I. R. Gabitov, A. I. Maimistov, V. M. Shalaev. Negative
Refractive Index Metamaterials, Progress in Optics, V. 51, Chapter 1, pp 1-68
(2008)
[21] A. Boltasseva, R. B. Nelson, C. Jeppesen, A. Kristensen, R. Bakker, Z. Liu, H.-K.
Yuan, A. V. Kildishev, and V. M. Shalaev, Fabricating Plasmonic Components for
Nano- and Meta-Photonics, chapter in “Metamaterials and Plasmonics:
Fundamentals, Modelling, Applications’, NATO Science for Piece and Security
Series – B: Physics and Biophysics; Eds: S. Zouhdi, A. Sihvola, and A. P.
Vinogradov, Springer, pp. 209-222, 2009.
[22] N. M. Litchinitser, I. R. Gabitov, A. I. Maimistov, and V. M. Shalaev, Linear and
Nonlinear Metamaterials and Transformation Optics, chapter for Taylor and Francis
book “Tutorials in Metamaterials”, (2010).
[23] N. M. Litchinitser and V. M. Shalaev, Optical Metamaterials: Invisibility in Visible
and Nonlinearities in Reverse, in Nonlinearities in Periodic Structures and
Metamaterials: Springer Series in Optical Sciences, Vol. 150, edited by C. Denz, S.
Flach, and Yu. S. Kivshar (Springer, 2009).
[24] N. M. Litchinitser, I. R. Gabitov, A. I. Maimistov, and V. M. Shalaev, Linear and
Nonlinear Metamaterials and Transformation Optics, pp. 1-27, in book "Tutorials in
Metamaterials", Eds. M. A. Noginov and V. A. Podolskiy; series in Nano-Optics and
Nanophotonics, Series Eds. S. Kawata and V. M. Shalaev; CRC Press, Taylor &
Francis Group, New York, NY, 2012. Pp. 2-28
[25] Sh. Xiao and V. M. Shalaev, Tunable and Active Optical Negative Index
Metamaterials, Chapter 9 in World Scientific Series in Nanoscience and
Nanotechnology - Vol. 4, PLASMONICS AND PLASMONIC METAMATERIALS
- Analysis and Applications, edited by G. Shvets & I. Tsukerman (2012). Pp. 255-
284
[26] S. Ishii. X. Ni, V. P. Drachev, M. D. Thoreson, V. M. Shalaev, and A. V. Kildishev,
“Active and Tunable Metallic Nanoslit Lenses, in book “Active Plasmonics and
Tuneable Plasmonic Metamaterials” Eds: A. V. Zayats and S. Maier, Wiley 2013.
19

Issued and Pending Patents:
[1] R.L. Armstrong, V.M. Shalaev, T.M. Shay, W.-T. Kim, Z.C. Ying, V.P. Drachev, V.P.
Safonov, Optical Enhancement with Nanoparticles and Microcavities, US patent 6,608,716
B1, Aug. 19, 2003
[2] R.L. Armstrong, V.M. Shalaev, T.M. Shay, W.-T. Kim, Z.C. Ying, V.P. Drachev, V.P.
Safonov, Optical Enhancement with Nanoparticles and Microcavities, Australian patent No.
767234
[3] R.L. Armstrong, V.M. Shalaev, H.V. Smith, Sensors Employing Nanoparticles and
Microcavities, U.S. Patent 6,781,690 B2, Aug. 24, 2004.
[4] "Optical Structures Employing Semicontinuous Metal Films," U.S. Provisional Patent
Application Serial No. 60/233,804.
[5] “Plasmonic and/or Microcavity Enhanced Optical Protein Sensing” US Patent
#7,298,474, issued Nov 20, 2007
[6] “Metal Tip-Substrate Nanoantennas and Molecule Counting for Bio-Molecule Raman
Imaging and Sensing”, P-03033
[7] “Raman imaging and sensing apparatus employing nanoantennas”, International patent
application, US Patent #6,985,223 (1/10/06)
[8] Plasmonic Nanophotonics Methods, Materilas and Apparatuses, US Patent 6,977,767
(12/20/05)
[9] A.V. Kildishev, V.M. Shalaev, Planar Lens, US Patent #8,094,378 B2, Jan. 10, 2012.
[10] Smolyaninov I.I., Smolyaninova V.N., Kildishev A.V., Shalaev V.M. ANISOTROPIC
METAMATERIALS EMULATED BY TAPERED WAVEGUIDES: APPLICATION TO
ELECTROMAGNETIC CLOAKING, US Patent # 8,509,578 B2, Aug. 13, 2013.
[11] Vladimir M. Shalaev, Alexander V. Kildishev, Vladimir P. Drachev, Wenshan Cai,
Near-field Raman imaging, US patent # 8,599,489 B2, Dec. 3, 2013.
[12] V. M. Shalaev, A. V. Kildishev, V. P. Drachev, W. Cai, Near-Field Raman Imaging, US
patent # 8,599,489 B2, Dec. 3, 2013
[13] W. Cai, V. M. Shalaev, U. K. Chettiar, A. V. Kildishev, “System, method and
applications for modifying the visibility properties of an object, US patent # 8,488,247 B2,
Jan 16, 2013
20

Activities as a Referee:
1993-present. Reviewing editor for Science. Referee for funding agencies (NSF, ACSPRF,
ARO, DoD, DOE, and others) and numerous research journals, such as Science,
Nature, Nature Photonics, Nature Materials, Physical Review and Physical Review
Letters, Surface Science, Journal of Physical Chemistry, Physica A, Applied Physics B,
Applied Physics Letters, Optical Communications, Metamaterials, Laser Physics
Letters, and several other journals. Regularly participate in various NSF panels. Invited
many times to serve as an external referee for PhD thesis defenses in different countries.
Served several times as a referee for evaluating European conference projects. Member
of NSF and NIH Committees for site visits of various Centers.
Editorial Positions:
[1] Editorial Advisory Board, International Journal of Theoretical Physics, Group
Theory and Nonlinear Optics, 2000-present
[2] Optical Properties of Random Nanostructures, Editor: V. M. Shalaev, Springer
Verlag, Topics in Applied Physics, Berlin 2001.
[3] Nanostructured Materials: Clusters, Composites, and Thin Films, V. M. Shalaev and
Martin Moskovits (eds.), ACS Symposium Series v. 679, ACS Books, 1997.
[4] Editorial Board Member for International Journal Laser Physics Letters
[5] Editorial Board Member for J. Nonlinear Optical Physics and Materials (JNOPM)
[6] Co-Editor of Applied Physics B – Lasers and Optics 2006-2013
[7] Co-Editor for Advances in Nano-Optics and Nanophotonics book series (Elsevier)
[8] Guest Co-Editor for J. of Optics B: Quantum and Semiclassical Optics special issue
on Metamaterials, 2005.
[9] Associate Guest Editor for IEEE's Journal of Selected Topics in Quantum [10]
Electronics (JSTQE) on Nonlinear Optics, 2005
[11] Guest Editor for Journal of Optical Society of America B (JOSA-B) Focus Issue on
Metamaterials, 2005
[12] Topical Editor for J. of Optical Society of America B, 2005-2011
[13] Editor for Special Issue of Applied Physics B on Optics on the Nanoscale, July-Aug.
2006
21
[14] Editorial Board Member for “Metamaterials” Journal, 2006-2013
[15] S. Kawata and V. M. Shalaev (Editors), Tip Enhancement (Advances in Nano-
Optics and Nano-Photonics), Elsevier, 2007.
[16] V. M. Shalaev and S. Kawata (Editors), Nanophotonics with Surface Plasmons
(Advances in Nano-Optics and Nano-Photonics), Elsevier, 2007.
[17] Editor for Feature Issue of J. of the Optical Society of America A and B on
“Photonic Metamaterials”, v. 24, #10, 2007
[18] Co-Editor for Series in Nanooptics and Nanophotonics, Taylor & Francis Books,
Inc.2008-
[19] Editorial Advisory Board Member for Laser and Photonics Reviews, 2008-
[20] Editorial Board Member for Journal of Nanotechnology, 2008-
[21] Guest Editor for IEEE's Journal of Selected Topics in Quantum Electronics
(JSTQE) on Negative Index and Metamaterials, 2009
[22] Reviewing Editor for Science, 2011-
[23] Editorial Board member for Nanophotonics, 2012-

Jonathan Phillips

Jonathan Phillips, professor i korstogshistorie, Royal Holloway, University of London.

Jonathan Phillips er uddannet ved Keele Universitet og blev ph.d. fra Royal Holloway, University of London i 1992. Efter korte ansættelser ved universiteterne i Southampton og York kom han til Royal Holloway i 1994, hvor han blev professor i korstogshistorie i 2005.

Jonathan Phillips har været aktiv i en periode, hvor religiøs overbevisning for alvor kom tilbage som forklaringsfaktor både i middelalderhistorie og i moderne politisk tænkning. Han har på en helt usædvanlig måde formået at vise, hvordan middelalderhistorien og korstogshistorien er relevant og vigtig for dagens samfund, samtidig med at han gennem nøje kildegranskninger og brede synteser afgørende har præget den seneste generations korstogsforskning internationalt. Han er kendt i en bred offentlighed, og samtidig er han anerkendt af fagfæller som en af de mest betydende korstogsforskere i dag.

Blandt Jonathan Phillips' mange større monografier sammenfatter fx The Fourth Crusade and the Sack of Constantinople (2004) og The Second Crusade: Extending the Frontiers of Christendom (2007) elegant og udtømmende den eksisterende forskning, bringer nye tolkninger og tager kritisk stilling til nogle af de store, gamle diskussionspunkter - var 2. korstog virkelig koordineret på tværs af hele Vesteuropa, som historikere har ment siden 1953, var 4. korstogs erobring af det kristne Konstantinopel et venetiansk komplot eller en beklagelig fejltagelse? Hans Holy Warriors. A Modern History of the Crusades (2010) er et velskrevet forsøg på at skildre komplicerede politiske og religiøse begivenheder fra aktørernes synspunkt, så personerne bliver levende. Som afslutning diskuterer den, helt originalt, hvorvidt den moderne mellemøstlige forståelse af korstogene måske også kan bygge på en lang, mundtlig overlevering og ikke kun er en moderne konstruktion fra det sene 1800-tal. Samtidig er Jonathan Phillips en flittig koordinator og udgiver af forskningsbidrag, blandt andet af den kommende prestigefyldte Cambridge History of the Crusades. Jonathan Phillips' bøger er oversat til en række sprog, blandt andet spansk, russisk, græsk og japansk.

Jonathan Phillips har spillet en stor rolle i at støtte korstogsforskningen internationalt, også blandt yngre forskere fx gennem forskeruddannelseskurser eller en række sessioner på internationale middelalderkongresser om "New trends in Crusading studies", som har været rammen om mange ph.d.-studerendes første internationale forelæsning. Samtidig har Jonathan Phillips med held forsøgt at løfte korstogsforskningen ud af den selvtilstrækkelighed, som store gamle forskningsområder nemt rammes af, ved bevidst at arbejde sammen med forskere fra flere forskellige discipliner og forskellige lande.

Endelig har Jonathan Phillips formået at nå langt ud over det akademiske publikum ved regelmæssigt at optræde i interviews og i serier på især BBC om korstog og andre historiske emner. Her har han bidraget til en bred debat om vigtige aktuelle temaer og brugen af historie til at forstå eller misforstå dem, som fx krig og religion, jihad, civilisationssammenstød

Sidst opdateret: 07.09.2021